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The fundaments of life
The genetic information of an organism 
is stored in its DNA. The impact that 
differences in DNA have on life is illustrated 
by the notion that two very similar objects 
like a chicken egg and a duck egg have 
completely different outputs1. Whether 
originating from chicken, duck or in fact 
from any other organism, the DNA looks 
like railings of a staircase spiraling towards 
the right2. The difference between DNA 
from different species can be found when 
the inside of the structure is studied; the 
sequence of four different types of “steps” 
that connect the two staircases will provide 
the information that ensures that chicken 
eggs will produce chicks and duck eggs will 
produce ducklings. Although crucial for life, 
the DNA does not directly provide for the 
tools required by the egg to yield a baby bird 
at all. The additional molecules necessary for 
life are the workforce of the cell: proteins. 
The importance of proteins is illustrated by 
the (rather cruel) experiment where the 
chicken or duck egg is boiled. Boiling the egg 
will cause all proteins to denature and lose 
their original shape, which was vital for them 
to exercise their function. This denaturing 
process is irreversible and as a consequence, 
the egg will never yield a bird. 
Chickens, ducks, but also humans, are built 
up from cells. A cell is the smallest living 
entity of an organism and fundamental for 
life3. With some exceptions, all cells within 
one organism contain the same DNA. The 
information stored in the DNA provides 
a blueprint for the proteins which ensure 
survival and proper functioning of the cell. 
To ensure that the many different cell types 
– such as brain, muscle, and blood cells – 
can be formed from this one set of DNA, 
additional regulation is necessary: specific 
parts of the DNA are switched on and off, 
so that only the information needed to form 
a specific cell-type is read. This versatile 
system is absolutely vital for the formation 
of an organism, but unfortunately, it is subject 
to disruption4. Disruption of the system can 
have deleterious consequences: imagine 
what would happen when a brain cell gains 
access to information intended for a blood 
cell. 
The origin of cancer
The DNA in our cells is constantly 
confronted with various assaults that 
threaten the integrity of its code, such as 
UV-light and X-rays5. Luckily, cells have 
an arsenal of DNA repair mechanisms at 
their disposal, which are able to detect and 
repair DNA-lesions inflicted by the assault. 
However, some DNA lesions may persist or 
are repaired erroneously. Resulting changes 
in the information encoded in the DNA, or 
mutations, may have severe consequences 
for a cell. For example, if the mutation 
causes a protein essential for survival to lose 
its function, the cell will die. Similarly, if the 
mutation causes a constitutive activation of 
a protein which is required for growth and 
which is normally tightly regulated, the cell 
will gain a growth advantage compared to 
other cells in its surroundings, which in turn 
can contribute to the formation of a tumor.  
Cancer is a prime example of the 
consequences of deregulation of the 
delicate balance that ensures normal cell 
function. However, one mutation is unlikely 
to cause cancer; in order for cancerous 
cells to survive and divide, they must have 
deregulated multiple parts that make up 
the normal balance. These deregulated 
characteristics are commonly referred to as 
the ‘hallmarks of cancer’, and they include 
properties that enable cancer cells to divide 
infinately, prevent them from dying, and help 
create an environment suitable to sustain 
the growing mass of cancer cells6,7. 
Cancer treatment
Cancer is the name used for an incredibly 
diverse group of diseases that may have 
devastating consequences for people 
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affected by it. In the Netherlands in 2016, 
300 people were diagnosed with cancer 
every day. This number has almost doubled 
over the past 26 years, and is predicted to 
continue to increase over the coming years8. 
To deal with the increasing number of cases, 
improve quality of life and lessen the burden 
of cancer, it is of utmost importance to 
improve cancer therapy, and reduce side-
effects of current cancer regimens without 
losing efficacy. 
Classically, cancer is treated using one 
or more of the three pillars of cancer 
treatments: surgery, radiotherapy and 
chemotherapy. Surgery involves the simplest 
and perhaps most effective way of disposing 
of a tumor by physically removing it. 
Unfortunately, this therapy is not available for 
all tumors, because they must be accessible 
to the surgeon and amenable to complete 
removal. Radiotherapy and chemotherapy 
both eradicate a tumor more indirectly, 
by targeting the fundamental molecules of 
cellular life. The most well-known target in 
this context is the DNA itself: by creating 
an overload of DNA breaks, an anti-cancer 
therapy aims for a cell to die. These types 
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Box I: Hyperthermia application in oncology
Hyperthermia is an anti-cancer treatment which involves 
elevation of temperature using externally applied energy. 
Temperatures reached during hyperthermia treatment range 
between 40 and 44 °C; temperatures exceeding this range are 
considered thermally ablative. Hyperthermia treatment modes 
are distinguished based on the part of the body heated as 
well as on the method of heating. Whole-body hyperthermia 
involves elevation of body temperature to 41-42 °C for 
the duration of one hour, and is usually employed when a 
patient has metastases. Perfusion hyperthermia involves the 
introduction of a heated liquid to an organ, body cavity or a 
limb, and is often accompanied with a cytotoxic agent. Local 
hyperthermia aims to increase the temperature of the tumor 
itself, while the normal tissue is spared from temperatures 
exceeding its tolerance level10,11.
Local hyperthermia is achieved by direction of electromagnetic 
or ultrasound energy towards the tumor. Applicators available 
to execute this task can be introduced into the body 
(intraluminally or interstitially), or are placed externally10,11. In 
Rotterdam, several applicators are available to treat various 
tumor types with local hyperthermia. Superficial hyperthermia 
(A) is applied to treat tumors to about 4 cm depth, such as 
breast tumors and melanomas12. The HYPER collar (B) has 
been developed to treat tumors in the head and neck region, 
an example of loco-regional hyperthermia13. Regional 
deep hyperthermia (C) is available to treat deep-seated 
tumors in the pelvic regions, such as bladder and cervical 
tumors14,15. 
Many clinical trials have been conducted and have proven 
the clinical advantage of addition of hyperthermia to 
radiotherapy or chemotherapy16. Just how substantial 
the contribution of hyperthermia to radiotherapy can 
be to the treatment outcome is illustrated by the long-
term survival benefit of patients with cervical cancer 
(D) (Figure redrawn from Franckena et al17).
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of therapy are very effective towards cancer 
cells, but also harm normal, healthy cells. For 
that reason, there is increased interest for the 
development of precision therapy. Precision 
therapy aims to eradicate the tumor without 
harming normal tissue, by targeting specific 
alterations which cancer cells have gained 
or lost during their development. However, 
an inherent disadvantage of this type of 
approach is the limited number of patients 
that can be treated with it, because specific 
alterations targeted by precision drugs 
are often only present in a small subset of 
tumors. It is therefore important to think 
about methods that 1) have the ability to 
improve classical DNA-damaging cancer 
therapies, or, 2) induce an alteration targeted 
by a precision drug in a localized fashion.
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Box II: Homologous recombination 
Homologous recombination (HR) is a DNA repair pathway that repairs DNA double strand 
breaks (DSBs) that might occur after irradiation, or as a consequence of problems during 
DNA replication. DSB-repair can be very complicated, because – as implied by the name – 
DSBs interrupt both strands of the helical DNA structure and therefore do not allow a simple 
template for repair. HR is classically regarded as one of two methods the cell has available 
for repairing DSBs, and indeed, the second DSB-repair method – non-homologous end-joining 
(NHEJ) – does not use a template for repair, but simply “glues” the two ends of a break together. 
HR does use a template to faithfully restore DNA, most commonly the sister chromatid which 
has arisen during replication. It is for this reason that HR is restricted to the phases of the cell 
cycle where a sister chromatid is present: S and G2-phase. 
HR can be regarded as a stepwise 
process, and the steps are briefly 
illustrated in the figure. 
After a DSB has been detected 
(A) and the conditions allow HR 
to occur, the process is triggered 
by end resection, the creation 
of single stranded DNA by 5’-3’ 
exonucleolytic activity (B). The 
newly generated single strand 
DNA is quickly coated with RPA, 
a single strand binding protein 
(B). The steps that follow end 
resection are critical for HR, and 
commence with replacement 
of RPA with RAD51. RPA has 
very strong affinity for single 
stranded DNA and displacement 
with RAD51 requires several 
mediators, among which 
BRCA2 is critical (C). RAD51 
subsequently drives formation of 
a D-loop by invading the strand of 
the sister chromatid (in red) (D). 
The following repair synthesis 
is guided by the information on 
the second DNA molecule, and 
finally, the intertwined structure 
is resolved (E)21.
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Local hyperthermia
A method which has the potential to fulfill 
both requirements of enhancing cancer 
treatment efficacy without increasing side-
effects is local hyperthermia: a treatment 
during which the temperature of a tumor 
is elevated (Box I)9. The benefits of treating 
cancer with heat have long been known 
and were already recognized by the father 
of medicine, Hippocrates (ca 460-370 BC), 
who stated “Who cannot cure disease with 
medicine, should operate. Who cannot 
operate, should heal with heat”. 
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Box III: PARP-inhibitors
PARP-inhibitors are a new class of drugs that specifically kill homologous recombination 
(HR) deficient tumors without harming normal cells, and are therefore regarded as precision 
therapy24,25. They are currently clinically approved for the treatment of patients with BRCA-
mutated ovarian cancer which have relapsed after initial cisplatin treatment26. 
The rationale of PARP-inhibitors is illustrated briefly. A cell has an estimated 10,000 single strand 
breaks (SSB) to deal with per day (A), and does so with the help of the Poly(ADP-ribose) 
polymerase 1 (PARP-1) (B). If PARP-1 is inhibited by a PARP-inhibitor, the SSBs are not repaired 
and consequently converted to a double strand break when the DNA is replicated (C). These 
one-ended double strand breaks require the HR-machinery to be repaired (D). However, when 
HR is not available in a cell, the damage cannot be repaired (E) and will accumulate, causing the 
cell to die25. 
PARP-inhibitors are a prime example of drugs that induce “synthetic lethality” in HR-deficient 
tumors. Synthetic lethal approaches exploit the situation during which the viability of a cell is 
dependent on two different pathways, in this example SSB-repair mediated by PARP and HR. A 
defect in of one of both pathways does not harm cells, while cells will die when both pathways 
are impaired27. Therefore, to be effective, PARP-inhibitors require a situation in which the tumor 
is HR-defective. For now, this trait is limited to patients that have BRCA-mutations. However, 
HR-deficiency can be induced in any heatable tumor, and therefore, application of hyperthermia 
has the potential to considerably enlarge the group of patients that may benefit from PARP-
inhibitors23. 
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Nowadays, hyperthermia is combined with 
radiotherapy or chemotherapy and thus part 
of a multimodality treatment. Temperatures 
reached during hyperthermia treatment 
range between 40 and 44 °C and are usually 
maintained for one hour. Hyperthermia has 
a range of effects on a tumor that cause it 
to be more sensitive to radiotherapy and 
some types of chemotherapy. For instance, 
hyperthermia increases blood perfusion, 
activates the immune system and increases 
cell membrane fluidity (a more detailed 
description of these effects can be found 
in chapter 2 of this thesis18). One of the 
most pronounced molecular effects of 
hyperthermia is on proteins, and the parallel 
to the boiled egg is easily made. Although 
temperatures reached during hyperthermia 
treatment are nowhere near temperatures 
used to boil and egg, they can still induce 
unfolding of specific proteins. If such a 
protein has essential tasks to perform, 
hyperthermia-mediated unfolding will have 
grave consequences for a cancer cell. 
Hyperthermia and DNA repair
Indeed, one of the reasons that explains why 
hyperthermia increases a cell’s sensitivity to 
DNA damaging agents such as radiotherapy19 
is the ability to affect proteins associated 
with DNA repair20. While protecting the 
DNA in normal cells, DNA repair enzymes 
counteract the efficacy of DNA damaging 
agents – such as radiotherapy – in cancer 
cells. Therefore, by affecting DNA repair 
enzymes, hyperthermia causes DNA 
damaging agents to gain efficacy. One 
specific DNA repair pathway affected by 
hyperthermia is homologous recombination 
(HR) (Box II)9. Hyperthermia sensitizes 
cells towards DNA double strand break 
inducing treatment by dramatically affecting 
two key HR-enzymes; hyperthermia inhibits 
localization of RAD51 to DNA breaks and 
causes BRCA2-degradation9. 
Hyperthermia-induced inhibition of 
HR: new opportunities
Hyperthermia-induced HR-deficiency 
contributes towards explaining why 
hyperthermia sensitizes to radiotherapy19, as 
well as to why hyperthermia increases the 
sensitivity to various chemotherapeutics 
that indirectly cause DNA double strand 
breaks, such as cisplatin, carboplatin and 
mitomycin C22. Moreover, hyperthermia-
induced HR-deficiency also provides 
rationale for new combination therapies23. 
By temporarily creating an environment 
in which HR is inhibited, hyperthermia 
creates a new niche for a precision therapy 
that is currently only available for patients 
with tumors with a genetic HR-deficiency 
(Box III). Hyperthermia therefore has the 
potential to expand the currently limited 
group of patients that may benefit from such 
treatments. 
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Scope of this thesis
Hyperthermia increases the efficacy of 
radiotherapy and chemotherapy in clinical 
practice19,22. Extensive scientific research has 
aimed to elucidate the biological mechanisms 
that cause this sensitization, with the 
accompanying goal to exploit these in the 
clinic. One of the mechanisms described 
has particular promise to guide future 
hyperthermia treatment: hyperthermia 
attenuates DNA repair by homologous 
recombination (HR) via degradation of 
BRCA29. Besides providing a satisfactory 
reason for why hyperthermia synergizes with 
DNA damage inducing agents, attenuation 
of HR provides rationale for a therapeutic 
strategy where hyperthermia and PARP 
inhibitors could be combined. The work 
presented here aims to further explore 
what hyperthermia-mediated degradation 
of BRCA2 can signify for current and future 
anti-cancer treatment. This thesis is divided 
in four parts which describe the journey of 
hyperthermia mediated BRCA2 degradation 
from bedside to bench and back again. 
The research that has identified BRCA2 as 
a target of hyperthermia is a prime example 
of ‘bedside to bench’ research. It provided, in 
part, a molecular / biological explanation for a 
clinical observation: hyperthermia increases 
the effects of radiotherapy. In Chapter 
2, we provide context to the importance 
of biological research for hyperthermia 
treatment, by illustrating the therapeutic 
targets that biological discoveries have 
yielded.
In Part II A step back, we take a 
figurative step back and consider what 
the requirements for exploiting heat-
mediated degradation of BRCA2 in the 
clinical setting are. Chapter 3 explores 
the effects of treatment temperature and 
duration – or thermal dose – on BRCA2 
degradation. In Chapter 4, we aim to define 
optimal scheduling for hyperthermia and 
radiotherapy, using attenuation of DNA 
repair as a read-out. 
Part III From Bench to Bedside explores 
current possibilities to exploit the biological 
discovery of hyperthermia-induced BRCA2-
degradation and resulting HR-deficiency 
in a clinical setting. A prerequisite for 
combination strategies that will exploit 
hyperthermia-induced HR deficiency, such 
as PARP-inhibitors and hyperthermia, is that 
the molecular mechanisms that mediate 
BRCA2-degradation are conserved in 
human tumors of various origins. We verify 
this in Chapter 5. We also ask whether 
observed BRCA2-degradation can be used 
as a biomarker for the effectivity of clinical 
hyperthermia applications. We continue this 
line of research in Chapter 6, and explore 
the feasibility of two ex vivo assays to predict 
hyperthermia-effectivity in bladder cancer.
Part IV From Bedside to Bench focuses 
on biological methods to enhance heat-
mediated BRCA2 degradation, keeping in 
mind possible future applications of heat-
mediated BRCA2 degradation in the clinic. 
In Chapter 7, we aim to understand the 
molecular mechanisms responsible for heat-
mediated BRCA2 degradation in order 
to define suitable targets for enhancing 
hyperthermia efficacy. One target that is 
suitable to do so is HSP90, on which we 
elaborate in Chapter 8.
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Introduction
Hyperthermia is an anti-cancer treatment 
in which tumors are heated using an 
exogenous energy source. Heat can directly 
kill cancer cells, but also greatly synergizes 
with radiotherapy and/or chemotherapy 
to increase the therapeutic window1,2. 
Although the effect of heat on the body 
has been studied for many decades, if not 
centuries, ‘modern’ hyperthermia has only 
been applied in the clinic since the 1980s. 
Early biological and physical studies revealed 
that the various physiological and cellular 
changes induced by hyperthermia are dose 
dependent3. Therefore, heat treatment can 
be defined by the temperature that is applied: 
hyperthermia (39-45 °C), with temperatures 
<42 °C further defined as mild temperature 
hyperthermia, and thermal ablation (>45 
°C). A second distinction in hyperthermia 
treatment is based on which part of the 
body is heated: whole-body hyperthermia, 
as the name suggests, subjects the complete 
body to increased temperature; in regional 
hyperthermia an isolated part of the body, 
such as body cavities, limbs or organs, is 
heated; and during local hyperthermia only 
the tumor is heated4. 
To understand how hyperthermia is applied 
nowadays, it is essential to realize that this 
treatment has an extensive history. Although 
the modern varieties of hyperthermia 
application can be traced back to the 1960s, 
elevated temperatures as a single modality 
have been employed to treat cancer for a 
much longer time, and can even be dated as 
far back as 5000 BC5. In the 18th and 19th 
centuries, hyperthermia treatment started 
to be more evidence based. The use of heat 
then was based on the observation that 
tumors from patients started to shrink when 
the patients suffered from febrile diseases 
such as malaria or erysipelas. As a result, 
the surgeon Fehleisen started to infect 
cancer patients with bacteria, thus causing 
erysipelas, with the aim of eliminating 
tumors. Around 1900, William B. Coley 
developed special toxins, Coley’s toxins, to 
achieve the same effect and he performed 
many studies on its effectiveness6. The 
following years were extremely important 
for the modern use of hyperthermia. It was 
the period in which exogenous sources, such 
as heated water baths, started to be used 
to increase the temperature of gynecologic 
tumors7. Moreover, radiotherapy was 
introduced around the same time, and when 
clinicians and researchers started combining 
it with heat, they found that hyperthermia 
increased sensitivity to radiation in tumors8. 
This breakthrough stimulated an increase in 
the number of both clinical and fundamental 
studies from the 1950s until present day. 
To this day, mild hyperthermia is used as 
Abstract
It has long been established that hyperthermia increases the therapeutic benefit of radiation 
and chemotherapy in cancer treatment. During the last few years, there have been substantial 
technical improvements in the sources used to apply and measure heat, which greatly increases 
enthusiasm for the clinical use of hyperthermia. These advances are converging with a better 
understanding of the physiological and molecular effects of hyperthermia. Therefore, we are 
now at a juncture where the parameters that will influence the efficacy of hyperthermia in 
cancer treatment can be optimized in a more systematic and rational manner. In addition, the 
novel insights in hyperthermia’s many biological effects on tumor cells will ultimately result in 
new treatment regimes. For example, the molecular effects of hyperthermia on the essential 
cellular process of DNA repair, suggest novel combination therapies with DNA damage response 
targeting drugs that should now be clinically explored. Here, we provide an overview of recent 
studies on the various macroscopic and microscopic biological effects of hyperthermia. We 
indicate the significance of these effects on current treatments and suggest how they will help 
design novel future treatments. 
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a sensitizer for radiotherapy, but also for 
chemotherapy. 
Initially, research on hyperthermia revolved 
around finding an optimal treatment 
temperature and time, or in short, an optimal 
thermal dose. These translational studies 
focused on creating a therapeutic window 
with maximum benefits of hyperthermia with 
minimal side-effects. However, those early 
studies assumed that hyperthermia was only 
effective if it would directly kills cells, which 
only occurred when temperatures exceeded 
at least 42°C. This made hyperthermia less 
feasible and thus less attractive in a clinical 
setting, causing a dampened enthusiasm 
for the treatment9. As a result, there was a 
strong demand to improve hyperthermia 
technology and a second line of hyperthermia 
research, focused on the physics of heating, 
quickly emerged. As of now, this field of 
research continues to improve not only 
the hyperthermia application techniques, 
but also the method of locally depositing 
heat and measuring it in the patient10. The 
measuring tools aid clinicians in treating 
their patients optimally and it helps them 
document treatment outcomes for clinical 
research. Another line of hyperthermia 
research that has raised enthusiasm for 
cancer treatment employing heat has a 
biological and fundamental nature. Biological 
research strives to understand the biological 
mechanisms of hyperthermia at every 
temperature. Although this type of research 
may not always be directly applicable to 
clinical treatment per se, it will ultimately 
result in revolutions in the way we use 
hyperthermia in the clinic, by exploitation 
of the many cellular and physiological effects 
that hyperthermia has in tumors (Figure 
1)5.
This review aims to illustrate the importance 
of biological research to mild hyperthermia, 
since hyperthermia in this temperature 
range is the most prominent in the clinic. To 
demonstrate the broad potential of heating 
tumors, we present an overview of the 
biological effects of mild hyperthermia and 
describe their relevance in current treatment 
regimes. Moreover, we will describe how the 
biological research continues to influence 
the way we think about hyperthermia 
by presenting examples of treatment 
innovations that are not or not yet clinically 
applied, but exploit one or more biological 
effects of heat.
Macroscopic effects of hyperthermia
When a tumor is heated a number of 
physiological changes occur. One of the 
earliest recognized physiological change 
induced by hyperthermia is its effect on the 
vascular system. Hyperthermia causes an 
increase in blood flow in the heated area, and 
by expanding the vessels the heat improves 
their permeability (Figure 1A)11–13. Most of 
the physiological changes upon hyperthermia 
treatment are secondary to effects on 
tumor blood flow14. In fact, blood flow is one 
of the predominant factors governing tumor 
response to heating15,16. It is a potent cooling 
mechanism thus influences the delivery of 
heat to a tissue. Blood flow in tumors is also 
a principal factor responsible for the micro-
environmental conditions within tumors, 
and since cells under oxygen deprived and 
highly acidic conditions are more responsive 
to the effects of heat17,18, blood flow will 
play a major role in influencing the cellular 
heat response, and subsequently that of the 
tumor.
How quickly the macroscopic changes of 
hyperthermia are seen and their degree 
of change generally depends on the time 
and temperature of heating. As soon as 
heat is applied to tumors the blood flow 
increases, but these effects are cancelled 
upon treatment with temperatures that 
surpass 44.5 °C11,19–25. However, the degree 
of increase and how long it is maintained is 
very heterogeneous depending on both the 
temperature applied and the tumor model 
used11,26. The primitive construction and poor 
organization of tumor vessels results in them 
being more permeable than normal tissue 
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vessels27. As flow increases in response to 
heat, fluid will begin to leak out of the vessels 
into the extracellular space25. This edema 
will eventually increase interstitial fluid 
pressure which subsequently causes vascular 
compression and a decrease in perfusion. This 
could explain the observations that vascular 
perfusion starts to decrease after about 30 
minutes of heating the tumor to 42.5 °C and 
above19,23–25. However, it should be noted 
that at least one study found that this did 
not occur until a temperature of 44.5 °C was 
achieved22. In addition, temperatures beyond 
44.5 °C will directly kill endothelial cells, and 
this will cause vascular damage, resulting in 
hemorrhage that accentuates the already 
decreased perfusion11,28. In some examples 
the inherent vascular damage in the tumor 
can be so severe that a total vascular shut 
down occurs, even at temperatures as low 
as 42.5 °C25. After heating, flow typically 
returns to normal at lower temperatures, 
but continues to decrease in those tumors 
where vascular damage was already 
initiated19,22,24,25. 
As mentioned above, the tumor vasculature 
is structurally and functionally abnormal 
and thus fails to meet the demands of the 
growing tumor mass, which is why tumors 
are characterized by regions of oxygen 
and nutrient deprivation, high lactate levels 
and extracellular acidosis27,29. Heat-induced 
vascular changes will further modify the 
micro-environmental parameters, although 
the mechanism is also dependent on the 
Dendritic cell
HSPs
Cytotoxic T-cell
Membranes
Fluidity and 
 permeability
C
DNA-repairE
Immune system
Tumor recognition
Direct activation
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Macroscopic
Vessel permeability
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A Heat Shock ResponseB
Figure I. Biological effects of local hyperthermia in the tumor.
A tumor, represented by the pictogram in the center, and the diverse physiological and molecular effects 
of heat are indicated.  A) Hyperthermia alters physiology of the centrally located tumor by affecting its 
vasculature: heat increases the blood flow and vessel permeability. B) Heat causes proteins to unfold and 
increases the intracellular amount of protein-chaperoning heat-shock proteins. C) Temperatures exceeding 
37 °C result in increased cell membrane fluidity, thereby influencing their permeability. Specific biological 
effects of heat on membranes may be further affected by altering properties of membrane-bound-
proteins. D) Local heat helps to activate the immune system and causes it to attack the tumor directly, 
but might also cause a systemic effect by which immune cells attack tumor cells distant from the heated 
tumor. E) Hyperthermia affects DNA damage repair pathways by inactivating specific repair proteins.
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applied temperature. High temperatures 
cause vascular collapse which will further 
reduce oxygen and nutrient delivery 
to tumor cells. This is reflected by an 
escalation in energy deprivation30, lactic acid 
accumulation31, acidity30, and hypoxia32,33. For 
lower temperatures the increase in perfusion 
is associated with an increased oxygen 
delivery32,34–37, but this greater availability of 
oxygen leads to an increased consumption 
of oxygen14,38,39. Even though an enhanced 
oxygen consumption could be expected to 
decrease the diffusion distance of oxygen 
and thus elevate the level of tumor hypoxia, 
this has not been shown. 
Although the macroscopic effects of 
hyperthermia can be classified as well-
studied, there is controversy about the 
improvement in oxygenation to how long 
those effects last. Some studies have shown 
that this improvement can last for up to 24 
hours after heating at mild temperatures34,36, 
and this has been suggested as one of 
the reasons why hyperthermia enhances 
radiation administered clinically in a 
fractionated schedule40. However, this 
prolonged improvement in tumor 
oxygenation is difficult to explain, because 
the physiological changes that are likely to 
account for improved oxygenation with mild 
heat treatments are unlikely to be maintained 
after the blood flow increase has ceased. 
More consistent with those physiological 
effects, other studies have shown that 
tumor oxygenation actually rapidly returns 
to normal when the heating at mild 
temperatures ceases35. Nonetheless, the 
several macroscopic effects of hyperthermia 
have established a central position in 
its modern use. Moreover, the transient 
increase in blood flow and resulting vascular 
leakage forms the basis for generating 
methods to increase drug delivery to a place 
of interest, for example, via the application of 
thermosensitive liposomes41–44.
The Heat Shock Response 
Heat activates a cellular mechanism 
that defends against protein stress. This 
heat shock response consists of a rapid 
production of heat shock proteins (HSPs), 
a specific group of proteins that chaperone 
denatured proteins and thereby prevent 
formation of toxic protein aggregates 
(Figure 1B)45–47. This defense mechanism 
is not limited to the response to heat, but 
is also activated by several other forms of 
stress, such as hypoxia and infection, and 
is therefore of vital importance for life47. 
However, when it comes to treating cancers 
with mild hyperthermia, the heat shock 
response has an undesirable side-effect: it 
causes tumors to become thermotolerant. 
Thermotolerance is a phenomenon that 
can be described as insensitivity to heat 
treatments within 48-72 hours after the 
initial treatment. It has a pivotal role in the 
hyperthermia field because it demonstrates 
the importance of properly scheduling 
hyperthermia sessions for patients.
HSPs have been recognized to play a role 
in the development of thermotolerance 
for a long time, because they are thought 
to protect tumor cells from protein 
denaturation induced by hyperthermia48–51. 
Moreover, tumors sometimes have a 
constitutively high level of HSPs that protect 
them from innately higher levels of protein 
stress, causing the tumors to be fully 
dependent on these high levels. Therefore, 
specific HSP inhibitors have been developed 
and found their way into the clinic52. Because 
of their availability and clinical use, employing 
these types of drugs together with 
hyperthermia should be considered in order 
to increase the effective therapeutic window 
and prevent thermotolerance. Although the 
detailed effects on thermotolerance are still 
rather unclear, the combination of heat and 
HSP inhibitors does increase cell sensitivity 
towards hyperthermia53. It has also been 
proposed that activation of the heat shock 
response is inhibited by acute acidification, 
and indeed, sensitivity of cells towards 
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heat is increased when it is combined with 
drugs that lower the pH in the cell, such 
as lonidamine, especially when cells already 
were slightly acidic already54. 
However, as will be described below, HSPs 
also occupy an important role in cancer 
immunology and in that context their role 
is actually thought to be beneficial for the 
patient. Therefore it will be essential to 
thoroughly investigate the implications of 
combining different variants of HSP inhibitors 
with hyperthermia on treatment efficacy, 
thermotolerance, and immunological effects, 
before applying them in a clinical setting. 
Cellular membrane and drug uptake
One of the ways hyperthermia contributes to 
sensitizing cells towards chemotherapeutics, 
is by increasing fluidity of the cytoplasmic 
membrane (Figure 1C). The cytoplasmic 
membrane consists of a phospholipid bilayer 
and proteins, and it forms the outer layer of 
the cell. Interactions between proteins and 
lipids in the membrane cause it to respond 
to temperature changes in a very dynamic 
fashion55. Regulation of the membrane fluidity 
is essential for homeostasis and therefore 
conserved in many species. It is clear that 
the membrane plays a considerable role in 
the stress response, including the response 
to heat-shock56–58. Membrane stress triggers 
various signaling cascades which transduce 
their signal to the heat shock transcription 
factor HSF1, which ultimately increases 
expression of the HSPs58,59. 
When the membrane becomes more fluid 
due to heat, its physical permeability for 
some compounds will increase60. This is 
probably one of the reasons why some 
chemotherapeutics will be able to pass 
the cell barrier more effectively when the 
cells are treated with hyperthermia. For 
example, several reports show that the 
concentration of the chemotherapeutic 
cisplatin increases in the cell when it is 
treated with hyperthermia61–63. Moreover, 
heat also contributes to structural changes 
in the membrane by altering the behavior 
of membrane-embedded proteins, and 
this will also increase cellular cisplatin 
concentrations; this is illustrated by heat 
facilitating multimerization of a copper 
transporter (CTR1) that is responsible for 
cisplatin uptake64. Knowledge about the 
altered behavior of the cell membrane in 
conditions of hyperthermia has mainly been 
used in regional hyperthermia treatment, 
where a heated chemotherapeutic is flushed 
on the a specific part of the body such as 
the peritoneum (HIPEC) or the bladder 
(HIVEC)43,65. However, the temperature-
mediated effects on the cell membrane will 
also play a role with the implementation of 
thermosensitive liposomes42.
The effects of hyperthermia on the membrane 
might be counteracted by an evolutionary 
conserved adaptation response. The exact 
mechanism by which cells compensate their 
membrane fluidity to heat is not known, but 
recent studies have revealed that the acyl-
CoA dehydrogenase downregulates a lipid 
desaturase upon heat in the model system 
Caenorhabditis elegans. This effectively creates 
a more rigid membrane structure that 
compensates for the increased fluidity66,67. 
Such an adaptive response might be relevant 
for the development of thermotolerance, 
thus it will be of importance to elucidate 
whether this mechanism also occurs in 
human cells after hyperthermia. In this 
context, it is important to realize that the 
composition of the membrane as well as its 
reaction to environmental changes can be 
deregulated in tumors, since this might have 
consequences for the treatment regime68. 
Ultimately, research done on the subject will 
deliver new strategies to either mimic or 
enhance the effects of hyperthermia on the 
membrane, or to prevent unwanted side-
effects. 
The immune system and hyperthermia
Fever and hyperthermia are both 
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characterized by increased temperatures, 
and both contribute to the activation 
of the immune system (Figure 1D)69,70. 
The treatment of cancer patients by using 
hyperthermia and stimulating their immune 
system have always been closely intertwined, 
as can be exemplified by the fact that William 
B. Coley is regarded as one of the fathers in 
the hyperthermia field, but is also seen as one 
of the pioneers in immunotherapy6,69. The 
many intriguing ways in which hyperthermia 
stimulates the immune system has great 
impact on the rationale of hyperthermia 
treatment in oncology, as is clear from the 
many reviews on the subject5,69–73. Currently, 
it is thought that there are two closely 
related ways in which local hyperthermia 
can modulate the immune system 5. The 
first effect of hyperthermia on immunity is 
localized to the heated tumor, but, secondly, 
local hyperthermia can also stimulate a 
systemic anti-tumor reaction that can strike 
tumor cells that are distant from the heated 
tumor69,70.
Increased temperatures affects both 
adaptive and innate immunity70,73. The way 
temperature regulates the immune system 
is not only dependent on the magnitude 
of the temperature increase that is applied 
or achieved, but also on the duration70,72,74. 
However, some effects occur quickly and are 
therefore relevant in hyperthermia treatment. 
The increased blood flow resulting from mild 
heating of the tumor can promote attraction 
of immune cells via improving trafficking 
between the tumor and the draining lymph 
nodes69. It has also been shown that heat 
causes changes in adhesion molecules of 
the tumor vasculature. Specifically the 
expression of the glycoprotein Intracellular 
Adhesion Molecule 1 (ICAM-1) is increased 
via heat-induced increased interleukin 6 (IL-
6) signaling. ICAM-1 then attracts effector/
memory T-cells69,75,76. Hyperthermia not 
only alters expression of vascular adhesion 
molecules, but also induces an increased 
expression of surface molecules on tumor 
cells. At 39 °C, heat increases the MHC class 
I polypeptide-related sequence A (MICA), a 
molecule which increases cell sensitivity to 
natural killer cells69,77. At a temperature of 43 
°C, heat will increase the level of MHC class I 
molecules, which attract cytotoxic T-cells69,78. 
Febrile temperatures also enhance functions 
of dendritic cells, and their enhanced antigen 
presenting function increases stimulation 
of T-cells70,79–81. It is thought that the heat-
mediated increase in membrane fluidity 
has effects on organizing the response of 
the adaptive immune system, promoting 
activation of T-cells in areas where the 
temperature is increased82–84. 
The most interesting connection between 
immunity and the heat-shock response is 
the function of the increased HSPs, especially 
that of HSP70. Like other HSPs, HSP70 is 
produced upon heat treatment, but it can 
be released from cells. In the extracellular 
environment, HSP70 will bind various 
immune cell surface receptors, which will 
in turn release various pro-inflammatory 
molecules. In this environment, HSP70 
stimulates dendritic cells and macrophages 
by acting as a damage-associated molecular 
pattern (DAMP)70. Moreover, HSP70s can 
stimulate the adaptive immune system by 
transferring chaperoned tumor proteins 
to antigen presenting cells, which evokes 
a tumor specific T-cell response69,85–87. This 
T-cell response presumably has the ability to 
target all tumor cells, including metastases88.
Although the role of hyperthermia in immunity 
has revolutionized the rationale behind using 
hyperthermia in oncology treatment, the 
connection has only recently gained more 
interest with the acknowledgement of 
the role for immunotherapy in oncology89. 
To exploit the effects of hyperthermia on 
the immune system in the future, it will be 
especially important to fully understand the 
temperature dynamics and corresponding 
effects of the HSPs, since their role 
provokes the most tumor-specific immune 
response90,91. This is illustrated by the finding 
that HSP70 can be used as an anti-cancer 
vaccine to mimic and maximize the response 
of hyperthermia92,93. 
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Hyperthermia and DNA repair
It has long been known that hyperthermia 
increases cancer cell sensitivity for agents 
that cause DNA damage or interfere with 
DNA metabolism. One of the earliest 
discoveries and well-studied examples of 
an agent that causes DNA damage, and 
synergizes with heat, is ionizing radiation94. 
However, heat also increases the degree 
of cell killing caused by certain types 
of chemotherapy, such as cisplatin and 
alkylating agents95. The mechanism by which 
hyperthermia sensitizes to DNA damaging 
agents has been extensively studied, but 
the results are often difficult to interpret 
because of the use of different temperatures 
and an overlap in the several DNA damage 
repair pathways. The many hypotheses that 
consider what effects hyperthermia has on 
DNA have recently been reviewed96.
Many researchers have tried to elucidate 
the mode of action of hyperthermia 
on DNA. Some early reports indicated 
that hyperthermia directly caused DNA 
damage and claimed that there were more 
chromosomal aberrations and DNA breaks 
after hyperthermia treatment97,98. Moreover, 
heating cells to 41.5 °C increased the 
amount of phosphorylation of histone 
H2AX (γH2AX), which is a considered a 
marker for DNA double strand breaks99. 
However, there is also a large body of 
literature that describes that hyperthermia 
has no direct damaging effect on DNA, but 
rather interferes with the activity of proteins 
important for repairing DNA caused by 
an exogenous agent, such as radiotherapy 
(Figure 1E)96. 
Identifying specific DNA repair pathways 
that are targeted by hyperthermia is not 
straightforward. This task has been attempted 
by employing a genetic approach, in which 
the sensitivity towards the combination of 
exogenously applied DNA damage and heat 
in wild-type cells is compared to cells that 
are deficient for a specific repair pathway. 
If hyperthermia results in inactivation of a 
repair pathway required for the repair of 
the induced DNA lesions, then heated wild-
type cells will be more sensitive towards 
the DNA damaging agent than cells that are 
not heated. In the scenario that the repair 
deficient cell line is deficient for a pathway 
that is targeted by hyperthermia, then the 
cells will not be further sensitized by the 
applied heat. However, the spectrum of 
different lesions induced by a single DNA 
damaging agent, as well as the possibility that 
hyperthermia targets multiple DNA repair 
pathways, prevents conclusive interpretation 
of data obtained using this genetic approach. 
Indeed, multiple DNA repair pathways, 
such as Base Excision Repair66 for single 
strand DNA lesions and Non-Homologous 
End Joining for double strand breaks100, are 
believed to be inhibited by hyperthermia96. 
However, the results obtained in these 
studies are often based on experiments 
done with temperatures above 43 °C, so it 
remains unclear whether inhibition of these 
DNA repair pathways add to the effects 
of mild hyperthermia. There is therefore 
still significant experimental ground to be 
covered before the mystery of how mild 
hyperthermia influences DNA metabolism 
is solved. 
Nonetheless, when we can identify the 
effects of hyperthermia on DNA in cancer 
cells, the information obtained can help the 
hyperthermia field with questions such as 
how to minimize side-effects and toxicity to 
healthy tissues, and how to maximize DNA 
damage load in the tumor. For example, 
is was discovered that hyperthermia 
functionally inhibits the DNA repair pathway 
of homologous recombination101,102. This 
repair pathway acts in the S-phase and G2-
phase of the cell cycle to faithfully restore 
double strand breaks by using an intact 
copy of broken DNA as a template for 
repair. When such a double strand break 
occurs, it triggers a cascade that results in 
nucleolytic processing of the double strand 
DNA ends into single strand DNA, which 
is subsequently coated by the single-strand 
binding protein RPA. This is then replaced by 
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RAD51 with the help of BRCA2. This RAD51 
recombinase protein is believed to be of 
vital importance for the subsequent search 
for homologous DNA and the invading of 
this DNA, and is therefore regarded as the 
most essential component in homologous 
recombination. After the missing DNA is 
restored based on the sequence information 
of its identical sister chromatid in the cell, 
the intertwined DNA structure is resolved 
leaving two whole DNA molecules103,104. In 
the aforementioned study, it was shown 
that hyperthermia (>40 °C) inhibits the 
accumulation of the RAD51 at sites of DNA 
damage via targeting the BRCA2 protein for 
proteasomal degradation101.
Homologous recombination is involved 
in repair of breaks caused by radiation 
treatment, and therefore the finding that 
hyperthermia inhibits this DNA repair 
pathway provides at least part of the 
explanation for hyperthermia’s sensitizing 
potential towards ionizing radiation. 
However, homologous recombination is 
not only responsible for repairing double 
strand breaks that result from exogenous 
sources, but also acts to repair breaks that 
result from collapsing of replication forks. 
The finding that hyperthermia inhibits 
homologous recombination is therefore 
of particular interest, because it opens up 
new possibilities of treatments that can 
be combined with hyperthermia, such as 
PARP-1-inhibitors105. PARP-1-inhibitors are a 
relatively new class of chemotherapy which 
cause collapse of replication forks106. These 
PARP-1-inhibitors gained clinical interest 
because they specifically kill cells that are 
deficient in homologous recombination, 
while showing little toxicity to normal 
cells106,107. Thus, PARP-1-inhibitors are a 
prime example of a precision treatment 
for tumors of BRCA1/2 -mutation carriers, 
as the tumor cells of these patients, but 
not their normal cells, are homologous 
recombination deficient. The demonstration 
that mild heat phenocopies BRCA-deficiency 
and induces homologous recombination 
deficiency provides a rational for extending 
PARP-1-inhbitor treatment outside of the 
limited group of BRCA-mutation carriers. 
Clinical trials should now be considered in 
which PARP-1-inhibitors are combined with 
hyperthermia to locally induce homologous 
recombination deficiency in tumors. This 
combination may have minimal side-effects, 
because both treatments, which have little 
toxicity on their own, will only need to be 
applied temporarily. Therefore, we predict 
that it will only be a matter of time before 
this combination therapy will be applied in a 
clinical setting. 
The future of hyperthermia
Hyperthermia has been used in the clinic 
for decades, and clinical studies have 
clearly demonstrated that heating tumors 
has benefit when added to radiation 
or to chemotherapy5,108–110. Moreover, 
hyperthermia is now readily available to 
treat a broad range of tumors, similar 
to radiotherapy and broad-spectrum 
chemotherapy, but unlike the latter two, 
hyperthermia has no severe side-effects10,111. 
These beneficial features of hyperthermia 
together with the physiological and molecular 
effects that we have summarized in this 
review (Figure 1), illustrate the potential of 
hyperthermia treatment in oncology. 
The impact of hyperthermia in cancer 
treatment will only increase in the future, 
as we learn how to more effectively exploit 
the multiple biological effects of the heat on 
the tumor. However, the time has already 
arrived to translate the biological findings 
about hyperthermia into benefits for cancer 
patients. The importance of thermal dose 
has always been recognized in the context 
of hyperthermia treatment, and finding the 
optimal thermal dose for each biological 
effect will result in insights that will enhance 
efficacy of the heat, and eventually in one 
or more doses that fit the treatment 
regimen envisioned by the practitioner. 
The possibilities to optimize hyperthermia 
treatment are greatly aided by the current 
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advantages in the application techniques for 
hyperthermia: the heating systems have not 
only become more specialized and effective 
in heating, but it is now also possible to 
measure real-time heat deposition by MRI5. 
Although hyperthermia itself is advancing 
beyond previous possibilities, the collection 
of possible synergizing agents are also 
emerging. With the expanding interest in 
the use of proton therapy in oncology, it 
has been suggested that cells harboring 
defects in homologous recombination are 
more sensitive towards proton irradiation 
than to photon irradiation112,113. Since, as 
we explained above, heat causes a defect 
in homologous recombination, there 
is a rational basis for the combination 
of hyperthermia with proton therapy. 
Ultimately, the collective efforts of clinicians, 
physicists and biologists will result in an 
effective, versatile and evidence-based use of 
hyperthermia in oncology that is bound to 
gain more popularity in the future. 
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Introduction 
Hyperthermia is an anti-cancer treatment 
during which external heat sources 
are employed to treat tumors. During 
the treatment, specialized equipment is 
used to regionally heat the tumor to a 
final temperature in the range of 40-44 
°C1, which is a safe and effective way to 
enhance the effectiveness of radiotherapy 
and some types of chemotherapy, such as 
cisplatin, carboplatin, cyclophosphamide, 
ifosfamide, melphalan and mitomycin C2,3. 
Hyperthermia’s sensitization effects towards 
radiotherapy and chemotherapy can be 
attributed to a plethora of biological effects 
in the tumor, both on a macroscopic and 
microscopic scale. Research that aims to 
elucidate the biological effects of heat has 
the potential to revolutionize the way in 
which hyperthermia will be employed in a 
clinical setting4–8. 
One of the effects of hyperthermia 
described more recently is the induction of 
degradation of the BRCA2-protein9. BRCA2 
is essential for repair of DNA double strand 
breaks via homologous recombination 
(HR)10. HR faithfully restores these breaks 
by copying the information from an intact 
copy of the damaged DNA, a process 
catalyzed by the protein RAD5111. BRCA2 
is necessary for the loading of RAD51 onto 
DNA breaks and by degrading BRCA2, 
hyperthermia causes aberrant localization of 
RAD519. This, in turn, causes the attenuation 
Table 1.  Thermal Doses.
An overview of the thermal doses employed in this study. 
Temperature Time 1 Time 2 Time 3 Time 4
40 °C 0 min 60 min 120 min 240 min
41 °C 0 min 60 min 120 min 240 min
42 °C 0 min 30 min 60 min 120 min
43 °C 0 min 15 min 30 min 60 min
43.5 °C 0 min 15 min 30 min 60 min
44 °C 0 min 15 min 30 min 60 min
Abstract
Hyperthermia has a number of biological effects that sensitize tumors to radiotherapy in the 
range between 40-44 °C. One of these effects is heat-induced degradation of BRCA2 that in 
turn causes reduced RAD51 focus formation, which results in an attenuation of DNA repair 
through homologous recombination. Prompted by this molecular insight into how hyperthermia 
attenuates homologous recombination, we now quantitatively explore time and temperature 
dynamics of hyperthermia on BRCA2 levels and RAD51 focus formation in cell culture models, 
and link this to their clonogenic survival capacity after irradiation (0-6 Gy). For treatment 
temperatures above 41 °C, we found a decrease in cell survival, an increase in sensitization 
towards irradiation, a decrease of BRCA2 protein levels, and altered RAD51 focus formation. 
When the temperatures exceeded 43 °C, we found that hyperthermia alone killed more 
cells directly, and that processes other than homologous recombination were affected by the 
heat. This study demonstrates that optimal inhibition of HR is achieved by subjecting cells to 
hyperthermia at 41-43 °C for 30 to 60 minutes. Our data provides a guideline for the clinical 
application of novel combination treatments that could exploit hyperthermia’s attenuation of 
homologous recombination, such as the combination of hyperthermia with PARP-inhibitors for 
non-BRCA mutations carriers.
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of DNA repair via HR, which at least partly 
explains hyperthermia’s sensitizing effects 
towards radiotherapy, the latter being based 
on the creation of an overload of cytotoxic 
DNA breaks in tumor cells. DNA repair 
pathways can counteract the cytotoxicity, 
and thus, by degrading BRCA2, hyperthermia 
provides a window of opportunity to 
leave DNA damage unrepaired. Moreover, 
hyperthermia-mediated BRCA2 degradation 
creates specific opportunities to increase 
treatment efficacy, because it induces a 
localized environment of HR-deficiency. 
This could potentially be exploited by new 
treatment regimens that reduce cancer 
treatment side-effects, such as combination 
Figure 1. Plating efficiency and colony cell survival at different thermal doses.
Four different cell lines (BLM, HeLa, FaDu and VH10-SV40) were submitted to hyperthermia and irradiated 
afterwards in six independent experiments; one for each temperature. The data points and error bars represent 
mean ± SEM of all pooled cell lines and the connecting curve is the result of a fitted regression. Multiple curves 
were predicted if the regression parameters differed significantly from each other (p<0.05). Exact p-value is 
embedded in the graphs. A) Plating efficiencies at 0 Gy for all temperatures, normalized to 37 ˚C. Curves 
were predicted by linear regression and the inset graph shows the predicted slope of the regression analysis 
(Mean ± SD). B) Surviving fractions upon irradiation, normalized to 0 Gy for each thermal dose. The curves are 
predictions made by linear-quadratic regression. At 40 °C, the single curve explains the variation in the data. 
Between the experiments, one regression line was predicted to explain survival towards irradiation at 37 ˚C. 
Clonogenic survival curves for the individual cell lines can be found in Supplemental Figure 1. 
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Figure 2. The BRCA2 protein is degraded at temperatures higher than 40 ˚C.
Cells from four different lines BLM (circle), HeLa (square), FaDu (triangle), VH10-SV40 (inverted triangle) were 
submitted to hyperthermia and subsequently lysed in six separate experiments; one for each temperature. 
A) BRCA2-signals of all separate samples on cropped immunoblots. PARP-1 is used as a loading control. 
B) Quantification of BRCA2-protein signals from A). Each hyperthermia-treated sample is represented as a 
percentage of the BRCA2 signal at 37 ˚ C. The error bars denote mean ± SEM. The statistical differences relative 
to 37 ˚C were determined by ANOVA and followed by Tukey’s Multiple Comparison Test. C) Quantification 
of BRCA2 after 60 minutes of a given temperature. Statistical differences were determined by ANOVA and 
followed by Tukey’s Multiple Comparison test.
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of hyperthermia with new classes of indirect 
double-strand break inducing agents, like 
PARP-inhibitors12,13. 
Before exploiting hyperthermia-mediated 
attenuation of HR in a clinical setting, it is 
important to understand the dynamics 
of BRCA2 degradation and HR-efficiency 
upon exposures to different temperatures 
and treatment lengths, or, thermal doses. 
By using a set of in vitro experiments, we 
systematically investigated the effects of 
various thermal doses (ranging from 40-44 
°C for up to four hours) on HR-parameters 
such as BRCA2 degradation and RAD51 
focus formation, and we examined the extent 
of cellular sensitization towards radiation. 
Our findings provide insight into threshold 
and saturation levels of BRCA2 degradation 
upon heat treatment and thereby give insight 
into the relation between thermal dose and 
HR-efficiency. 
Results
Thermal dose is a determinant for 
radiosensitisation
To investigate the influence of thermal dose 
on HR, we first established the thermal 
doses to be used in this study (Table 1). 
Because we are interested in the influence 
of thermal doses currently achieved and 
aimed for in a clinical setting, we selected 
them based on temperatures in the range 
of 40-44 °C, and on the current duration of 
60 minutes. Additional lengths of treatment 
were chosen to determine an optimum dose 
for HR-inhibition.
To provide a framework for the assays in 
which we will determine inhibition of HR 
by hyperthermia, we established the ability 
of these selected thermal doses to kill cells 
directly, and determined their capability to 
sensitize cells to irradiation. To get a general 
overview of the biological principles that 
guide inhibition of HR by hyperthermia, 
we combined the results of four different 
cell lines. We started by establishing colony 
survival curves of three different cell lines 
that represent various cancer types that are 
treated with hyperthermia: BLM (melanoma), 
HeLa (cervix) and FaDu (head and neck), 
and a cell line that represents a p53-negative 
tumor: simian virus 40-immortalized 
fibroblasts (VH10-SV40). We treated the 
cells with the selected thermal doses and 
with doses of radiation ranging from 0 – 6 
Gy. Consistent with previous studies14–16, 
the colony plating efficiency for each cell 
line was reduced after treatment with 
temperatures higher than 40 °C (Figure 
1A), demonstrating hyperthermia’s ability to 
kill cells directly. 
To closely examine radiosensitisation by 
hyperthermia, we normalized each colony 
survival curve belonging to a certain thermal 
dose for plating efficiency at 0 Gy to 100% 
(Supplemental Figure 1). We then 
combined the data points from all four cell 
lines, and fitted a linear-quadratic curve to 
the pooled data (Figure 1B)17. This analysis 
resulted in an overview of the response 
to heat and irradiation in the employed 
cell lines: hyperthermia at 40 °C failed to 
increase sensitivity to irradiation, indicated 
by the prediction of one curve to explain 
the data variation17. For all thermal doses 
employing temperatures higher than 41 °C 
multiple curves were obtained, indicating 
these thermal doses sensitized the tumor 
cells to irradiation. The maximum extent 
of radiosensitisation at 41 °C was reached 
after two hours of treatment, while the same 
effect was already reached after one hour 
at 42 °C.  Doubling the treatment times did 
not increase radiosensitisation any further, 
indicating a saturation of the effects of heat 
over time. The time-dependent saturation 
was not observed when cells were treated 
with 43 °C, 43.5 °C or 44 °C (Figure 1B). 
Temperatures higher than 40 °C cause 
significant degradation of functional BRCA2 
proteins
Hyperthermia at 42.5 °C inhibits HR 
by inducing proteasomal degradation of 
the BRCA2 protein9. To study the effects 
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of thermal dose on HR, we started by 
examining the ability of the selected thermal 
doses to induce degradation of the BRCA2 
protein, by measuring the BRCA2-protein 
levels in whole cell extracts from the four 
cell lines treated with the thermal doses by 
immunoblot (Figure 2A). We quantified 
the BRCA2-signals on the immunoblot and 
normalized these to the signal at 37 °C 
(Figure 2B). Although each thermal dose 
had an effect on BRCA2 protein level, the 
extent of the effect was quite different. For 
the four cell lines tested, the lowest mean 
BRCA2 protein level (22%) was reached 
after 60 minutes treatment at 43 °C, while as 
much as 64% of the BRCA2 signal remained 
after four hours of treatment at 40 °C 
(Figure 2B). This indicates that BRCA2 
degradation is dependent on the applied 
thermal dose, and presumably, that treatment 
at 40 °C might be insufficient to achieve a 
significant reduction in BRCA2 protein levels 
and thereby in HR. Upon examination of the 
BRCA2 protein levels after treatment for 60 
minutes at the different temperatures, we 
noticed the most significant decrease in the 
level between 41 °C and 42 °C (Figure 2C). 
Interestingly, when temperatures surpassed 
42 °C, the degradation of BRCA2 observed 
in the whole cell lysates seemed similar 
or even less efficient than at 42 °C itself, 
which is especially pronounced in FaDu cells 
(Figure 2C).  
We therefore investigated whether the 
BRCA2-signal in the whole cell extract at 
temperatures exceeding 43 °C represents a 
functional pool of the BRCA2 protein. Since 
degradation of BRCA2 is mediated by the 
proteasome, a heat-mediated malfunction 
of proteasomes could lead to a failure to 
detect declining BRCA2-signals in a whole 
cell extract. When the proteasome inhibitor 
MG132 is added to cells previous to 
hyperthermia treatment, the BRCA2-protein 
levels are rescued in a whole cell extract9. 
However, when the cell lysates from cells 
treated with MG132 and hyperthermia are 
fractionated, the entire fraction of protected 
BRCA2 is found in the pellet instead of in 
the supernatant, indicating that the heat 
caused the protein to become insoluble 
(Figure 3A). To investigate what happens 
with the BRCA2-proteins found at 44 °C, 
we performed the same simple fractionation 
of HeLa cells treated with the thermal doses 
employing temperatures of 42 °C and 44 °C 
(Figure 3B and C). 
The reduction of the BRCA2 signal in the 
whole cell extract in this experiment was 
clearly visible when the cells were treated 
with 42 °C and 44 °C (Figure 3B). However, 
cells treated for 60 minutes at 42 °C seemed 
to have lower BRCA2-levels than cells 
treated for 60 minutes at 44 °C, confirming 
our results from Figure 2C. Strikingly, the 
localization of BRCA2 in the extracts was 
very different: we found that the BRCA2 
levels in the supernatant were lower at 44 
°C than at 42 °C, indicating that the higher 
temperature is a stronger inducer of BRCA2-
degradation (Figure 3C and D). In contrast 
to the supernatant, the BRCA2 protein 
detected in the pellet increased over time 
when temperature was set from 37 to 44 °C, 
while it decreased over time when cells were 
treated with 42 °C (Figure 3C). This finding 
indicates that although the BRCA2 protein 
is still present in the whole cell extract at 
the higher temperatures, it represents a pool 
of protein that has aggregated in a fraction 
that ends up in the pellet, and is therefore 
unlikely to be functional.
Localization of RAD51 in cells is differentially 
affected by thermal dose
Because we found different levels of 
BRCA2 protein in response to different 
thermal doses, and found that temperatures 
exceeding 43 °C did not completely 
eradicate BRCA2 protein levels in the whole 
cell extract (Figure 3), we investigated the 
presence of RAD51 foci upon treatment 
with the different thermal doses. These foci 
represent the localization of the RAD51-
protein onto DNA double strand breaks 
and are a read-out for effectivity of HR, 
in particular for the functionality of the 
BRCA2-protein18. Correlating to BRCA2-
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degradation upon hyperthermia treatment 
(41-42 °C), RAD51 fails to localize onto 
double strand breaks in cells treated at these 
temperatures9. To investigate the appearance 
and behavior of RAD51 foci upon treatment 
with the various thermal doses, we treated 
HeLa cells with these doses, irradiated 
them with 4 Gy, and fixed them either 30, 
60 or 120 minutes after the irradiation. HR 
requires a copy of the damaged DNA, usually 
the sister chromatid, and is therefore limited 
to the S- and G2-phase of the cell cycle11. 
Therefore, to confirm the cells’ ability to 
form RAD51 foci, we used a positive signal 
for incorporated EdU as a prerequisite for 
cells to be analyzed.
Upon examining the RAD51 signal in the 
EdU-positive cells, we found three very 
distinguished foci-patterns, which we refer 
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Figure 3. BRCA2 moves to an insoluble fraction after treatment with MG132 or 44 ˚C.
A) BRCA2 protein levels at 37 ˚C and 42 ˚C in HeLa cells treated with or without 50 µM MG132 on cropped 
immunoblots. Signals shown are from the whole cell extract (left), and from two fractions after centrifugation: 
the supernatant (middle) and in the pellet fraction (right). HSP90 is used as a loading control. B) BRCA2 protein 
levels on cropped immunoblots at 42 ˚C (upper panel) and 44 ˚C (lower panel) in HeLa cells in the whole 
cell extract (left), and from the two fractions after centrifugation: the supernatant (middle) and in the pellet 
fraction (right). HSP90 is shown as a loading control. C) Quantification of BRCA2 signals in B), corrected for the 
37 ˚C control. A linear-quadratic regression indicates three separate curves for each series of measurements, 
indicating a significant difference in BRCA2-protein levels in the whole cell extract, supernatant and pellet. The 
error bars denote mean ± SEM obtained in three experiments D) Bars zoom in on the 60-minute treatment 
point in C). Statistical differences of column pairs were determined using a student’s t-test. 
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to as Category 1-3 foci. Cells in Category 1 
presented with many large foci, or “normal”, 
based on our extensive experience19–21. Cells 
with the Category 2 focus pattern displayed 
fewer, but quite large foci. The Category 3 
focus pattern was represented by cells with 
many, but mostly very small foci (Figure 
4A). To objectively describe these focus 
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Figure 4. RAD51 foci behave differently depending on the thermal dose. 
A) Representative pictures of RAD51-staining pattern upon 4 Gy irradiation in EdU-positive nuclei of HeLa 
cells. The RAD51 pattern shown in picture 1 is characterized as ‘normal’. In picture 2 only few foci can be seen, 
and in picture 3, many, but mostly very small foci can be distinguished. B) 2D-representation of measured 
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the Y-axis the mean integrated density per focus. Thermal doses are indicated with the different colors. A shift 
of the dot-cloud represents a different appearance or, qualification of the RAD51 focus. C) Representative 
pictures of RAD51-staining pattern in EdU-positive nuclei in unirradiated cells.
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structures, we designed an image analysis 
tool that measures several aspects of RAD51 
foci in a cell nucleus: the number of foci, 
their average area and their average intensity 
(Supplementary Figure 2). Since both 
area and intensity can be used to classify 
the response of the foci to temperature, we 
combined them by multiplication, resulting in 
the mean integrated density per focus per 
nucleus. We plotted the integrated density 
and the number of RAD51 foci per cell in a 2D 
histogram (Figure 4B). While there is little 
to no difference between cells that received 
heat treatment at 40 °C or treatment at 
37 °C, cells treated with hyperthermia at 
the higher temperatures (indicated by the 
cloud of red points), shifted away from the 
cells treated at 37 °C (cloud of blue points) 
(Figure 4B). Compared to cells that were 
treated at 37 °C, cells that were treated with 
41 °C, 42 °C, or, up to 15 minutes with 43 °C 
or 43.5 °C had mostly fewer foci (Category 
2) (Figure 4B). However, cells treated with 
44 °C or with more than 15 minutes at 43 
or 43.5 °C had foci that were smaller in size 
and intensity (Category 3) (Figure 4B). 
Upon examination of the Category 
3-type foci, we noticed that they also 
were present in cells that had not been 
irradiated (Figure 4C), indicating that they 
form spontaneously upon heat treatment. 
The Category 3 RAD51 foci have been 
described earlier as a representation of 
stalled replication forks, which are able to 
form independently of functional BRCA2 
protein22. These structures might therefore 
be additional proof for the hypothesis that 
hyperthermia with temperatures exceeding 
43 °C causes problems in the S-phase of 
the cells16. Concordantly, we found that cells 
with Category 3 foci had a less intense EdU-
signal compared to cells that had normal 
foci (Category 1) or less foci (Category 
2) (Supplemental Figure 2E). The EdU-
signal did recover two hours after stopping 
hyperthermia treatment, hinting that the 
problems in S-phase could be reversible over 
time. This combined evidence suggests that 
the disappearance of the Category 1 RAD51 
foci after treatment with temperatures 
higher than 40 °C indicates inhibited HR, and 
that the Category 3 foci represent another 
effect of hyperthermia. 
Discussion
The elucidation of the mechanisms of 
the biological processes responsible for 
the sensitizing effect of heat towards 
radiotherapy and various chemotherapies 
is an active field of research. Among these 
processes DNA repair pathways are 
attractive targets of hyperthermia because 
their activity modulates the cytotoxicity 
of DNA breaks in tumor cells, on which 
the efficacy of radiation and chemotherapy 
is based23. Although many DNA repair 
pathways are thought to be affected by heat, 
one pathway is of specific interest in this 
context: HR. This is because the discovery 
that hyperthermia can be used to locally and 
on demand inhibit the activity of the HR 
DNA repair pathway opens up avenues to 
novel combination therapies; specifically the 
combination of hyperthermia with PARP-
inhibitors. PARP-inhibitors selective kill HR-
deficient cells and are currently clinically 
applied for patient with HR-defective 
tumors due to genetic BRCA deficiency24–26. 
Inhibition of HR by hyperthermia carries 
the promise that PARP-inhibitors can be 
successfully used in much broader patient 
populations, as it will temporarily inactive 
HR, irrespective of the patient’s genetic 
make-up9,12. 
In this study, we systematically explored the 
influence of various thermal doses on HR 
by a set of in vitro experiments. We used 
two parameters of HR-effectivity: BRCA2 
protein levels and RAD51 focus formation 
upon irradiation, and established survival 
curves at the same thermal doses to relate 
HR parameters to a functional outcome 
(Supplemental Table 1). Based on the 
obtained data employing the thermal doses, 
we can describe three distinct responses of 
HR towards hyperthermia. 
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The first response is a presumed failure to 
effectively attenuate HR. Cells heated at 
40 °C have more than 60% of the BRCA2 
protein relative to the non-heated cells, 
and the formation of RAD51 foci is barely 
affected by this temperature. This correlates 
with the finding that hyperthermia at 40 °C 
does not significantly increase the sensitivity 
of the cells to irradiation. With respect to 
the survival results, it should be noted 
that the average treatment temperatures 
currently reached in the clinic, ranging 
between 40 and 41 °C, does strongly 
enhance treatment outcome27–32. This could 
be explained by two reasons, the first being 
that the cells in culture are treated with 
hyperthermia and radiotherapy only once, 
thus even small, non-significant differences 
in our colony survival assay could result in 
larger, significant effects when treatment is 
repeated multiple times, as is the case in 
the clinic. The second explanation is that 
hyperthermia has multiple biological effects, 
including increased blood flow33, increased 
oxidation34, and activation of the immune 
system35, which are obviously not taken 
into account in our in vitro experimental 
set-up, but might very well mediate the 
treatment outcome in patients treated with 
hyperthermia at lower temperatures5–8. 
The second response group is characterized 
by an attenuation of HR, and presents itself 
when cells are treated with 41 °C, 42 °C or 
with 15 or 30 minutes at 43 °C. At 41 °C, 
60% of the baseline BRCA2 levels remain 
after 60 minutes of treatment, and continue 
to drop with longer treatment times, as 
do the number and integrated density of 
RAD51 foci. Moreover, cells are sensitized 
to irradiation when they are treated for 
60 minutes at 41 °C, and this effect can be 
exaggerated when cells are treated for two 
hours. However, an additional two hours 
results only in a small decrease in survival, 
indicating a saturation of the hyperthermia-
mediated effects on the cells. The effects 
of heat on cell survival and on HR in cells 
treated with hyperthermia at 42 °C, or for 
15-30 minutes at 43 °C are similar to those 
in cells treated with 41 °C, but more rapid.
The last group within the set of thermal doses 
employed here encompasses the reaction of 
cells that are subjected to 60 minutes at 43 
°C, or temperatures higher than 43 °C. These 
thermal doses seem to not only induce 
HR-deficiency, but affect the cells in many 
more ways36. For example, consistent with 
previous studies, we find that heat’s ability to 
directly kill cells and sensitize to irradiation 
is increased, and keeps doing so with longer 
treatment length14,15. In contrast, BRCA2 
protein levels in the whole cell extract cease 
to decrease over time after the initial drop. 
However, similar to when cells are treated 
with a proteasome inhibitor, treatment with 
hyperthermia at 44 °C causes BRCA2 to 
accumulate in a pellet fraction, while the 
amount of BRCA2 in the supernatant cell 
fraction keeps decreasing over time. This 
could be explained by possible defects in 
the functionality of the proteasome, which 
interferes with the molecular removal of 
unfolding BRCA2 proteins37. Consistent with 
this reaction, RAD51 focus morphology, the 
read-out used to determine functionality 
of BRCA2, alters greatly in this last group. 
We show that foci become much smaller in 
size and somewhat less in intensity and that 
they appear independently of irradiation, 
indicating they form spontaneously upon 
heat. These structures resemble RAD51 
foci described before to form independent 
of the BRCA2 protein, and could be 
stalled replication forks22. The possibility 
that hyperthermia > 43 °C directly affects 
progression in S-phase has previously been 
described, and is supported by the low 
intensity of the EdU-signal in cells treated 
in our assays, which is indicative of a lack 
in DNA synthesis16. All these findings prove 
that many more biological mechanisms than 
HR are affected by temperatures surpassing 
43 °C and that these mechanisms result in a 
lower specificity of the heat treatment.
Concluding, our study demonstrates that 
if hyperthermia treatment is aimed at 
optimally inhibiting HR, the temperature 
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which should be strived for is 42 °C. The 
minimal thermal dose to achieve defects in 
this DNA repair pathway is 41 °C for one 
hour, but it is not necessary to surpass 30 
minutes at 43 °C. Taking into consideration 
that in current hyperthermia treatments 
temperatures higher than 43 °C are rarely 
reached in the patient31, our findings can be 
regarded as reassuring of the current clinical 
guidelines and possibilities, but can be used 
to guide technological development of next 
generation hyperthermia systems. Moreover, 
it demonstrates that BRCA2 degradation 
and RAD51 focus formation could both 
be potential biomarkers for efficiency of 
hyperthermia treatment. However, the 
acquired data will be of particular interest as 
a guideline for potential clinical application 
of anti-cancer strategies that exploit the 
heat-mediated attenuation of HR, such as 
PARP-inhibitors24,25 or proton therapy38,39, 
will be combined with hyperthermia in a 
clinical setting8,12. 
Material and methods
Experimental set-up, hyperthermia and 
irradiation
We studied the effects of hyperthermia on 
HR by exposing cells in 60 mm petri dishes 
to increased temperatures ranging from 
40-44 °C in an incubator with a controlled 
atmosphere (5% CO2 and 20% O2) set at 
the appropriate temperature. Indicated 
treatment times always exclude the 15 
minutes required for the medium to reach 
the set temperature. The control samples 
were treated at 37 °C. The cells were exposed 
to γ-irradiation from a caesium-137 source 
with a dose rate of 0.64 Gy/min within 15 
minutes after hyperthermia treatment.
Cell culture
The following four human cell lines were 
used: BLM, HeLa, FaDu and VH10-SV40. All 
cell lines were cultured in a 1:1 mixture of 
DMEM (4.5 g/L Glucose, with Ultraglutamine 
1) and Ham’s F-10 (BioWhittaker™), 
supplemented with 10% fetal calf serum and 
1% penicillin/streptomycin (Sigma-Aldrich), 
and were maintained in an incubator set at 37 
°C and with an atmosphere of 5% CO2 and 
20% O2. Frozen aliquots from same passages 
were used to minimize experimental 
variation. The cells were mycoplasma-free 
and distinguished by morphology.
Clonogenic assays
Cells were allowed to recover from freezing 
by being cultured for six days: after thawing 
on day one, the cells were split on day 2 and 
were allowed to grow exponentially. Finally 
on day 5, 24 hours prior to seeding the 
clonogenic assay, 2*106 BLM or Hela cells 
and 3*106 FaDu or VH10-SV40 were seeded 
in 10 cm dishes. At the end of the sixth day, 
cells were trypsinized, counted with a coulter 
counter and seeded in triplicates at different 
concentrations in 60 mm dishes; for the 
control irradiation (0 Gy), 200 BLM or HeLa 
cells were seeded, or 300 for either FaDu or 
VH10-SV40. The amount of seeded cells was 
doubled for each 2 Gy increase in irradiation 
dose. The cells were allowed to attach 
overnight (~14 h) and were treated with the 
different thermal doses and irradiation the 
next morning. Cell colonies were allowed to 
form for 10 days (HeLa and BLM) or 20 days 
(FaDu and VH10-SV40), after which they 
were fixed and stained in 45% methanol, 45% 
dH2O, 10% Acetic acid and 0.25% Coomassie 
Brilliant Blue (Sigma-Aldrich). Colonies 
containing more than 30 cells were counted 
using a stereomicroscope. 
Cell lysis and protein assay
The day before the experiment, 0.8*106 (BLM 
and Hela) or 1.2*106 (FaDu and VH10-SV40) 
cells were seeded in a 60 mm dish. All cell 
lysates were made within 30 minutes after 
hyperthermia treatment, and were in the 
incubator together with the cells used for 
clonogenic survival or immunofluorescence 
analysis. After washing with PBS, the cells 
were scraped and then lysed in Laemmli 
sample buffer (2% SDS, 10% Glycerol and 60 
mM Tris pH 6.8) and heated at 95 °C for 5 
minutes. The sample was passed through a 
syringe several times to reduce viscosity. 
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For fractionation experiments, cells in 
15 cm dishes were treated with MG132 
(Calbiochem) one hour before the start 
of hyperthermia, or without MG132 at 
the indicated temperatures. Immediately 
following treatment, the cells were lysed in 
NETT buffer (50 mM Tris-HCl pH7.5, 100 
mM NaCl, 5mM EDTA 0.5% Triton-X-100, 1x 
protease inhibitors (Complete, Roche®) and 
1 mM pefabloc). After 30 minutes, the cells 
were scraped and centrifuged at 12000 rpm 
for 15 minutes at 4 °C. After centrifugation, 
the pellet and supernatant were separated 
and the pellet was resuspended in PBS. 
Laemmli buffer was added to both samples 
and the mixture was boiled at 95 °C for 5 
minutes. Before immunoblotting, the protein 
concentration was estimated using the Lowry 
protein assay40, after which protein samples 
were prepared by adding loading buffer (final 
concentration: 0.01% bromophenol blue and 
0.5% β-mercaptoethanol). 
Immunoblotting
The samples were run on an SDS-PAGE gel 
or a 3-8% Tris-Act gel (Novex, ThermoFisher 
Scientific). Protein transfer on a PVDF 
membrane was achieved by wet blotting at 
300 mA for two hours at 4 °C, using transfer 
buffer (0.4 M Glycine, 5 mM Tris, 20% 
Methanol). After transfer, the membrane 
was blocked in 3% dry skimmed milk in PBS 
with 0.05% Tween-20. The primary antibody 
was incubated overnight at 4 °C and the 
secondary antibody was incubated for 1-2 
hours at room temperature. After adding 
ECL substrate (1:1 mixture of A: 0.1M 
Tris-HCl pH 8.5, 2.5 mM Luminol, 0.4 mM 
p-Coumaric acid and B: 0.1 M Tris-HCl pH 
8.5, 0.02% hydrogen peroxide), blots were 
imaged in Alliance 4.7 (Uvitec Cambridge). 
The antibody signals from the immunoblots 
were quantified using the ‘Analyze Gels’ 
tool in FIJI (Image J1.50i41). Equal protein 
loading was always checked by staining the 
post-transfer gel with Colloidal Coomassie 
(0.008% Coomassie Brilliant Blue G-250 
and 0.35% glacial HCl in distilled water) by 
heating for ~25s, shaking for 30 minutes, and 
subsequent destaining using distilled water.
EdU incorporation and cell fixation
One day prior to the experiment, 0.4*106 
Hela cells were seeded in a coverslip-
containing 30 mm dish. The cells were 
fixed after hyperthermia treatment and 
irradiation. To distinguish S-phase cells, 10 μM 
EdU (Invitrogen) was added to the cells 45 
minutes prior to fixation. After the indicated 
time after irradiation, the cells were rinsed 
with PBS and subsequently incubated for 1 
minute in a pre-extraction buffer containing 
Triton-X-100 (0.5% Triton-X-100; 20 mM 
HEPES-KOH, pH 7.9; 50 mM NaCl; 3 mM 
MgCl2 and 300 mM sucrose)
42. After rinsing 
with PBS, the cells were fixed by incubating 
them for 15 minutes in 4% paraformaldehyde 
in PBS, followed by another wash in PBS.
Immunofluorescence
EdU was detected with the use of a Click-IT® 
reaction. First the cells were permeabilized 
with 0.5% Triton-X-100 for 30 minutes, then 
they were washed twice with 3% BSA in 
PBS. Next, the cells were incubated for 45 
minutes at room temperature in a cocktail 
containing a final dilution of 43 mM Tris-HCl 
pH 7.5, 1.6 mM CuSO4· 5H2O, 25 μM ATTO 
390 Azide (ATTO-TEC GmbH) and 1 mM 
Ascorbic Acid. Before labelling RAD51, the 
cells were washed once more with 3% BSA 
and continued by a wash step (three times 
a short wash and two times 10 minutes 
incubation with PBS 0.1% Triton-X-100), 
followed by 30 minutes blocking in PBS+ 
(0.5% BSA and 0.15% Glycine in PBS), 
overnight incubation at 4 °C with the 
first antibody in PBS+, another wash step, 
incubation with secondary antibody for two 
hours at room temperature. After another 
wash step and a short wash in PBS only, 
the samples were embedded in Vectashield 
(Vector Laboratories) and sealed with nail 
polish.
Antibodies
For immunoblotting, the following antibodies 
and dilutions were used: mouse anti-BRCA2 
(1:1000, OP95, Ab-1, Merck Millipore), 
mouse anti-PARP-1 (1:5000, C2-10, Enzo 
Lifesciences), mouse anti-HSP90 (1:1000, 
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AC88, Abcam) and HRP-conjugated Sheep 
anti-mouse IgG (H+L) (1:2000, Jackson 
ImmunoResearch). For immunofluorescence 
rabbit anti-RAD51 (1:10000, 43) and an Alexa 
Fluor® 594 goat anti-mouse (1:1000) were 
used.
Image acquisition and foci counting
The images were obtained with a Leica TCS 
SP5 confocal microscope, using the 63x oil 
immersion (n.a. 1.4) objective with an image 
size of 1024 x 1024 pixels and 82 x 82 μm. Per 
coverslip, at least four areas that contained 
EdU-positive cells were imaged in Z-stacks 
with 14 slices and an increment of 1 μm. 
Before image analysis, maximum projections 
were made using FIJI image analysis software 
(Image J1.50i41). For quantification of foci a 
homemade image analysis macro within FIJI 
was used. In short, regions of interest (ROIs) 
in the EdU-channel were selected, and 
within these ROIs a threshold was set for 
RAD51 positive spots using the MaxEntropy 
algorithm. The ‘Analyze Particles’ function 
was used to count particles with a minimum 
size of 0.05 nm and a maximum size of 5 nm. 
Statistics
All graphs and statistical analyses were 
generated in GraphPad Prism 6.0. Statistical 
tests for each experiment can be found in 
the figure legends.
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Temper-
ature
Duration 
of treat-
ment CEM43a
Cell 
survival 
at 0 Gyb
Relative 
survival 
fraction 
at 4 Gyc
Relative 
BRCA2 
protein 
leveld
Relative 
RAD51 
foci 
numbere
Relative 
RAD51 
integra-
ted 
densityf
40 °C 60 min 8 min 104% 40% 76% 81% 87%
120 min 15 min 93% 37% 70% 86% 98%
240 min 30 min 95% 37% 64% 54% 83%
41 °C 60 min 15 min 87% 33% 60% 66% 72%
120 min 30 min 88% 34% 41% 62% 66%
240 min 60 min 73% 28% 34% 71% 79%
42 °C 30 min 15 min 114% 39% 44% 56% 67%
60 min 30 min 91% 32% 29% 49% 66%
120 min 60 min 68% 25% 29% 37% 60%
43 °C 15 min 15 min 92% 39% 44% 39% 55%
30 min 30 min 97% 41% 30% 9% 44%
60 min 60 min 74% 32% 22% 109% 49%
43.5 °C 15 min 21 min 99% 38% 50% 24% 50%
30 min 42 min 78% 29% 36% 61% 45%
60 min 85 min 65% 26% 33% 116% 52%
44 °C 15 min 30 min 94% 42% 60% 49% 45%
30 min 60 min 86% 37% 53% 76% 45%
60 min 120 min 49% 22% 36% 61% 46%
Supplemental Table 1. Summary of all measured outcomes.
a CEM43: Cumulative Equivalent Minutes at 43 °C, a dosimetric unit which is commonly used to convert time-
temperature doses into a single equivalent dose at 43 °C; in this case calculated based on radiosensitisation 
parameters (R = 2 for temperatures higher than 43 °C; R = 0.5 for temperatures lower than 43 °C) 14,44
b Mean percentage cell survival after hyperthermia alone, normalized to treatment at 37 °C. Full survival curves 
are presented in Figure 1A.
c Mean percentage cell survival after 4 Gy irradiation, normalized to unirradiated cells. Full survival curves are 
presented in Figure 1B.
d Mean percentage of BRCA2-protein levels in whole cell lysates. Full data are presented in Figure 2B.
e Mean percentage of remaining RAD51 foci one hour following 4 Gy irradiation and hyperthermia, relative to 
the number of foci at 37 °C. Full data are presented in Figure 4C and Supplemental Figure 2A.
f Mean percentage of integrated density of RAD51 foci one hour following 4 Gy irradiation and hyperthermia, 
relative to the number of foci at 37 °C. Full data are presented in Figure 4C and Supplemental Figure 2B.
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Supplemental figure 1. Colony cell survival at different thermal doses.
Colony survival curves of four cell lines (BLM, HeLa, FaDu and VH10-SV40) submitted to hyperthermia and 
irradiated afterwards in six independent experiments; one for each temperature. The points and bars represent 
mean ± SEM of triplicate measurements.
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Supplemental figure 2. Quantification of RAD51 foci upon heat.
Each dot in the graphs represents an EdU-positive cell that was submitted to hyperthermia and irradiated with 
4 Gy directly afterwards, either fixed 30, 60 or 120 minutes after irradiation (X-axis) and stained for EdU and 
RAD51. The bars represent mean ± SEM for each thermal dose and fixation time. Several qualities of RAD51 
foci and cells were measured: A) Number of foci per cell, B) Mean integrated density per cell, C) Mean focus 
area per cell, and D) Mean focus intensity per cell. The statistical differences, indicated by asterisks, were 
determined by ANOVA followed by Tukey’s Multiple Comparison Test. 
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Supplemental figure 2. Quantification of RAD51 foci upon heat, continued.
E) EdU intensity per cell. Statistical differences are not given, some samples had a less intense EdU staining 
due to experimental variation and artefacts. However, the low EdU intensity at 43, 43.5 and 44 °C can be 
attributed to effects of hyperthermia, since they are consistent with each other. F) Protein samples made 
from cells that were incubated at the different thermal doses simultaneously with the cells stained for RAD51. 
Immunoblot is a cropped representation of probing for BRCA2 and for PARP-1 as a loading control and confirms 
the effectiveness of BRCA2 degradation by heat. 
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Introduction
A majority of cancer patients (~50%) is 
treated with radiotherapy, either to cure 
the cancer or relief patients from symptoms 
caused by it1. Radiotherapy is available to 
treat many different tumour types, which, 
together with its effectivity, explains why it 
remains one of the main treatments used 
in oncology to date. During the treatment, 
high-energy particles are delivered to 
the tumour by methods that ensure the 
maximum radiation dose is given to the 
tumour, while the dose in the surrounding 
tissue is minimised2. Minimising the dose 
in normal tissue is necessary because the 
emitted particles induce damage in biological 
molecules of all irradiated cells, of which 
damage to the DNA is particularly harmful3. 
The DNA lesions cause cells to arrest and, 
when enough damage has been inflicted, to 
die4. However, cells have biological means to 
cope with DNA damage: the DNA damage 
response (DDR)4,5. The DDR protects cells 
from the effects of radiotherapy by arresting 
the cells and meanwhile repairing DNA. 
DNA repair is beneficial in the case of 
normal cells, but counteracts radiotherapy’s 
effectivity in cancer cells and it is therefore 
that treatments that inhibit DNA repair 
pathways in the tumour are of great interest 
to enhance the anti-cancer effectivity of 
radiotherapy6. 
A currently available and potent method 
that sensitizes tumours to radiotherapy is 
hyperthermia7, a treatment during which 
the tumour temperature is increased to 
reach 40-43 °C for one hour8. Similar to 
radiotherapy, hyperthermia treatment aims 
to reach the maximum temperature in the 
tumour and to spare surrounding tissues 
from toxic doses8,9. Hyperthermia is known 
to maximally sensitise to radiotherapy when 
both modalities are given simultaneously10,11, 
but the complexity of application of both 
hyperthermia and radiotherapy imposes a 
limitation: there is no equipment available 
to treat humans with both treatment 
methods at the same time. Therefore, 
a recurrent uncertainty in fractionating 
hyperthermia treatment is how to schedule 
both treatments relative to each other12. 
Currently, most patients are first treated 
with radiation therapy, which is followed by 
treatment with hyperthermia either once or 
Abstract
Background and Purpose: Hyperthermia is a potent method to increase radiation effectivity. 
A recurrent uncertainty in clinical use of hyperthermia is how to schedule both treatments 
relative to each other. The current schedule, hyperthermia following radiotherapy, is based 
on several biological effects of hyperthermia and on clinical trial results. Here we re-evaluate 
hyperthermia scheduling in the context of a new addition to the plethora of biological effects 
of hyperthermia: inhibition of DNA repair via homologous recombination (HR).
Material and methods: We assessed HR parameters RAD51 focal accumulation and BRCA2 
levels as well as cell survival of HeLa-cells treated with or without hyperthermia (45 minutes, 
42 °C) up to five hours before or after irradiation.
Results: Hyperthermia before radiotherapy only inhibited RAD51 focus formation when applied 
within a two-hour time frame. Hyperthermia applied after radiotherapy affected RAD51 
foci either at its formation stage or its assembly stage depending on the time between the 
treatments.
Conclusions: A short time-interval between radiotherapy and hyperthermia is most effective. 
However, because hyperthermia can disrupt HR at multiple stages after irradiation, application 
of hyperthermia after irradiation is the most flexible strategy to achieve optimal results.
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twice per week. This current fractionation 
of hyperthermia is based on biological 
processes that were found to contribute to 
the radiosensitising effects of hyperthermia 
in the 1970s, and has proven to be effective 
in several clinical trials7,10. 
In the 1970s and 1980s, hyperthermia 
treatment temperatures aimed for exceeded 
42 °C, as these temperatures cause direct 
cell death as a consequence of severe protein 
denaturation. However, with the currently 
available equipment, such temperatures 
are difficult to achieve in large parts of 
the tumour due to perfusion in the human 
body13,14. Despite these lagging temperatures, 
clinical evidence of efficacy has clearly been 
demonstrated8. One explanation that could 
account for radiosensitisation at lower 
temperatures could be hyperthermia-
mediated inhibition of DNA repair15,16. 
Although the knowledge of hyperthermia-
mediated inhibition of DNA repair is 
increasing, it has hardly been studied on the 
molecular level in the context of scheduling 
hyperthermia and radiotherapy, while such 
knowledge is essential before changes in 
scheduling can be contemplated12. 
One specific DNA repair protein which 
is actively degraded by hyperthermia is 
BRCA215. BRCA2 is an essential protein for 
homologous recombination (HR)17, one of 
the DNA repair pathways that copes with 
the most toxic lesions that can arise upon 
irradiation: DNA double strand breaks3,4,18. 
During HR, a copy of the broken DNA is 
used as a template for accurate repair of the 
break. The protein which is most important 
for the central step of strand invasion is 
the RAD51 recombinase, which localizes to 
breaks with help of its mediator BRCA217. 
By degrading BRCA2, hyperthermia prevents 
accumulation of RAD51 at sites of DNA 
damage, known as RAD51 foci, and ultimately 
inhibits HR15. Because the attenuation of HR 
caused by hyperthermia is temporary, the 
timing between irradiation and hyperthermia 
is likely to be very relevant for the degree 
of tumour radiosensitisation. Therefore, 
it is important to re-evaluate the current 
scheduling of hyperthermia within the newly 
revealed biological context of inhibited 
HR. In this article, we aim to understand 
the dynamics of hyperthermia’s inhibitory 
effects on HR when it is given at different 
time points relative to radiotherapy, using a 
quantitation of the amount of RAD51-foci as 
a measure for HR-effectivity in HeLa cells. 
Finally, we present or results in the context 
of the current basis for clinical scheduling of 
hyperthermia.
Results
Hyperthermia inhibits formation of RAD51 foci 
and disrupts existing RAD51 foci
In order to evaluate hyperthermia 
fractionation effects on HR, HeLa cells 
were subjected to hyperthermia at various 
intervals relative to irradiation at 4 Gy 
(Figure 1A). We examined the presence of 
RAD51 foci as a measurement of BRCA2 
function and, indirectly, of HR (Figure 1B-
E)15. Because HR only acts in specific phases 
of the cell cycle because it requires a sister 
chromatid, we used a positive EdU-signal to 
limit our analyses to cells in S-phase. Cells 
treated with hyperthermia one hour or 
directly before irradiation had fewer foci 
than cells treated with hyperthermia three 
or five hours before irradiation and cells 
treated without hyperthermia (Figure 1B 
and D). Reduction of BRCA2 protein levels 
is another hallmark of hyperthermia-induced 
HR-deficiency. We therefore analysed 
BRCA2 levels at the moment of cell fixation. 
BRCA2 levels were reduced in samples 
treated with heat shortly before irradiation, 
while they had recovered in cells treated 
with hyperthermia 3 or 5 hours before 
irradiation (Figure 1F). 
Over time, the number of foci changed in 
cells fixed at different time-intervals after 
irradiation, peaking when cells were fixed two 
hours after irradiation (+1 time point), and 
gradually diminishing afterwards (Figure 1C 
and E). Remarkably, hyperthermia reduced 
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the number of RAD51 foci regardless 
of treatment interval after irradiation, 
demonstrating that hyperthermia is able 
to disrupt existing RAD51 accumulations 
(Figure 1C and 1E).
Sensitivity towards hyperthermia is influenced by 
cell cycle distribution
As a functional control for hyperthermia 
effectivity, we set out to analyse survival 
capacity of cells treated with hyperthermia 
before or after irradiation in a colony survival. 
Unexpectedly, we found that hyperthermia 
applied five hours after irradiation was most 
effective in radiosensitising cells (TER: ~4-
fold compared to treatment with 37 °C, 
Figure 2A). The maximum effectivity of 
hyperthermia five hours after irradiation 
is in clear contrast with data presented in 
previous publications10,19, and is therefore 
most likely unique for this cell line. 
Spurned by the marked increase in effectivity 
of hyperthermia given five hours after 
irradiation, we checked BRCA2 levels in 
protein lysates made directly following 
hyperthermia treatment (Figure 2B). In 
absolute terms, the residual BRCA2 level 
after hyperthermia treatment in the +5 
time-point did not differ from other residual 
BRCA2 levels after hyperthermia (Figure 
2B). However, the level relative to the 
unheated control for each time point varied 
between 25% and 63%, and the greatest 
difference between unheated and heated 
(25%) was at the +5 time point (Figure 2B). 
The contrast between absolute and relative 
BRCA2 levels is due to the increase of the 
BRCA2 levels of in the unheated cells over 
time (Figure 2B). These differences were 
not found in the loading control (PARP-1), 
indicating that the rise of BRCA2 protein 
levels is not due to the increase of the 
number of lysed cells. BRCA2 is regulated in 
a manner dependent on cell cycle20,21, so the 
increasing BRCA2 levels over time might be 
caused by an increase in the relative amount 
of S-phase cells over time. We investigated 
this possibility by determining the fraction 
of EdU-positive cells in the samples used for 
analysing RAD51 foci. While we detected 
no large differences in the fraction of EdU-
positive cells in samples that were treated 
with hyperthermia before irradiation, we 
found this fraction increased in samples fixed 
at different time intervals after irradiation 
(Figure 2C). 
The increase in the fraction of S-phase cells in 
the population could be explained by fixation 
at different time-intervals after seeding. 
However, in contrast with this argument, 
we found that the fraction of EdU-positive 
cells in samples treated with hyperthermia 
before irradiation resembled the fractions in 
the +0 and +1 time points, while, timewise, 
they were fixed between the +3 and +5 
hour time point (Figure 2C). Therefore, we 
argue that alterations in the EdU-positive 
fraction in the cell population is a result of 
synchronizing effects of irradiation rather 
than time. Because hyperthermia affects 
cells in S-phase more severely than cells in 
other phases22,23, the increase in the fraction 
of S-phase cells five hours after irradiation 
could very well contribute to the particular 
heat-sensitivity of these cells.
Discussion
Combination strategies that enhance the 
effects of radiation are of great interest in 
oncology24. One example of a well-known 
and safe strategy to sensitise tumours 
to radiotherapy is hyperthermia25. The 
current clinical treatment often comprises 
of multiple fractions of radiotherapy in 
one week, of which one or two fractions 
are followed by hyperthermia. The theory 
about the synergism between radiotherapy 
hyperthermia thus far argues that both 
modalities should be applied simultaneously 
to reach a maximum therapeutic gain10,11,26. 
However, in practice, the equipment is 
not available to combine both modalities 
as such, and therefore current scheduling 
of hyperthermia only partly considers 
biological mechanisms of hyperthermia that 
sensitise cells to radiotherapy. In the current 
57
Timing of hyperthermia
4
-5h -3h -1h -0h Time 
IR
4 Gy
fix
+0h +1h +3h +5h
fixfix fix
10 μm
RAD51
(not linear)
RAD51
fix
A
B
D
F
E
BRCA2
PARP-1
-5h -3h -1h -0h37 °C
110% 97% 52% 65% Mean (n=3)
10 μm
C
42˚C
37˚C100
80
100
80
0
37 ˚C -5 -3 -1 -0 +0 +1 +3 +5
60
40
20
0
60
40
20
n.s.
***
***
*** ***
n.s. ***
***
#R
AD
51
 fo
ci
 p
er
 c
el
l
Hyperthermia treatment ending time
relative to 4 Gy irradiation (hours)
Hyperthermia treatment starting time
relative to 4 Gy irradiation (hours)
#R
AD
51
 fo
ci
 p
er
 c
el
l
Figure 1. Effects of timing of hyperthermia relative to radiotherapy on homologous recombination.
A) Schematic representation of treatment schedule. HeLa-cells were treated with hyperthermia at 42 °C for 45 
minutes (red thermometers), or with a sham treatment (blue thermometers). These sessions were scheduled to 
end either five hours (-5), three hours (-3), one hour (-1) or directly (-0) before irradiation, or to start either directly 
(+0), one hour (+1), three hours (+3) or 5 hours (+5) after irradiation. For the RAD51 assay, samples treated with 
hyperthermia before irradiation were fixed one hour after irradiation, while samples treated with hyperthermia 
after irradiation were fixed directly after hyperthermia. B) and C) Representative images of cells containing RAD51 
foci in samples treated with or without hyperthermia at the in panel A indicated time-intervals before (B) or after 
(C) irradiation. The dotted line indicates the boundaries of an EdU-positive nucleus. D) and E) Quantification of 
the number of RAD51 foci in cells treated with hyperthermia before or after irradiation at the indicated time-
intervals. Every dot represents one EdU-positive cell. The error bars indicate mean ± 95% confidence interval from 
at least 80 cells imaged in three independent experiments. There was significant difference between groups as 
determined by one-way ANOVA (p<0.0001). A Bonferroni post-analysis was performed on the indicated columns, 
and found significant differences (p<0.0001) in the comparisons indicated with ***. F) To assess BRCA2-protein 
levels after hyperthermia-treatment at the time of irradiation, protein samples were made of cells treated with 
hyperthermia at the indicated time-points directly following irradiation. The immunoblot IS representative for three 
independent experiments. PARP-1 is shown as a loading control. The numbers below the blot are a mean of the 
quantified BRCA2 levels relative to the 37 °C control.
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study, we use HeLa cells to explore the 
influence of scheduling hyperthermia relative 
to irradiation on the DNA repair pathway 
homologous recombination (HR) in vitro15. 
We use formation of RAD51 foci and 
BRCA2 protein levels as read-outs for 
HR functionality, and find that both the 
number of RAD51 foci and the BRCA2 
level is lowest when hyperthermia is 
applied within two hours before irradiation 
(Figure 1D and 1F). Irrespective of the 
time-interval passed between irradiation 
and hyperthermia, at least up to five hours, 
hyperthermia application after irradiation 
affected RAD51 foci either at its formation 
stage or its assembly stage (depending on 
the time between the treatments). This 
implies that hyperthermia interrupts HR 
- and thus the repair process of double 
strand breaks inflicted by irradiation at any 
stage. Because DNA damage is repaired 
over time (demonstrated by the reduction 
of the number of RAD51-focus in unheated 
cells 2-6 hours after irradiation (Figure 
1E), hyperthermia disturbs repair of 
the maximum number of double strand 
DNA lesions when applied shortly after 
radiotherapy. Nonetheless, the fact that 
hyperthermia disrupts HR after radiotherapy 
could be very beneficial in the cases where 
practical limitations prevent radiotherapy 
and hyperthermia treatments close to each 
other in time.
The maximum disturbance of repair may 
partly explain why hyperthermia synergises 
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Figure 2 - S-phase distribution before and after irradiation with 4 Gy.
A) The thermal enhancement ratio (TER) was calculated by dividing the fraction of surviving cells after 4 Gy 
irradiation treated with hyperthermia by the fraction treated without hyperthermia. The TER is plotted as a 
function of hyperthermia treatment scheduling relative to 4 Gy irradiation in HeLa cells, and is determined 
by three independent colony survival assays. Error bars denote mean ± standard error of the mean. B) As 
a measure for the effectivity of hyperthermia-treatment, protein samples were made of cells treated with 
hyperthermia at the indicated time-points after each hyperthermia session. The immunoblots results for BRCA2 
are representative for three independent experiments. PARP-1 is shown as a loading control. The numbers below 
the blot are the mean values of quantified BRCA2 levels in the 42 °C-sample relative its 37 °C control of three 
independent experiments. C) The bar graph represents the percentage of EdU-positive cells as a measurement 
of the amount of cells in S-phase in samples treated with hyperthermia before (-) or after irradiation (+). 
Error bars indicate mean ± standard error of the mean from at least 5000 cells imaged in two independent 
experiments. 
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4with radiation is usually most effective when both modalities are given simultaneously10,27,28. 
However, in contrast to these reports, our 
survival assay indicated that HeLa cells are 
most sensitive to heat when hyperthermia is 
applied five hours after radiotherapy. As cells 
in S-phase are considerably more sensitive 
to hyperthermia than cells in other phases 
of the cell cycle22,23, we hypothesise that 
the increased radiosensitisation is caused 
by the increase in the fraction of S-phase 
cells five hours after irradiation. It is likely 
that cells are synchronised by irradiation, 
and although the alterations in cell cycle 
profiles upon irradiation will most probably 
vary in individual cell lines, synchronising 
cells by irradiation could be a powerful 
tool to temporarily enhance hyperthermia 
susceptibility.
Although inhibition of DNA repair by 
hyperthermia has been thought to be one 
of the dominant reasons why hyperthermia 
sensitises to radiotherapy, other biological 
modes of action of hyperthermia are also 
able to augment the biological effects 
of radiotherapy and have influenced 
the rationale for current fractionation 
schedules12,29. Firstly, hyperthermia is able to 
directly kill cells. Because it is independent 
of radiotherapy, this effect is not influenced 
by the sequence of radiotherapy and 
hyperthermia. Secondly, hyperthermia alters 
local tumour physiology by affecting vascular 
properties within the tumour; heat disturbs 
the epithelium of the vessels and increases 
blood flow30,31. In turn, changes in perfusion 
alter the microenvironment of the tumour 
tissue by increasing oxygen levels and 
First 
author and 
reference Tumourtype n Outcome
Outcome
RT+HT
Outcome
RT TER
Harima34 Cervix 40 CR rate 80 50 1.6
Huilgol35 Head and Neck 56 CR rate 78.6 42.4 1.85
Kakehi36 Rectum 14 response rate 100 20 5
Overgaard37 Melanoma 134 2 yr LC 46 28 1.64
Perez38 Various 218 CR rate 32 28 1.14
Shchepotin39 Stomach 293 3 yr survival 57.6 35.5 1.62
Valdagni40
Lymph Nodes 
of Head & Neck 
tumours
36 CR rate 82.3 36.8 2.24
Valdagni41
Lymph Nodes 
of Head & Neck 
tumours
36 5 yr LC 68.6 24.2 2.83
van der 
Zee42 
Bladder, rectum, 
cervix 358 CR rate 55 39 1.41
Vasanthan43 Cervix 110 LC 3 yr 68.5 68.5 1
Combined and weighed TER ± SD 1.53±1.39
Table 1. Clinical studies in which hyperthermia followed radiotherapy.
A summary of clinical studies that specifically mention that hyperthermia followed radiotherapy. Thermal 
Enhancement ratio (TER) of each study is calculated by dividing outcome RT+HT by outcome RT. 
RT = Radiotherapy; HT = Hyperthermia; TER = Thermal Enhancement Ratio; CR = Complete Response, LC = 
Local Control
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reducing hypoxia, which allow increased 
formation of reactive oxygen species (ROS). 
Increased levels of ROS increase the amount 
of damage inflicted by radiation in an indirect 
fashion1. These microenvironmental changes 
affect the radio sensitivity of a tumour 
temporarily and therefore argue it is most 
efficient to apply hyperthermia shortly 
before radiation11. However, the reverse 
scheduling might be useful to enhance 
tumour selectivity, as tumours vessels are 
usually in worse shape than normal vessels 
and hypoxia selectively occurs in tumours, it 
can be expected that hyperthermia affects 
oxygenation the longer in tumours tissue 
than normal tissue12,32. 
The microenvironment bases the sequencing 
of radiotherapy prior to hyperthermia mainly 
on tumour specificity. A number of pre-clinical 
studies have confirmed that this approach is 
probably one of the strongest arguments 
for applying the current fractionation of 
treatments10,33. To our knowledge, there 
are no clinical studies that investigate the 
clinical benefit of combining hyperthermia 
with radiotherapy in a specific sequence. 
Most studies have examined the clinical 
benefit of hyperthermia when it followed 
radiotherapy34–43 (Table 1); only three clinical 
studies describe patients that were treated 
with radiotherapy after hyperthermia44–46 
(Table 2). Upon combination of the TERs 
listed in Tables 1 and 2, we did not find 
a significant difference between the two 
sequencing modalities (p=0.129, Students’ 
t-test), and therefore conclude that with 
respect to clinical benefit, the sequence 
will probably not matter, as long as patients 
are treated with both modalities in a short 
period of time. 
In summary, hyperthermia has many 
modes  of action by which it sensitises 
to radiotherapy, all of which affect the 
rationale for scheduling hyperthermia 
and radiotherapy. We now show that with 
respect to inhibition of the DNA damage 
repair pathway HR, hyperthermia is able 
to interfere with RAD51 foci that have 
already formed, indicating that heat disturbs 
HR irrespective of the stage in which it is 
performing. Our data provide a molecular 
basis that strengthens the current clinical 
fractionation schemes, in which hyperthermia 
always follows irradiation.
Material and Methods
Experimental outline
The effects hyperthermia relative to 
radiotherapy on HR were studied by 
subjecting cells to hyperthermia at various 
time intervals: cells were placed in an 
incubator with a controlled environment 
First 
author and 
reference Tumourtype n Outcome
Outcome
RT+HT
Outcome
RT TER
Berdov44 Rectum 56 resectability 55.4 27.1 2.04
Datta45 Cervix 64 CR rate 55 31 1.77
Datta46 Primary Head and Neck 65
response 
rate 76 59 1.29
Combined and weighed TER ± SD 1.69±0.31
Table 2. Clinical studies in which radiotherapy followed hyperthermia.
A summary of clinical studies that specifically mention that hyperthermia was applied prior to radiotherapy. 
Thermal Enhancement ratio (TER) of each study is calculated by dividing outcome RT+HT by outcome RT. 
RT = Radiotherapy; HT = Hyperthermia; TER = Thermal Enhancement Ratio; CR = Complete Response
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(42 °C, 5% CO2 and 20% O2) for one hour 
up to five hours before or after irradiation 
(Figure 1A). The medium was allowed 
fifteen minutes to reach 42 °C, and effective 
hyperthermia lasted 45 minutes. Control 
samples received a sham treatment at 37 °C, 
and followed the same time intervals relative 
to irradiation as their hyperthermia-treated 
counterparts. The cells were irradiated with 
4 Gy γ-rays from a caesium-137 source with 
a dose rate of 0.62 Gy/min. 
Cell culture
HeLa cells were maintained as described 
previously47. All experiments were performed 
within ten cell passages. 
Cell lysis, protein assay and immunoblots
One day prior to seeding the experiment, 
3.2*106 cells were seeded in 60-mm dishes. 
The next day, cells in the appropriate dishes 
were treated and lysed at the time-intervals 
indicated in the figure legends. Experimental 
details and buffer components involving cell 
lysis, protein assay and immunoblots have 
been described previously47. Briefly, cells 
were harvested by scraping them from the 
plate and lysed in Laemmli buffer. Proteins 
(50 μg) were separated on a 3-8% Tris-Act 
gel (Novex, ThermoFisher Scientific) and 
blotted on a PVDF membrane. Membranes 
were incubated with mouse-anti-BRCA2 
(1:1000, OP95, Ab-1, Merck Millipore) or 
mouse-anti-PARP-1 (1:5000, C-2-10, Enzo 
Life Sciences) and subsequently with sheep-
anti-mouse IgG (H+L) (1:2000, Jackson 
ImmunoResearch). After signal detection on 
an Alliance 4.7 (Uvitec Cambridge), signals 
were quantified using the ‘Analyze Gels’ tool 
in FIJI (Image J1.50i48).
EdU-incorporation, cell fixation, 
immunofluorescence and image analysis
A fixed number (0.8*106) of HeLa cells was 
seeded on a 30-mm dish containing a coverslip. 
The next day, the cells were treated and fixed 
at the appropriate time points according the 
scheme in Figure 1A. Experimental details 
concerning immunofluorescence can be 
found elsewhere47. Briefly, EdU was added to 
cells 75 minutes before fixation with 4% PFA. 
EdU was labelled with an ATTO 390 or 488 
Azide (ATTO-TEC GmbH) first, after which 
RAD51 was labelled with rabbit anti-RAD51 
(1:1000049) and an Alexa Fluor® 594 goat 
anti-mouse (1:1000) antibody. Before sealing 
the coverslips with nail polish, they were 
embedded in DAPI-containing Vectashield 
(Vector Laboratories) when the ATTO 488 
Azide was used, or, when ATTO 390 was 
used, in Vectashield without DAPI. 
All images were obtained with a Leica TCS 
SP5 confocal microscope. The image settings 
and macro used for RAD51 quantification 
were as described previously47. EdU 
positivity was determined with a second 
semi-automatic home-made macro in FIJI 
(Image J1.50i48). In the images (maximum 
projections, 15 slices, 1024 x 1024 pixels, 
775 x 775 μm, increment 2 μm), cells were 
selected based on DAPI-positivity, and the 
EdU intensity of these cells was measured 
and subsequently thresholded to determine 
EdU-positivity.
Colony survival
Two million cells were plated in a 10-cm 
dish one day prior to seeding the survival, 
to ensure exponential growing of cells. 
Late the next day, an appropriate number 
of cells (200-1600, depending on radiation 
dose) was seeded in triplicate 60 mm 
dishes. After ~14 hours attachment, cells 
were treated according to the treatment 
schedule (Figure 1A). After 10 days, 
surviving colonies were fixed and stained 
in 45% methanol, 45% dH2O, 10% Acetic 
acid and 0.25% Coomassie Brilliant Blue. 
Colonies containing more than 30 cells were 
counted using a stereomicroscope. After 
the plating efficiencies were calculated for 
each dish, the surviving fractions at 4 Gy 
were expressed as a percentage of surviving 
fractions in the non-irradiated control. A 
Thermal enhancement ratio (TER) was 
calculated by dividing the survival fraction of 
a hyperthermia-treated sample by the non-
hyperthermia-treated control. 
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Statistics
To test EdU-positivity, two independent 
experiments were performed. All other 
experimental results were obtained in 
three independent experiments. Statistical 
differences were calculated using one-way 
ANOVA, and Bonferroni post-hoc t-tests 
were used to compare selected columns.
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Introduction
Hyperthermia is an anti-cancer therapy 
that increases efficacy of radiation therapy 
and of several chemotherapeutic agents1,2. 
During hyperthermia treatment, external 
applicators are positioned in such a way that 
the temperature of the tumor is elevated to 
40-44 °C. Hyperthermia application devices 
have been designed to heat various tumor 
types in a localized fashion. A broad range 
of tumors can be treated with hyperthermia 
including, but not limited to, those occurring 
in the breast3,4, cervix5,6, head and neck7,8, and 
bladder9–11, resulting in growing interest for 
using hyperthermia as a means to increase 
the effectiveness and specificity of cancer 
treatment while minimizing side-effects12. 
Hyperthermia sensitizes tumor cells to 
radiation and chemotherapy by altering 
tumor biology, both at the physiological 
and molecular level13,14. The most well-
investigated and well-known physiological 
effects of hyperthermia are the increase 
in local blood flow and the alterations 
in vascular permeability, and the change 
in tumor microenvironment14,15. Another 
physiological effect of hyperthermia that 
has recently gained more attention is the 
activation of the immune response by 
heat16,17. On the molecular level, hyperthermia 
induces membrane stress and it causes 
protein structures to unfold. All effects of 
hyperthermia are very dependent on the 
temperature reached in the tumor and the 
duration of the treatment. For example, 
most proteins remain relatively stable with 
temperatures in a near-physiological range 
(< 42 °C)18. However, one known exception 
is the protein BRCA2, which is degraded at 
temperatures as low as 41 °C19.
BRCA2 is an essential player in the DNA 
repair pathway homologous recombination 
(HR). This DNA repair pathway is employed 
by cells to aid in the repair of numerous 
aberrant DNA structures or DNA lesions20. 
A prime example of a complicated lesion 
that can be repaired through HR is a DNA 
Abstract
Purpose: Hyperthermia (40-44 °C) effectively sensitizes tumors to radiotherapy by locally 
altering tumor biology. One of the effects of heat at the cellular level is inhibition of DNA 
repair by homologous recombination via degradation of the BRCA2-protein. This suggests 
that hyperthermia can expand the group of patients that benefit from PARP-inhibitors, a drug 
exploiting homologous recombination deficiency. Here, we explore whether the molecular 
mechanisms that cause heat-mediated degradation of BRCA2 are conserved in cell lines from 
various origins and, most importantly, whether, BRCA2 protein levels can be attenuated by heat 
in freshly biopted human tumors.
Experimental Design: Cells from four established cell lines and from freshly biopsied material of 
cervical (15), head- and neck (9) or bladder tumors (27) were heated to 42 °C for 60 minutes ex 
vivo. In vivo hyperthermia was studied by taking two biopsies of the same breast or cervical tumor: 
one before and one after treatment. BRCA2 protein levels were measured by immunoblotting. 
Results: We found decreased BRCA2-levels after hyperthermia in all established cell lines and in 
91% of all tumors treated ex vivo. For tumors treated with hyperthermia in vivo, technical issues 
and intra-tumor heterogeneity prevented obtaining interpretable results.  
 
Conclusions: This study demonstrates that heat-mediated degradation of BRCA2 occurs in tumor 
material directly derived from patients. Although BRCA2-degradation may not be a practical 
biomarker for heat deposition in situ, it does suggest that application of hyperthermia could be 
an effective method to expand the patient group that could benefit from PARP-inhibitors.
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double strand break. Once a DNA double 
strand break has occurred in one chromatid, 
HR taps into the information on the 
undamaged sister chromatid to repair the 
break, thereby ensuring faithful restoration. 
The necessity for the presence of a sister 
chromatid, limits HR to the S- and G2-
phases of the cell cycle20. The main driver 
proteins of HR are RAD51 and its mediator 
BRCA221. Absence of the BRCA2-protein 
abrogates HR by causing defects in RAD51 
loading onto the processed end(s) of the 
DNA double strand break22,23. 
By degrading BRCA2 in tumor cells, 
hyperthermia attenuates HR and creates 
a temporary window for DNA damage to 
persist, which is one of the explanations for 
how it sensitizes to DNA-damaging anti-
cancer treatments, such as radiation therapy 
and chemotherapy19. Likewise, tumors that 
harbor a heritable BRCA2-mutation resulting 
in a dysfunctional BRCA2-protein also lack 
functional HR, causing the tumors to be very 
sensitive to a specific type of drugs: PARP-
inhibitors24,25. PARP-inhibitors target the 
PARP-1 (Poly [ADP-ribose] Polymerase 1) 
protein, which is involved in repair of single 
strand DNA breaks. When PARP-1 is not 
available to repair these DNA breaks, the 
single strand lesions are converted to double 
strand breaks during DNA replication. These 
replication-induced DNA double strand 
breaks are extremely toxic to cells, and have 
to be repaired via the HR-pathway in order 
for cells to survive26. This explains why HR-
defective tumors are extremely sensitive to 
PARP-inhibitors, while they are much less 
toxic to HR-proficient cells24,25. This results 
in PARP-inhibitors being excellent precision 
medicine to treat patients with HR-deficient 
cancers, because the patients themselves 
will experience minimal side-effects, while 
the tumor is very sensitive to the drug. 
Recent approvals of two variants of PARP-
inhibitors (Olaparib/Lynparza, AstraZeneca 
and Rucaparib, Clovis) for treatment of 
BRCA-mutated ovarian tumors by the FDA 
demonstrate the popularity and effectivity of 
this type of anti-cancer approach27. 
Although this precision treatment method 
is very elegant, one inherent drawback 
is the small group of patients that are 
eligible for these drugs, because a BRCA-
mutation is rare28. By inducing temporary 
HR-deficiency in tumors in a local fashion, 
hyperthermia could have the potential to 
enlarge the patient group that might benefit 
from PARP-inhibitors, irrespective of their 
BRCA gene status. However, it is unknown 
whether the molecular mechanisms present 
in established tumor cell lines, and necessary 
for hyperthermia-mediated degradation 
of BRCA2, are also functioning in primary 
tumor tissue. Therefore, we explore 
hyperthermia’s ability to degrade BRCA2 in 
primary tumor material of tumors that can 
clinically be heated, as a proof-of-concept 
study and as a first step towards application 
of PARP-inhibitors and hyperthermia in 
a clinical setting. Moreover, because the 
currently available heating techniques in vivo 
harbor large variability in heating patterns 
and their quality assurance is challenging, we 
also explore the possibility to use BRCA2 
degradation in tumors as a biomarker for 
the effectivity of hyperthermia. 
BRCA2
PARP-1
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Figure 1. BRCA2 degradation in established 
cell lines of various tumor origins.
Immunoblots of cells without treatment (37 °C) or 
treated with hyperthermia (42 °C) for 60 minutes 
effectively, excluding 15 minutes of pre-heating time. 
Upper row of the panels show the BRCA2-signal, the 
lower panel shows the PARP-1-signal. Each panel 
represents a set samples from a different cell line, 
from left to right: HeLa (cervical), FaDu (Head- and 
Neck), T24 (Bladder) and MDA-MB-231 (Breast). 
Percentages at the bottom of each panel indicate the 
relative intensity of the BRCA2 signal (corrected to 
PARP-1) in the heat-treated sample compared to the 
non-treated sample.
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Results
Mild hyperthermia induces BRCA2 degradation 
in various established cell lines
We started our proof-of-concept study 
by testing whether hyperthermia induces 
BRCA2 degradation in established cell lines 
of various origins. The selected cell lines, 
HeLa (Cervix), FaDu (Head and Neck), 
T24 (Bladder), and MDA-MB231 (Breast), 
correspond to tumor types that are routinely 
treated with hyperthermia in the Erasmus 
MC Cancer Institute. After 60 minutes of 
effective hyperthermia, the cells were lysed, 
immunoblotted and the intensity of the 
BRCA2-signal was analyzed. We observed 
that in all cell lines employed the BRCA2-
signal was markedly decreased by treatment 
with 42 °C (Figure 1), demonstrating that 
hyperthermia is able to degrade BRCA2 in 
multiple tumor cell lines.
Hyperthermia-induced BRCA2 degradation in 
primary material
We extended our study by analyzing BRCA2 
degradation upon hyperthermia in fresh 
tumor material. We collected tumors from 
different sites that are treated with mild 
hyperthermia: cervix (15), head and neck (9) 
and bladder (27). The tumors were directly 
transported to the laboratory, dissociated 
upon arrival and the resulting suspension 
was divided in two aliquots: one aliquot 
was incubated ex vivo at 37 °C and the 
other at 42 °C for 75 minutes total. We 
then lysed the cells, analyzed the resulting 
samples by immunoblot and subsequently 
quantified the BRCA2-signals, when possible 
(Figure 2). Because we were not always 
able to prevent loading differences between 
the two samples of the same tumor, we 
normalized the BRCA2-signals to the 
ORC2-signal in the same sample. We then 
expressed the normalized BRCA2-signal 
in the hyperthermia-treated sample as a 
percentage of that in the untreated sample. 
The loading difference was mainly caused 
by the relatively mild nature of the 
employed dissociation method and the 
60 min
Figure 2. Schematic representation of tumor 
collection.
Fresh biopsies obtained are dissociated enzymatically 
and mechanically. Dissociated suspensions of 
tumors collected were prepared for treatment by 
centrifugation (5 minutes, 300 rcf) and subsequent 
resuspension in RMPI supplemented with 10% FCS. 
The resulting cell suspension was divided over two 
separate culture dishes: one was incubated at 37 °C 
for 75 minutes in a controlled environment (37 °C, 
5% CO2, 20% O2), while the other was incubated at 
42 °C in a similarly controlled environment for the 
same amount of time, allowing 15 minutes to pre-
heat the medium and thus resulting in 60 minutes 
of effective heating. After the treatment, cells in both 
samples are lysed and the proteins are analyzed on 
an immunoblot. 
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Figure 3. BRCA2 degradation in tumors heated ex vivo.
Immunoblots of A) 11 cervical tumors, B) 5 head and neck tumors, and C) 16 bladder tumors. Each pair 
of samples represent the non-hyperthermia-treated and treated samples of a tumor sample. ORC2 is shown 
as a loading control. Percentages at the bottom of each panel indicate the relative intensity of the BRCA2 
signal (corrected to ORC2) in the heat-treated sample compared to the non-treated sample. *For clarity of 
presentation, the shadow values were reset from 0 to 175 in Adobe Photoshop. **PARP-1 is shown as a loading 
control and as an alternative to ORC2, because the latter could not be detected in this sample. 
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differences in tumor structure, sometimes 
resulting in incomplete homogenization of 
the tumor samples. Even though we used 
the Lowry protein assay to determine the 
total protein content in the lysates and 
corrected for the amount measured, loading 
differences within the same tumor set could 
not always be prevented. When necessary, 
we re-ran samples, by adjusting the amount 
loaded based on the previous obtained 
result. However, this was not always possible, 
because relative to the size of the samples 
obtained, a significant amount of material 
is needed to detect BRCA2 on a Western 
blot. To solve this, we normalized the signal 
to ORC2 (Origin Replication Complex 2), 
its signal intensity being comparable to that 
of BRCA2. For one bladder tumor we used 
the PARP-1 signal to normalize, because no 
ORC2-signal could be detected (marked 
with ** in Figure 3C). 
Due to technical issues during dissociation 
or immunoblotting, not all tumors included 
could be analyzed, but we were able to obtain 
results of 11 out of 15 cervical tumors, 5 
out of 9 head- and neck tumors and 16 
out of 27 collected bladder tumors. In the 
cervical tumors we detected degradation 
of BRCA2 in all ex vivo treated samples, 
the residual BRCA2-levels varying between 
8% and 66% (Figure 3A). In the head and 
neck tumors, we found BRCA2 degradation 
in four samples (33%-59% remaining levels 
after 42 °C), but hyperthermia did not result 
in degradation of the BRCA2 protein in the 
fifth (Figure 3B). In material obtained from 
bladder tumors, hyperthermia degraded 
BRCA2 in 14 samples (20%-79% residual 
protein levels), but in two samples we found 
no clear alteration of BRCA2-protein levels 
upon heat treatment (Figure 3C).  
BRCA2 degradation as a biomarker for heat 
deposition
Next, we checked if BRCA2 degradation in 
biopsy material can be used as a biomarker 
for effectivity of hyperthermia4,32,33.To this 
end, two pilot studies were set up in which 
we investigated BRCA2 protein levels in 
biopsies of recurrent breast and primary 
cervical tumors that were taken before and 
directly after clinical treatment with mild 
hyperthermia. 
In the first pilot study, we included a total 
Breast 1 Breast 2
B
A
BRCA2
ORC2
BRCA2
ORC2
BRCA2
ORC2
pre postpre post
Cervix 1
381% 108%
pre post 42 °C
21% 37%
Cervix 2
pre post 42 °C
408% 36%
Cervix 3
pre post 42 °C
262%
Cervix 4
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Cervix 5
88% 125%
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Cervix 6
43% 21%
*
*
pre post42 °C
*
*
BRCA2
ORC2
Figure 4. BRCA2 protein levels in biopsies 
taken before and after hyperthermia 
treatment in vivo.
Immunoblots of biopsies taken before (pre) and 
after (post) hyperthermia in A) breast tumors and 
in B) cervical tumors. Samples marked with ‘42 °C’ 
received ex vivo hyperthermia as an internal control. 
Shown are BRCA2 and ORC2. The percentages at the 
bottom of each panel indicate the relative intensity of 
the BRCA2 signal (corrected to ORC2) in the heat-
treated sample compared to the non-treated sample. 
*For clarity of presentation the shadow values were 
reset from 0 to 175 in Adobe Photoshop.
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of four patients with local recurrent breast 
cancer without distant metastases, of which 
one patient was included twice. The biopsies 
we tested were taken from previously 
irradiated areas of the tumor, as only patients 
with these lesions have a standard indication 
for treatment with hyperthermia. Moreover, 
superficial hyperthermia elicits higher 
temperatures, has a more homogeneous 
heating pattern and is less demanding for 
patients, compared to deep hyperthermia3,6. 
Unfortunately, we found that the dissociation 
of the biopsies obtained from these areas 
was insufficient, in contrast to our previous 
experiences with primary biopsies. These 
difficulties might be caused by macroscopic 
changes in the extracellular matrix and 
tumor structure in the re-irradiated areas. 
Owing to the insufficient dissociation, we 
were only able to detect a BRCA2-signal on 
the immunoblot in the biopsy material from 
two patients, and never in both biopsies 
from the same patient (Figure 4A). Because 
the technical problems in this patient group 
prevented us from investigating the effect 
of clinically applied hyperthermia on the 
BRCA2-protein levels in the tumors, we 
decided to terminate this study.
In the second pilot study, we included six 
patients with locally advanced cervical 
tumors, who are treated with a combination 
treatment of hyperthermia and radiotherapy 
as a standard of care6. In all biopsies tested, 
we were able to detect BRCA2 (Figure 
4B). We compared the BRCA2 signal of the 
two biopsies taken before and directly after 
the end of the hyperthermia to examine the 
effects of in vivo hyperthermia and found: (1) 
lower BRCA2-levels post-hyperthermia than 
pre-hyperthermia in two cases (Cervix 2 and 
6, Figure 4B); (2) similar levels of BRCA2 in 
both biopsies in one case (Cervix 5, Figure 
4B); and (3) considerably more (>2 fold) 
BRCA2 in the post-hyperthermia biopsy in 
three cases (Cervix 1, 3 and 4, Figure 4B).
In five of these tumors, the amount of 
material obtained was sufficient to include an 
ex vivo hyperthermia treatment on the same 
biopsy material taken before the clinical 
hyperthermia treatment, as a control for the 
effectivity of hyperthermia in vivo (Figure 
4B, indicated with 42 °C). In contrast to the 
cervix tumor samples presented in Figure 
3A, where ex vivo hyperthermia triggered 
BRCA2 degradation in all cases, the same 
treatment did not induce degradation of 
BRCA2 in two tumors within this set (Cervix 
1 and 5, Figure 4B). However, importantly, 
we did observe that the increase in BRCA2 
found in the post-hyperthermia biopsies 
of Cervix 1 and 3 did not occur in the 
controlled ex vivo hyperthermia, and were 
therefore most probably not inherent to 
molecular mechanism in the tumor itself. 
The variability in relative BRCA2 levels in 
the tumor biopsy taken after hyperthermia 
treatment in vivo might be explained by tumor 
heterogeneity, which would cause inherent 
differences between the two biopsied parts 
of the tumor. To test this possibility, we took 
biopsies (designated biopsy A and B) from 
two macroscopically similar parts of the same 
cervical tumor during an examination under 
anesthesia, and ex vivo incubated half of each 
biopsy at 37 °C and the other half at 42 °C. 
In both sample-sets, we observed BRCA2 
degradation to an equal extent upon heat. 
A B
51% 53%
42°C37°C 42°C37°C
BRCA2
ORC2
Figure 5. Tumor heterogeneity contributes to 
pre-hyperthermia protein levels of BRCA2 in 
cervical tumors.
Immunoblots of two biopsies (A and B) taken from 
the same cervical tumor and treated ex vivo in 
the same hyperthermia-session at 42 °C. Upper 
panel shows the BRCA2-signal, the lower ORC2. The 
percentages at the bottom of the panel indicate the 
relative intensity of the BRCA2 signal (corrected to 
ORC2) in the heat-treated sample compared to the 
non-treated sample for each biopsy.
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However, the initial BRCA2-levels at 37 °C 
were very different (Figure 5). Theoretically, 
if biopsy B would have been the biopsy taken 
before hyperthermia in vivo, and if biopsy 
A was taken after hyperthermia, we would 
have found no differences in BRCA2-levels, 
while BRCA2 was in fact degraded by the 
heat treatment (Figure 5).
Discussion
Treatment with hyperthermia (41-42 °C, 
60 minutes) induces degradation of the 
BRCA2 protein in established cell lines, 
resulting in a temporary inhibition of 
the DNA repair pathway homologous 
recombination (HR)19. This provides a 
possible explanation for hyperthermia’s 
sensitizing effects towards irradiation and 
chemotherapeutic compounds that induce 
double strand breaks, such as cisplatin34,35 
and Trabectedin36. Moreover, attenuation of 
HR by hyperthermia sensitizes cultured cells 
and mouse tumors to PARP-inhibitors19,37–39, 
a class of therapeutics that specifically target 
cells deficient in HR. PARP-inhibitors are 
currently available as personalized treatment 
to patients with ovarian cancer that harbor 
a BRCA-mutation and have relapsed after 
initial platinum-containing treatment27. Via 
inhibition of HR, mild hyperthermia has the 
potential to enlarge the group of patients 
eligible for this treatment, especially because 
it can be applied in a loco-regional fashion 
and is available to treat a broad range of 
tumors40.
In this study, we aimed to demonstrate 
that hyperthermia induces degradation of 
BRCA2 not only in established cell lines, 
but also in fresh, human tumors. We focused 
on tumor types that can be treated with 
hyperthermia in daily practice: cervix, head 
and neck, bladder and breast. We first show 
that BRCA2 is degraded upon heat (60 
minutes at 42 °C) in established cell lines 
of these tumor types. We then collected 
cervix, head and neck and bladder tumors, 
and tested BRCA2 protein degradation by 
shifting the temperature ex vivo from 37 °C 
to 42 °C for 60 minutes. The BRCA2 protein 
levels after hyperthermia were lower 
than without treatment in 11/11 cervical 
tumors in 4/5 of the head and neck tumors 
and in 14/16 of the bladder tumors origin 
(summarized in Supplemental Figure 1), 
demonstrating that the molecular pathways 
that mediate BRCA2-degradation upon 
heat are functional in fresh tumor material, 
independent of its origin.
Our final aim was to determine whether 
BRCA2-degradation could be used as 
a biomarker for efficiency of clinical 
hyperthermia treatment. We investigated 
this by obtaining two biopsies of the same 
breast tumor or cervical tumor: one 
taken before and one taken after in vivo 
hyperthermia treatment. Due to unforeseen 
technical problems with the preparation of 
the material obtained in the breast cancer 
study, we were unable to obtain interpretable 
results. In the six cervical cancer patients 
included, we found unexpected variation 
in the BRCA2-levels in the biopsy taken 
after clinically applied hyperthermia relative 
to the levels in the biopsies taken before 
hyperthermia. 
The possibility that thermal doses reached 
in the clinical setting are not sufficient 
to induce BRCA2 degradation does not 
explain the observed increase in BRCA2 
protein levels after hyperthermia. However, 
there are several other factors that could 
contribute to the variability in relative 
BRCA2-levels in tumor biopsies taken after 
hyperthermia treatment in vivo. The first 
explanation is the inherent variability of 
BRCA2-protein levels in each biopsy, caused 
by intra-tumor heterogeneity (Figure 5), a 
feature which commonly occurs in cervical 
tumors41–43. Differences in the cell cycle 
distribution within a tumor part would 
influence the BRCA2 protein levels, because 
its expression depends heavily on the cycling 
state of the cells44. These inherent tumor 
differences might be amplified by the fact 
that, in four of the six cases, we opted to 
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obtain the pre-hyperthermia biopsy up to a 
month before the start of the treatment, in 
order to reduce the burden on the patient 
(Figure 4B, Cervix 1, 2, 5 and 6). Other 
biological events that may have contributed 
to the increase in BRCA2 protein levels 
after hyperthermia, are the physiological 
effects of hyperthermia in vivo: the increased 
blood flow and the immunological response 
upon heat could introduce new cells to the 
tumor, in which the BRCA2 proteins have 
not had a chance to be affected by heat45. 
Since the logistics in this study limited us 
to taking the second biopsy approximately 
45 minutes after the end of hyperthermia, 
non-heated, non-tumor cells potentially 
could have infiltrated the tumor after the 
end of treatment, clouding the effects of 
hyperthermia on BRCA2. 
The results obtained in the studies that 
examine the effects of clinically applied 
hyperthermia on BRCA2, demonstrate that 
no valid conclusions can be drawn when 
comparing immunoblot signals resulting 
from two separate biopsies. In a clinical 
setting, the BRCA2-signal in a first biopsy 
can therefore not be used as a control 
for the BRCA2-signal in the biopsy taken 
after hyperthermia. However, the results 
do imply that an experimental approach 
where a tumor biopsy is taken before 
hyperthermia and another one after could 
be a valuable method to identify differences 
in the cell populations in the biopsies upon 
hyperthermia, elucidating physiological or 
immunological mechanisms of hyperthermia.
In this study we aimed to explore 
hyperthermia’s ability to degrade BRCA2 
in freshly biopsied tumor material. We have 
indeed demonstrated that heat-induced 
BRCA2 degradation is not limited to 
established cell lines, but is also applicable 
to tumors heated ex vivo. We also explored 
whether BRCA2-degradation could be 
a feasible biomarker for determining 
effectivity of heat deposition by clinically 
applied hyperthermia, but found that this 
is not the case: due to technical difficulties 
in dissociation of some tumors and intra-
tumor heterogeneity, it was not possible to 
accurately determine BRCA2-levels after 
hyperthermia in vivo. However, the results 
of this study indicate that hyperthermia 
is an effective method to create a local 
environment of HR-deficiency in tumors, 
and could indeed provide a rational basis 
to increase the group of patients that could 
potentially benefit from PARP-inhibitors.
Material and methods
Cell culture
HeLa, FaDu, T24 and MDA-MB-231 were 
cultured as previously described19.
Tumor collection (ex vivo study)
The effects of hyperthermia on BRCA2 
protein levels were studied in tumor material 
by subjecting collected biopsies to heat ex 
vivo. All described specimens were obtained 
between August 2012 and December 2016 
within the Erasmus MC Cancer Institute, 
Rotterdam (MEC 2017.234). All tumors 
included in this study were leftover tissues 
after pathological reviews, and could 
therefore be used for research according to 
the “Code Proper Secondary Use of Human 
Tissue”, founded by the Dutch Federation 
of Medical Societies (www.fmwv.nl). All 
patients were informed by letter that they 
might refuse the use of leftover tissue for 
research purposes, in an opt-out manner. 
Tumor tissue specimens were anonymized 
by coding, so that they could not be traced 
back to individual patients. 
Fresh cervical tumor tissue was taken with 
a biopsy forceps from patients with locally 
advanced cervical carcinoma (FIGO stage 
IIB-IVA) or recurrent disease, undergoing 
pelvic examination under anesthesia. All head 
and neck specimens were primary tumors 
originating from the tongue and obtained 
during COMMANDO-surgery. Bladder 
specimens of both primary and recurrent 
tumors were collected during transurethral 
resection procedures. 
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Tumor collection and hyperthermia treatment 
(in vivo studies)
The study was continued by investigating 
BRCA2 protein levels in biopsies of breast 
and cervical tumors taken before and 
after clinical application of hyperthermia 
(in vivo). In the first study (MEC 2012.559) 
we aimed to include twelve patients who 
had local recurrent breast cancer without 
distant metastases for whom treatment 
with superficial hyperthermia was feasible. 
Patients with a BRCA1 or BRCA2 germline 
mutation were excluded from this study. The 
biopsies were taken with a 4-mm cutter from 
a previously irradiated area, right before and 
directly after an extra hyperthermia session 
before the start of the combined treatment. 
The study-related hyperthermia treatment 
was limited to one 433 MHz Lucite cone 
applicator29 for superficial hyperthermia 
and given for 30 minutes. Due to technical 
problems, the study was closed after 
inclusion of five biopsy sets originating from 
four patients.
For the second study (MEC 2014.469) we 
aimed to include 16 patients with locally 
advanced cervical carcinoma that underwent 
hyperthermia as part of their primary 
treatment. The included patients were 
treated with hyperthermia according to the 
standard treatment protocol with the BSD-
2000 3D system (Pyrexar Medical Systems, 
Salt Lake City, UT). If possible, the first 
biopsy was taken during the examination 
under anesthesia, approximately four weeks 
before the start of the treatment, to reduce 
patient burden. To prevent radiotherapy-
induced alterations of tumors included 
in this study, the sequence of the first 
radiotherapy and hyperthermia combination 
was altered: before the patient received the 
first radiotherapy fraction, the second biopsy 
was taken after one hour hyperthermia 
treatment (excluding pre-heating time). The 
remaining four hyperthermia treatments of 
the treatment cycle were delivered directly 
after radiotherapy. 
The patients in these two studies were 
recruited between July 2013 and May 
2016, and a written informed consent was 
obtained from all patients.
Tumor dissociation and ex vivo hyperthermia 
treatment
Tumor biopsies were first transferred to the 
Department of Pathology, for inspection by a 
pathologist. After analysis, remaining material 
was transported to the laboratory in RPMI 
medium (Sigma-Aldrich, St Louis, MO), 
supplemented with penicillin/streptomycin. 
The material was processed immediately 
upon arrival, and macroscopically visible 
blood vessels and fat were removed. The 
tumor was manually cut into small pieces (one 
mm3). The samples were then homogenized 
using a human Tumor Dissociation kit and 
corresponding protocol (Miltenyi Biotec, 
Bergisch Gladbag, Germany). Cells in the 
homogenized mixture from tumors collected 
within the context of the in vivo study were 
lysed immediately, while cells from tumors in 
the ex vivo study were treated as described 
in Figure 2. 
Cell lysis
Cells were lysed as previously described19. 
Prior to lysis, the cell suspension from tumor 
material was harvested by centrifuging 
(5 minutes, 300 rcf, 4 °C). The pellet then 
washed twice by resuspension in cold 
PBS supplemented with 5 mM EDTA and 
subsequent centrifugation. If necessary, 
blood was removed from the pellet by 
resuspension and subsequent incubation 
for 2 minutes at room temperature in ACK 
buffer (150 mM NH4Cl, 10 mM KHCO3, 
0.1 mM Na2EDTA, pH 7.3), after which 
the sample was centrifuged and washed 
once more with cold PBS. Following the 
last centrifugation step, the pellet was 
resuspended in an appropriate amount of 
PBS, supplemented with 5 mM EDTA, 2.5x 
cOmplete™ Protease Inhibitor cocktail 
(Roche, Basel and Switserland) and 1 mg/ml 
Pefabloc® SC (Sigma-Aldrich, St Louis, MO). 
Immunoblotting procedure
After determining protein concentration 
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in the samples using a Lowry assay30, 50 to 
75 μg of the tumor lysate was loaded and 
run on a 3-8% gradient Tris-Act gel (Novex, 
Thermo Fisher Scientific, Waltham, MA). 
The separated proteins were blotted on 
a PVDF membrane in a tank containing 
transfer buffer (0.4 M Glycine, 5 mM Tris, 
20% Methanol) at a constant rate of 300 
mA for two hours at 4 °C. The membrane 
was horizontally cut into three separate 
pieces, which were blocked for at least one 
hour in 3% milk in PBS-T (0.05% Tween). 
The primary antibodies, BRCA2 (1:1000, 
OP95, Calbiochem, San Diego, CA), PARP-
1 (1:5000, Alexis/ENZO, Pharmingdale, NY) 
and ORC2 (1:1000, BD Pharmingen, San 
Diego, CA), were diluted in PBS-T with 3% 
milk and incubated overnight at 4 °C. Blots 
were washed in PBS-T and incubated with a 
secondary antibody (Sheep-anti-mouse HRP 
conjugated 1:2000, Jackson Immunoresearch, 
Suffolk, UK) for two hours at room 
temperature. The signal was detected in 
an Alliance (Uvitec Cambridge Cleaver 
Scientific, Warwickshire, UK) at several 
exposure times. The signal was detected by 
enhancing the signal with ECL (Amersham, 
GE Life Sciences, Chicago, IL), but if the 
BRCA2 signal proved too weak to detect, 
an enhanced version of ECL (Supernova, 
Cyanagen, Bologna, Italy or Pierce, Thermo 
Fisher Scientific, Waltham, MA) was used. 
In the presentation of the blots, an asterisk 
indicates that the detected signals were 
enhanced by changing the shadows-value 
from 0 to 175 in the ‘Levels Adjustment’ tool 
in Photoshop (CS6, Adobe). This adjustment 
was necessary for a clear impression of the 
relative signal intensities.
Blot quantification
Antibody signals on the immunoblot 
were quantified using the FIJI31 ‘Analyze 
gels’ tool. To minimalize saturation of the 
quantified signals, different exposure times 
were analyzed. The BRCA2 signals were 
normalized to ORC2 to correct for unequal 
loading, with notable exception of one 
bladder tumor where we did not find ORC2 
expression and used PARP-1 instead. In the 
figures, the 42 °C signal is always expressed 
as a percentage of the matched 37 °C 
control.
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Introduction
Bladder cancer is the fifth most common 
malignancy in Europe, accounting for 
150,000 cases per year1. Bladder tumors are 
associated with specific clinical problems 
that are highly distressing for patients and, 
in monetary terms, make bladder cancer 
the most expensive malignancy per treated 
patient2. The disease presents itself as either 
non-muscle invasive bladder cancer (NMIBC, 
75%) or muscle-invasive bladder cancer 
(MIBC, 25%)3. Although the 5-year survival 
rate of NMIBC patients is more than 90%, 
as much as 50% of all NMIBC patients will 
recur after transurethral resection (TUR) of 
the tumor. Therefore these patients require 
thorough follow-up and adjuvant intravesical 
therapies3. One of the major clinical 
challenges is to improve adjuvant therapies 
to reduce the risk of recurrences, thereby 
minimizing patient burden and costs. MIBC 
is therefore often treated by neo-adjuvant 
chemotherapy and radical surgery, which 
is associated with high morbidity rates and 
even mortality4. Nonetheless, the 5-year 
survival rate of patients with MIBC is a mere 
55% and this has not improved over the last 
decades4,5. All these clinical traits of bladder 
cancer clearly illustrate the necessity to find 
new, more effective and less burdensome 
therapies6–8. 
One of the most widely used approaches 
to reduce the risk of recurrence and 
progression of NMIBC cancer is intra-
vesical treatment, which involves flushing 
the bladder with a therapeutic compound. 
A commonly used compound in this 
setting is mitomycin C (MMC)9. Systemic 
administration with cisplatin is the most 
preferred drug for MIBC in the neoadjuvant, 
adjuvant or palliative setting. Interestingly 
the efficacy of both MMC and cisplatin 
increases upon addition of hyperthermia, 
during which the tumor is heated to 40-44 
°C10. Hyperthermia has therefore attracted 
much attention to complement current 
Abstract
Introduction: Bladder cancer is a common malignancy characterized by high recurrence rates 
and intense clinical follow-up, indicating the necessity for more effective therapies. Current 
treatment regimens include intra-vesical administration of mitomycin C (MMC) for non-
muscle invasive disease and systemic cisplatin for muscle-invasive or metastatic disease. 
Hyperthermia, heating a tumor to 40-44 °C, enhances the efficacy of these chemotherapeutics 
by various modes of action, one of which is inhibition of DNA repair via homologous 
recombination. Here, we explore whether ex vivo assays on freshly obtained bladder tumors 
can be applied to predict the response towards hyperthermia. 
Material and methods: The cytochrome C release assay (apoptosis) and the RAD51 focus 
formation assay (DNA repair) were first established in the bladder cancer cell lines RT112 
and T24 as measurements for hyperthermia efficiency, and subsequently tested in freshly 
obtained bladder tumors (urothelial carcinoma, n=59). 
Results: Hyperthermia significantly increased the fraction of apoptotic cells after cisplatin or 
MMC treatment in both RT112 and T24 cells and in most of the bladder tumors (8/10). The 
RAD51 focus formation assay detected both morphological and numerical changes of RAD51 
foci upon hyperthermia in the RT112 and T24 cell lines. In 64% of 37 analyzed primary bladder 
tumor samples, hyperthermia induced similar morphological changes in RAD51 foci. 
Conclusion: The cytochrome C assay and the RAD51 focus formation assay are both feasible 
on freshly obtained bladder tumors, and could serve to predict the efficacy of hyperthermia 
together with cytotoxic agents, such as MMC or cisplatin. 
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bladder cancer treatment modalities. 
Adding hyperthermia  to intra-vesical MMC 
treatment has previously demonstrated to 
improve its efficacy8,11,12. 
Hyperthermia has a plethora of biological 
effects on cells that cause cells to be more 
sensitive to the cross-linking agents MMC 
and cisplatin13,14. For instance, hyperthermia 
enhances blood flow and increases vessel 
permeability, which causes more of the 
chemotherapeutic drug to be delivered to 
the tumor10. Cisplatin uptake is enhanced in 
the cell by hyperthermia-mediated alteration 
of cellular membrane properties: it becomes 
more fluid15, and the copper transporter 
CTR1, responsible for transport of cisplatin 
into the cell, is upregulated16. Moreover, in 
the specific case of the bladder wall, it has 
been suggested that hyperthermia might aid 
in overcoming its impermeable structure17. 
Thus, hyperthermia helps to overcome 
drug transport barriers of bladder tumors. 
However, once the drug has penetrated into 
T24
0 2 4 6
0.1
1
10
100
42 °C
Dose (Gy)
Su
rv
iv
in
g 
fra
ct
io
n 
(%
)
37 °C
A
RT112
0 2 4 6
0.1
1
10
100
42 °C
Su
rv
iv
in
g 
fra
ct
io
n 
(%
)
37 °C
C
T24
0 2 4 6
0.1
1
10
100
42 °C
Cisplatin [µM]
Su
rv
iv
in
g 
fra
ct
io
n 
(%
)
37 °C
RT112
0 2 4 6
0.1
1
10
100
42 °C
Su
rv
iv
in
g 
fra
ct
io
n 
(%
)
37 °C
B
T24
0.1
1
10
100
42 °C
MMC [µg/ml]
Su
rv
iv
in
g 
fra
ct
io
n 
(%
)
37 °C
0.0 0.1 0.2 0.3 0.4
RT112
0.1
1
10
100
42 °C
Su
rv
iv
in
g 
fra
ct
io
n 
(%
)
37 °C
0.0 0.1 0.2 0.3 0.4
D RT112
C
yt
oc
hr
om
e 
C
-r
el
ea
se
 (%
)
0 20 40 60
0
10
20
30
40
50
42 °C
37 °C
T24
MMC [µg/ml]C
yt
oc
hr
om
e 
C
-r
el
ea
se
 (%
)
0 20 40 60
0
4
8
12
16
20
42 °C
37 °C
***
***
p = 0.11
p = 0.19*** ***
20 µm
DAPI Cyt C
E
RT112
C
yt
oc
hr
om
e 
C
-r
el
ea
se
 (%
)
0 5 20 40
0
10
20
30
40
50
42 °C
37 °C
T24
Cisplatin [µg/ml]C
yt
oc
hr
om
e 
C
-r
el
ea
se
 (%
)
0 5 20 40
0
4
8
12
16
20
42 °C
37 °C
*** ***
*** *** ***
n.d.
Figure 1. Survival 
responses of tumor 
cell lines to MMC and 
cisplatin.
A)-C) Colony survival 
assays of bladder cancer 
cell lines RT112 and 
T24. Cells were treated 
without (blue) or with 
hyperthermia (red), and 
exposed to either A) 
irradiation up to 6 Gy, B) 
MMC up to 0.4 µg/ml and 
C) cisplatin up to 6 µM. D) 
and E) Graphs presenting 
percentages of cells with 
cytochrome C-release 24 
hours after treatment 
with hyperthermia and 
indicated doses of D) 
MMC or E) Cisplatin. Cells 
were treated with caspase-
inhibitor Q-VD-OPh to 
prevent full completion 
of the apoptosis-program. 
The arrow in the figure 
embedded in panel D) 
T24 indicates a cell scored 
as Cytochrome C-release-
positive. At least 500 cells 
were analyzed for each 
condition, bars represent 
proportion ± standard 
error of the proportion. 
Asterisk indicate 
significance as determine 
by Students’ t-tests: * 
p<0.05; ** 0.001<p<0.01; 
*** p<0.001.
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the cells, hyperthermia has other means to 
increase cisplatin and MMC efficacy, namely 
by inhibiting DNA repair18,19. 
Both cisplatin and MMC are DNA 
crosslinking agents that can cause inter-
strand crosslinks (ICLs). These lesions 
are extremely toxic for cells and their 
restoration requires a tightly organized 
combination of DNA repair pathways20. 
The major ICL repair pathway produces a 
double strand break (DSB), which requires 
repair via homologous recombination 
(HR)21–23. HR uses the information from an 
intact copy of the broken DNA to faithfully 
restore the break. This step requires strand 
invasion, during which the 
broken DNA infiltrates the 
intact sister chromatid, a 
process orchestrated by the 
recombinase RAD5121,24. 
RAD51 localization to DNA 
breaks is aided by BRCA225, 
a protein which is specifically 
degraded by hyperthermia18. 
By degrading BRCA2, 
hyperthermia inhibits HR and 
thereby a late step of DNA 
repair for damage inflicted by 
the ICL-inducing agents MMC 
and cisplatin.
Here, we explore whether 
hyperthermia-mediated inhibition 
of HR can be used as a marker 
for increased treatment 
efficacy of bladder cancer. We 
use recently developed ex vivo 
assays on fresh bladder tumor 
biopsies26 to (1) determine 
hyperthermia’s potentiation of 
MMC and cisplatin treatment 
of bladder tumor cells, using 
a cytochrome C-release assay, 
and (2) determine the ability 
of the cells to form RAD51 
foci after hyperthermia as a 
potential biomarker for efficacy 
of hyperthermia treatment27,28.
BA
C D
E F
G H
B135
C
yt
oc
hr
om
e 
C
-r
el
ea
se
 (%
)
MMC Cispt
0
20
40
60
42 °C
37 °C
B141
C
yt
oc
hr
om
e 
C
-r
el
ea
se
 (%
)
MMC Cispt
0
20
40
60
42 °C
37 °C
B142
C
yt
oc
hr
om
e 
C
-r
el
ea
se
 (%
)
MMC Cispt
0
20
40
60
42 °C
37 °C
B143
C
yt
oc
hr
om
e 
C
-r
el
ea
se
 (%
)
MMC Cispt
0
20
40
60
42 °C
37 °C
B147
C
yt
oc
hr
om
e 
C
-r
el
ea
se
 (%
)
MMC Cispt
0
20
40
60
42 °C
37 °C
B149
C
yt
oc
hr
om
e 
C
-r
el
ea
se
 (%
)
MMC Cispt
0
20
40
60
42 °C
37 °C
B150
C
yt
oc
hr
om
e 
C
-r
el
ea
se
 (%
)
MMC Cispt
0
20
40
60
42 °C
37 °C
B154
C
yt
oc
hr
om
e 
C
-r
el
ea
se
 (%
)
MMC Cispt
0
20
40
60
42 °C
37 °C
*** ***
***
***
*** ***
*** ***
***
***
* ***
***
***
*** **
***
*
***
***
Ctrl Ctrl
CtrlCtrl
Ctrl Ctrl
CtrlCtrl
n.d.
n.d. n.d. n.d.
p = 0.50
p = 0.22
p = 0.08
n=
10
35
n=
16
33 n=
10
21
n=
15
25
n=
71
1
n=
32
5
n=
33
3
n=
72
n=
60
n=
16
9
n=
31
2
n=
31
6
n=
29
5
n=
36
5
n=
71 n=
53
n=
93
n=
90
n=
46
n=
20
1
n=
22
1 n
=2
58
n=
19
7
n=
18
5
n=
26
8
n=
90
8
n=
83
1
n=
62
n=
68
n=
62
4
n=
30
4
n=
40
6
n=
49
6
n=
35
n=
37
5
Figure 2. Cytochrome C release in dissociated bladder tumors. 
Graphs representing the percentage of Cytochrome-C-positive cells in dissociated bladder tumors. Tumor cells 
were cultured for 1-2 days before being subjected to hyperthermia in combination with 40 µg/ml MMC or 40 
µg/ml cisplatin. After treatment, medium was refreshed and the caspase-inhibitor Q-VD-OPh was added. After 
24 hours, cells were fixed, stained and scored for Cytochrome C-release positivity. A)-H) all represent different 
tumors. N.d. = not determined. The number of cells analyzed are indicated in each bar, which represent 
proportion ± standard error of the proportion. Asterisk indicate significance as determine by Students’ t-tests: * 
p<0.05; ** 0.001<p<0.01; *** p<0.001. 
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Results
Differential sensitivity to chemotherapeutics in 
RT112 and T24 cell lines
With the goal to find preclinical markers 
which can predict whether hyperthermia is 
a useful addition to the treatment of bladder 
treatment, we started by establishing a 
functional survival assay suitable for freshly 
obtained bladder tumors. We first set up the 
assay in two established bladder cancer cell 
lines that have been used in hyperthermia 
research before: T24 and RT11233. We 
determined the clonogenic survival capacity 
of heated or unheated RT112 and T24 cells 
treated with irradiation (Figure 1A), MMC 
(Figure 1B) and cisplatin (Figure 1C). 
In both cell lines, hyperthermia sensitized 
cells to irradiation (Figure 1A), but there 
was clear difference in the sensitivity to 
both chemotherapeutics: T24 was relatively 
resistant to MMC treatment and could hardly 
be sensitized by hyperthermia, while RT112 
was very sensitive to MMC, and this was 
further enhanced by hyperthermia (Figure 
1B). This difference in MMC-sensitivity in 
these cell lines has previously been described, 
although tested with 43 °C hyperthermia and 
by employing the MTT assay, which provides 
a measure of proliferation and does not test 
genetic viability34. For cisplatin we found the 
opposite of MMC sensitivity in RT112 and 
T24 cell lines (Figure 1C). The differential 
response towards cisplatin in unheated 
conditions in RT112 and T24 cells has been 
described before, and was attributed to 
a 2.5 fold-increased formation of ICLs in 
T24 relative to RT112, and increased levels 
of glutathione, a molecule associated with 
cisplatin-resistance, in RT11235,36.
To investigate chemotherapeutic sensitivity 
in tumors, an alternative approach to the 
colony survival assay is needed. Although 
bladder cancer tissue can be dissociated and 
cultured outside of the body, this can only be 
done temporarily, and therefore an alternative 
survival assay should be short-term26. We 
therefore selected an easily detectable, 
early step in the apoptosis pathway: release 
of mitochondrial cytochrome C37. During 
the assay, cells were exposed to selected 
treatments and subsequently treated with 
an apoptosis-inhibitor (Q-VD-OPh). The 
apoptosis inhibitor prevents cells from 
undergoing the full apoptotic program and 
therefore release of cytochrome C from 
the mitochondria can be quantified. After 24 
hours, the cells were fixed and stained for 
cytochrome C, and the fraction undergoing 
release was determined (Figure 1D). 
The cytochrome C-release assay was tested 
on RT112 and T24 cells, with or without 
hyperthermia, treated with increasing doses 
of MMC (Figure 1D) and cisplatin (Figure 
1E). Importantly, hyperthermia itself did not 
induce cytochrome C-release (Figure 1D-
E). MMC did induce cytochrome C release 
in both RT112 and T24 cells but, as in the 
colony formation assay, RT112 was more 
sensitive, as a much higher percentage of 
cells displayed MMC-induced cytochrome 
C release compared to T24. Interestingly, 
the cytochrome C release assay detected 
maximum treatment effects of MMC at 40 
μg/ml. This is illustrated in RT112, where 
the number of apoptotic cells diminished 
when the concentration of MMC was 
increased from 40 to 60 μg/ml. Moreover, 
hyperthermia elevated the percentage of 
apoptotic cells at lower concentrations of 
MMC (20-40 μg/ml), but failed to do so at 60 
μg/ml MMC in both cell lines (Figure 1D). 
It is possible that the high concentration of 
MMC induces necrosis, which is not inhibited 
by the apoptosis inhibitor and therefore 
not detected in the cytochrome C release 
assay. Corresponding to results from the 
colony survival assay, RT112 was relatively 
insensitive to cisplatin, while a significant 
amount of T24 did undergo apoptosis upon 
treatment (Figure 1E). In both cell lines, 
hyperthermia elevated the percentage of 
cells with released cytochrome C (Figure 
1E).
Cytochrome C in tumors
In both RT112 and T24, the cytochrome C 
release-assay could be used to quantitate 
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their sensitivity towards cisplatin and MMC, 
and demonstrate their enhanced sensitivity 
upon additional hyperthermia treatment. 
We therefore continued by testing the 
suitability of the assay to detect sensitivity of 
dissociated tumors. Because the number of 
coverslips that could be obtained was usually 
small, we selected limited conditions to be 
tested: control, 40 μg/ml MMC and 40 μg/
ml cisplatin. Because hyperthermia by itself 
did not induce apoptosis in RT112 and T24, 
only MMC and cisplatin treatment were 
combined with hyperthermia. 
Out of 13 bladder tumors dedicated for the 
cytochrome C release-assay, eight tumors 
produced sufficient numbers of attached 
bladder cells to perform the assay (Figure 
2A-H). Because the size of bladder tumors 
obtained was limited, or because cells did 
not attach to coverslips, not all samples 
were tested for the full set of conditions. 
For the five tumors for which unheated 
control data was obtained (Figure 2A, C, 
D, G, H), the percentage of cells undergoing 
cytochrome-C release increased upon 
MMC treatment in four samples (Figure 
2A, C, D, H), as was the case in all cisplatin 
treated samples. Hyperthermia increased 
the percentage of apoptotic cells in six 
out of seven samples treated with MMC 
(Figure 2A, C, D, F, G, H) and decreased 
the percentage in one (Figure 2B). This 
decreased number of apoptotic cells upon 
hyperthermia treatment may again be due to 
an increase in necrosis rather than apoptosis. 
For cisplatin treatment, hyperthermia 
increased the percentage of apoptotic cells 
in six out of eight samples (Figure 2A, B, C, 
D, F, G) and did not alter the percentage in 
the remaining two (Figure 2E, H). 
Quantitative and morphological differences in 
RAD51 foci in T24 and RT112 lines 
The ex vivo RAD51 focus formation assay has 
been used successfully to determine the HR-
status of freshly isolated mamma tumors27,28. 
To check whether this assay can be used to 
determine the effectivity of heat-induced 
HR-deficiency in bladder tumors, we first 
studied the appearance of RAD51-foci in 
the T24 and RT112 cell lines33. To measure 
hyperthermia-induced HR-deficiency in 
these cell lines, we first confirmed that 
BRCA2 was degraded upon hyperthermia in 
these cell lines (Figure 3A). The initial level 
of BRCA2 relative to the loading control 
PARP-1 was higher in RT112 than in T24, 
possibly because BRCA2 is mostly expressed 
in S-phase38, in which relatively more RT112 
cells than T24 cells reside39. However, the 
BRCA2-levels dropped substantially in both 
cell lines when hyperthermia was applied, 
implying that hyperthermia indeed affects 
HR in these two bladder cancer cell lines 
(Figure 3A). 
Next, we analyzed the effects of 
hyperthermia treatment on the appearance 
of RAD51 foci at different time points after 
5 Gy irradiation. Proper quantification of 
RAD51 focus formation capacity under 
different experimental conditions requires 
identification of S-phase cells40. Therefore, 
EdU was included in the culture media 
for an hour prior to fixing the cells, and 
only cells positive for EdU-staining were 
analyzed. Within the EdU-positive cells, 
the RAD51-foci were analyzed for both 
number per cell and integrated density, an 
Figure 3. Hyperthermia induces distinct changes in RAD51 foci in RT112 and T24 cell lines.
A) Immunoblots of samples treated with or without hyperthermia, probed for BRCA2 and PARP-1 as a loading 
control. B) RT112 cells were treated with or without hyperthermia and subsequently irradiated with the 
indicated dose. Cells were then incubated at 37 °C, and fixed at indicated time-points afterward irradiation. 
EdU was present for one hour prior to fixation to identify S phase cells. Cells were stained for EdU and RAD51. 
Pictures are a maximum projection of a Z-stack, and the dotted lines denote the perimeter of EdU-positive 
nuclei. C) The 2-dimensional graph expresses a quantified classification of RAD51 foci. Each dot in the graph 
represents one cell, plotted based on the number of RAD51 foci in its nucleus (y axis) and their integrated 
density (x axis); a derivate of intensity and area per nucleus. Cells without foci are presented in the embedded 
figure noting ‘0 foci’. D) and E) As panel B and C, but for T24 cells.
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Figure 4. Classification of RAD51-focus morphology upon hyperthermia in human bladder 
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A) Two hours after DNA-damage induction irradiation or zeocin, tumors were fixed and prepared for 
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RAD51-foci. Panels below the blue thermometer received no treatment before damage induction; panels below 
red thermometers were first treated with hyperthermia. The images are maximum projections of Z-stacks from 
representative areas of the tumors. B) Graph representing the frequency distribution of the morphological 
response of RAD51-focus upon hyperthermia treatment. The white part of the bar represents foci which have 
become smaller and more dispersed upon hyperthermia, the black part represents foci that did not change in 
morphology. Each bar contains the number (n) of analyzed tumors below. C) Frequency distribution based on 
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are classified in both methods of tumor preparation, because both were performed on the same tumor, and 
had the same result. No differences were found in the foci-response distribution between the technical methods 
(Fisher’s Exact test, p-values stated in the figure). D) Distribution of RAD51-foci response upon hyperthermia 
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test). p-values are indicated in the figure.
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expression of their intensity and area32. 
In the RT112 cell population, we found an 
average of 11 foci per nucleus when cells 
had not been irradiated (Figure 3B and 
C). When cells were irradiated, this number 
of foci increased to 35 foci at 60 minutes. 
Hyperthermia lowered the number of 
RAD51-foci and changed their morphology 
to less intense, smaller, and more dispersed 
at all time-intervals after irradiation. This 
change in their visual appearance (Figure 
3B) was reflected in a reduction in their 
integrated density, as more objective 
measurement of their morphology (Figure 
3C). The hyperthermia-induced reduction in 
foci number and change in appearance lasted 
at least until 60 minutes after irradiation 
(as indicated by the separation of the 
populations of red and blue dots in Figure 
3B, lower panel, 60 min). At two hours after 
irradiation cells with an increased number of 
foci with a larger integrated density started 
to re-appear in the population (Figure 
3C, 120 min). The RAD51-focus behavior 
observed in the T24 cell line was markedly 
different from the RT112 cell line: almost 
all unirradiated cells had no RAD51 foci, 
and they were induced only at a slow rate. 
The number of cells that did not have any 
foci greatly increased upon hyperthermia 
(Figure 3D and E). Moreover, the average 
number of foci in a hyperthermia-treated cell 
was much lower relative to 37 °C controls 
(Figure 3D and E). 
Ex vivo RAD51 focus formation assay on fresh 
bladder tumor biopsies
The number and appearance of RAD51-foci 
altered substantially upon hyperthermia in 
both bladder cancer cell lines, indicating that 
RAD51-focus formation could be a suitable 
biomarker for determining the effectivity 
of hyperthermia in bladder tumors. Out 
of 57 collected tumor samples, 48 samples 
contained sufficient tumor material to 
perform a RAD51-focus formation assay. 
We tested both intact tissue and dissociated 
tumors that were cultured for 1-2 days, to 
test the robustness and versatility of the 
assay. RAD51 foci were induced using either 
irradiation (5 or 10 Gy) or the radiomimetic 
agent Zeocin41. After DNA damage induction 
the cells were incubated at 37 °C for two 
hours before fixation to allow RAD51 foci 
to form. Fixed tissue or cells were stained 
for RAD51, while geminin (GMNN) was 
used as a marker for S- and G2-phase cells. 
Upon analysis, we excluded a number of 
samples because there were no GMNN-
positive cells detected (n=6) or no visible 
RAD51-foci in cells that did not undergo 
hyperthermia treatment (n=5). In the 
remaining samples (n=37), we distinguished 
two categories of RAD51 focus patterns 
upon hyperthermia: (1) foci became smaller 
and dispersed or, (2) foci morphology 
appeared to be unaltered (Figure 4A). 
Tumors which exhibited a clear response 
towards hyperthermia, visible as small and 
dispersed RAD51-foci, represented the 
majority of the samples (64%, Figure 4B). 
We subdivided the frequency distribution 
based on technical preparation of the 
samples (undissociated or dissociated) and 
on the manner of damage-induction, but did 
not find statistically significant differences in 
distribution of RAD51-focus within these 
categories (Figure 4C). Moreover, two 
tumors that were subjected to the assay in 
both undissociated and dissociated format 
could be analyzed, and in these cases the 
individual experiments were qualified within 
the same RAD51-category. Furthermore, a 
frequency distribution subdivision based on 
clinical parameters available for 34 tumors 
revealed that the reaction of RAD51-foci 
upon hyperthermia was not dependent on 
tumor grade, stage, recurrence or EAU risk 
stratification42 (Figure 4D). 
Discussion
In this work, we explored two ex vivo assays 
that are directed towards determining 
the effects of hyperthermia on bladder 
tumor cells. For both assays, bladder tumor 
tissue or dissociated tumor cells were 
treated with hyperthermia ex vivo and the 
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effects were measured in a short period 
afterwards. Specifically, we studied the effect 
of hyperthermia on induction of apoptosis 
by quantitating cells displaying cytochrome 
C release and on HR DNA damage repair 
capacity by qualitative and quantitative 
analysis of RAD51 foci. 
Cytochrome C-release is an early step in 
the apoptosis response, which makes it an 
ideal candidate to measure the fraction of 
apoptotic cells at an early stage after certain 
treatments37. Therefore, we tested the 
cytochrome C-release assay to determine 
sensitivity of bladder tumors towards 
cisplatin and MMC, and to determine 
if hyperthermia adds to the cell killing 
potential of these therapies. We started 
with models of bladder cancer, the bladder 
cancer cell lines RT112 and T24, and find 
that cell killing in the cytochrome C-release 
corresponds to the survival fraction in 
colony survival. Importantly, this assay was 
successfully performed in 8/13 fresh tumors, 
and within this set different responses to 
specific therapeutic combinations are found. 
Moreover, the assay detects enhanced 
apoptosis by addition of hyperthermia in 
bladder cells, and could therefore be useful 
to predict treatment response ex vivo.
The enhanced apoptosis response found 
when hyperthermia is combined with 
cisplatin and MMC in bladder cancer can be 
due to one or more of the many modes of 
action that might enhance sensitivity towards 
cisplatin and MMC17. One of the effects 
which might be of particular importance 
and can easily be measured is hyperthermia-
induced degradation of BRCA2, which 
alters RAD51-focus behavior and ultimately 
inhibits HR18. Studying RAD51-foci formed 
ex vivo has been used as a functional assay to 
determine the genetic HR-status of breast 
cancer tissue indirectly27,28, and we therefore 
tested whether this assay can be used on 
bladder cells to determine the effects of 
hyperthermia on HR. We find that although 
hyperthermia induced BRCA2 degradation 
in both cell lines, there is a distinct 
difference in RAD51-focus appearance upon 
hyperthermia. In RT112 cells, foci became 
small and dispersed, while in T24 cells the 
number of foci decreased dramatically, but 
the morphology of the remaining RAD51 
foci remained mainly intact. Both changes 
in RAD51-focus formation and morphology 
have been observed earlier, albeit at different 
temperatures32. This indicates that both 
a decrease in focus number as well as a 
change in morphology can be considered 
as a positive signal in the context of 
hyperthermia-effectivity. Interestingly, the 
small and dispersed foci in RT112 cells are 
also found when HeLa-cells were treated 
with temperatures exceeding 43 °C. This 
type of foci has been suggested to form 
independent of BRCA2, and might be a result 
of replication stress32,43. This hypothesis is 
supported by the large number of spontaneous 
RAD51-foci in RT112 cells, indicating high 
levels of endogenous DNA breaks. 
Tumor RAD51 focus response TER MMC TER 
cisplatin
B135 n.d. 2.1 5.0
B141 Small/Dispersed 0.61 5.0
B142 Similar 2.0 1.2
B143 n.d. 1.5 1.9
B147 Similar n.d. n.s.
B149 Small/Dispersed 1.4 1.3
B150 n.d. (small Foci before HT) 1.1 1.4
B154 Similar 1.3 n.s.
Table 1. RAD51 focus 
response and TER. 
TER = Thermal Enhancement 
Ratio. Calculated using the 
percentages of apoptotic 
cells treated with indicated 
chemotherapeutic detected in the 
Cytochrome C-assay. Percentage 
of apoptotic cells found with 
hyperthermia divided by that 
found at normal temperature. 
n.d. = not determined
n.s. = not significant, therefore no 
TER calculated
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Next, we applied the RAD51 focus formation 
assay to 48 freshly isolated bladder tumor 
samples. Interestingly, five samples had no 
visible RAD51-foci prior to hyperthermia, 
suggesting that ~10% of the bladder tumors 
are inherently HR-deficient, a percentage 
similar to that previously reported for 
primary breast cancers27. Thus, in bladder 
cancer, this ex vivo assay can potentially be 
used to identify a group of patients that 
might benefit from precision anti-cancer 
treatments directed against HR-defective 
tumors (i.e. PARP-1 inhibition)44. An 
additional six tumor samples were excluded 
for technical reasons.
In the majority of the 37 samples that we 
could analyze (64%), we found a clear 
response after hyperthermia: induction 
of small and dispersed RAD51 foci. In the 
remainder of the samples, hyperthermia did 
not alter the morphology of the RAD51-foci. 
Unfortunately, factors like cell heterogeneity, 
a small number of GMNN positive cells 
and the possibility that a paraffin section 
did not contain an entire nucleus, restrict 
analysis of the outcomes of extensive 
quantification and qualification as performed 
in the cell lines. Because we cannot measure 
the number of RAD51 foci accurately, 
the group where RAD51 foci had similar 
morphology before and after hyperthermia 
can potentially contain samples where HR-
deficiency was induced and where samples 
were non-responsive towards hyperthermia. 
It is likely that a number of the samples with 
morphologically similar foci before and after 
hyperthermia is indeed refractory to the 
effects of heat, as is illustrated by combining 
the RAD51-focus results with thermal 
enhancement ratios (TERs) calculated 
based on the results from the cytochrome 
C-release assay (B147 and B154, Table 1). 
Using a small number of bladder tumors, 
our study provides a basis for the use of 
two ex vivo assays to classify the response 
of bladder tumors upon hyperthermia 
or chemotherapy. The cytochrome 
C-release assay could potentially be useful 
to predict the response of a tumor to a 
chemotherapeutic, and to predict whether 
hyperthermia might add to this treatment. 
We also demonstrate that the RAD51-focus 
formation assay can be used as a marker 
for hyperthermia-mediated induction of 
HR-deficiency in bladder cancer specimens, 
and that the RAD51-focus response could 
potentially be a biomarker for hyperthermia-
efficacy. Although these first and small scale 
tests indicate that both assays are feasible 
for bladder tumors, a larger follow-up study 
that matches patient data to investigated 
tumors is needed to determine the clinical 
relevance of the results. 
Material and methods
Experimental outline and treatment timing
To explore the effects of hyperthermia 
on HR and cell killing, the bladder cancer 
cell lines (RT112 and T24) and freshly 
obtained bladder tumors were subjected 
to hyperthermia and various anti-cancer 
treatments. Hyperthermia was given in an 
incubator set at 42 °C with a controlled 
environment (5% CO2 and 20% O2), while 
the control was left in the 37 °C incubator. 
Cell cultures were placed in the 
hyperthermia incubator for 75 minutes, 
allowing 15 minutes for the medium to 
reach desired temperature and 60 minutes 
of effective hyperthermia. If cells or tissues 
were irradiated, they received the indicated 
dose from a cesium-137 source at 0.64 Gy/
min, directly following hyperthermia. When 
cells were treated with the radiomimetic 
agent Zeocin (0.5 mg/ml, InvivoGen), 
MMC (Sigma-Aldrich) or cisplatin (Accord 
Healthcare Limited), the dose was added 
directly before hyperthermia. Two hours 
after addition of the chemotherapeutic, the 
cells were washed once with PBS and the 
medium was refreshed.
Sample collection
Bladder tumors (n=59) were collected 
at Erasmus Cancer Institute Rotterdam, 
the Netherlands between 2012 and 2016. 
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All samples were urothelial carcinomas 
obtained by Trans Urethral Resection (TUR), 
and directly afterwards were transported to 
the laboratory in RPMI-1640, 10% fetal calf 
serum and 1% Penicillin/Streptomycin. The 
tumors were collected as surgical residual 
material under the “Code Proper Secondary 
Use of Human Tissue”, founded by the Dutch 
Federation of Medical Societies (www.fmwv.
nl). Patients could choose not to participate 
by means of an opt-out system. Patient data 
was blinded for the researchers by unique 
coding, so that individual data could not 
be traced back to the patients. This study 
was approved by the local Medical Ethical 
Committee (MEC-2012-113).
Sample handling
Upon arrival in the laboratory, the sample 
was examined macroscopically and 
was either left whole or subjected to 
dissociation. Whole tissue material was 
manually cut into smaller pieces (maximally 
3 mm) that allowed it to stay alive ex vivo for 
the duration of the RAD51 focus formation 
assay (~four hours). After performing an 
experiment, the intact material was formalin 
fixed overnight and subsequently paraffin 
embedded (FFPE). Tumors were dissociated 
using the gentleMACSTM Dissociator and 
the corresponding protocol (Miltenyi 
Biotec). The resulting cell suspension was 
subsequently cultured on coverslips in 
Amniomax C-100 medium (Gibco Life 
Technologies) as previously described26. 
Both the RAD51 focus formation assay and 
cytochrome C release assay were performed 
on the dissociated tumors between 24-48 
hours culturing. After an experiment, cells 
were fixed in 4% PFA for 15 minutes.
Cell culture
Both RT112 and T24 were maintained in 1:1 
DMEM/F10 culture medium, supplemented 
with 10% FCS and 1% Penicillin/Streptomycin 
in an incubator set at 37 °C, 20% oxygen 
and 5% CO2. Cells were kindly provided 
by dr. Ellen Zwarthof and regularly tested 
for mycoplasma and distinguished on 
morphology. 
Sample preparation and immunoblotting
RT112 and T24 cells were exposed to 
hyperthermia and lysed directly afterwards 
in Laemmli sample buffer (2% SDS, 10% 
Glycerol and 60 mM Tris pH 6.8 in PBS) 
by heating at 95 °C for 5 minutes. The 
sample was passed through a syringe to 
reduce viscosity. Protein concentration was 
determined by the Lowry protein assay29, 
before 50 μg protein was prepared with 
loading buffer (0.01% bromophenol blue 
and 0.5% β-mercaptoethanol). Samples 
were then separated on a 5% SDS-PAGE 
gel and transferred to a PVDF membrane. 
Proteins were detected with primary 
antibodies mouse-anti-BRCA2 (OP95, 
Calbiochem, 1:1000) or mouse-anti-PARP-1 
(Alexa 1:1000) and HRP-conjugated Sheep 
anti-mouse IgG (H+L) (1:2000, Jackson 
ImmunoResearch) as secondary antibody. 
Prior to signal detection on an Alliance 
4.7 (Uvitec Cambridge), membranes were 
incubated with ECL substrate (1:1 mixture 
of A: 0.1M Tris-HCl pH 8.5, 2.5 mM Luminol, 
0.4 mM p-Coumaric acid and B: 0.1 M Tris-
HCl pH 8.5, 0.02% hydrogen peroxide).
RAD51 focus formation assay
The RAD51 focus formation assay on intact 
bladder tissue was performed as described 
previously27. Briefly, after hyperthermia 
treatment, samples were irradiated with 
5 Gy and fixed two hours after irradiation 
ended. After FFPE-treatment, the samples 
were sliced in 4 μm thick sections, and 
prepared for immunofluorescent labelling 
with primary antibodies mouse-anti-RAD51 
(1:200, GeneTex clone14B4 GTX70230) 
and rabbit-anti-GMNN (1:400, Proteintech 
Group 10802-1-AP), and secondary 
antibodies Alexa Fluor® goat-anti-rabbit 594 
and goat-anti-mouse 488 (ThermoFisher 
Scientific). 
The RAD51-assay performed on established 
cell lines RT112 and T24 and on attached 
cells from dissociated tumors, was slightly 
altered: (1) cells were fixed with 4% PFA 
for two hours after irradiation, unless 
stated otherwise in the figures, and (2) 
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the deparaffinization and target retrieval 
steps were omitted. S-phase cells in RT112 
and T24 cell lines were detected by EdU 
instead of geminin. Cells were labelled 
with 10 μM EdU (Invitrogen) 75 minutes 
prior to fixation, which was detected 
using a Click-IT® reaction according to 
manufacturer’s protocol (Invitrogen), prior 
to immunostaining of RAD51.  
Clonogenic survival
Clonogenic survival was performed using 
an “immediate plating after treatment” 
protocol30. In brief, a feeder layer of 20,000 
primary fibroblasts irradiated with 40 Gy and 
100,000 RT112 or T24 cells were seeded on 
separate 60 mm dishes. The next day, RT112 
or T24 cells were subjected to indicated 
treatments, immediately trypsinized and 
seeded at appropriate densities. Colonies 
were allowed to grow for 10 days before 
being fixed and stained in 45% methanol 
(v/v), 45% dH2O (v/v) and 10% Acetic Acid 
(v/v) and 2.5% Coomassie Brilliant Blue 
(w/v). 
Cytochrome C release assay
Cells were treated with hyperthermia in 
combination with the indicated chemotherapy. 
After two hours, medium was refreshed and 
1:1,000 of the apoptosis inhibitor Q-VD-
OPh (20 μM, MP Biomedicals) was added for 
24 hours, after which the cells were fixed 
with 4% PFA for 15 minutes. Fixed cells 
were subsequently labelled with mouse-anti-
Cytochrome C (1:100, BD Pharmingen) and 
secondary antibody Alexa Fluor® goat-anti-
mouse 488 (ThermoFisher Scientific). 
Image acquisition and foci counting
All images for RAD51 foci analysis were 
maximum projection of Z-stacks with an 
increment of 1 μm, obtained with a Leica 
TCS SP5 confocal microscope with a 63x 
oil immersion (n.a. 1.4) objective. Image 
size was 1024 x 1024 pixels and 82 x 82 
μm. Foci were quantified using a previously 
described home-made macro within FIJI 
(Image J1.50i31)32 was used to quantify foci. 
Cells were selected based on the perimeter 
of EdU staining, and the MaxEntropy 
thresholding algorithm was prior to the 
‘Analyze Particles’-function. Images for 
measurement of Cytochrome C-release 
were obtained with the same confocal 
microscope but with different settings: a 
20x dry objective was used to obtain images 
sized 1024 x 1024 pixels and 247 x 247 μm. 
Cells were manually analyzed and counted 
using Z-stacks with an increment of 2 μm on 
5-10 independent stacks from one sample.
Statistics
All graphs were generated in GraphPad Prism 
5.02. For the apoptosis assay, the proportion 
apoptotic cells, and a standard error of the 
proportion were determined by dividing the 
number of cytochrome C releasing cells by 
the total population. Statistical tests used 
to determine significance of the results are 
indicated in the text or figure legends. 
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inhibitors of poly [ADP-ribose] polymerase 
1 (PARP-1)8–10. PARP-1 inhibitors have been 
used to target the DDR in clinical practice11, 
and are an example of precision treatment: 
while normal cells can compensate for a 
deficiency in DDR-pathways involving PARP-
1 related repair by using the HR-machinery, 
tumours that are HR-deficient cannot. Thus, 
clinical efficacy of PARP-1 inhibitors in turn 
renders HR an attractive therapeutic target: 
if one could inhibit HR in a tumour, it would 
become more sensitive to these treatment 
modalities. 
HR is one of the two pathways that repair 
DNA double-stranded breaks (DSBs), the 
other being non-homologous end joining 
(NHEJ). While, in essence, NHEJ repairs DNA 
by directly re-joining the two ends of a DSB 
together and is active throughout the cell 
cycle, HR faithfully restores DSBs by using 
an intact copy of the DNA as a template. 
This copy usually is the sister chromatid that 
arises during replication, which limits HR 
activity to the S and G2-phases of the cell 
cycle. HR is tightly regulated, and involves an 
orchestrated series of events mediated by 
many different proteins12. The start of the HR 
pathway is characterized by the generation 
of 3’ single strand overhangs by DNA end 
resection, a process mediated by BRCA1, 
Introduction
The DNA damage response (DDR) 
consists of various intricate pathways that 
maintain the integrity of the DNA in our 
cells, which is continuously threatened by 
endogenous and exogenous agents1–3. The 
DDR deals with DNA damage inflicted by 
these assaults by detecting its presence, 
signalling to the pathways controlling cell 
cycle, and finally repairing or bypassing the 
damage2. However, the protection provided 
by the DDR has justly been described as a 
double edged sword; by safeguarding the 
DNA, it prevents accumulation of mutations 
in genes that might lead to cancer, but also 
counteracts the efficacy of many anti-cancer 
therapies that are based on cytotoxicity of 
DNA damage4. It is because of the latter 
aspect that inhibition of the DDR is of great 
interest in the context of cancer treatment5.
That the DDR is of importance for treatment 
efficacy is illustrated by tumours harbouring 
defects in a specific pathway of the DDR: 
homologous recombination (HR), examples 
of which are breast and ovarian tumours with 
BRCA1 and BRCA2 mutations. These tumours 
are not only very sensitive to specific 
chemotherapeutics such as cisplatin and 
carboplatin6,7, but also to a new class of drugs, 
Abstract
The DNA damage response (DDR) is a designation for a number of pathways that protect our 
DNA from various damaging agents. In normal cells, DDR is extremely important in maintenance 
of genome integrity, but in cancer cells these mechanisms counteracts therapy-induced DNA 
damage. Inhibition of the DDR could therefore be used to increase the efficacy of anti-cancer 
treatments. Hyperthermia is an example of such a treatment which inhibits a sub pathway of the 
DDR called homologous recombination (HR). It does so by inducing proteasomal degradation of 
BRCA2 -- one of the key HR enzymes. Understanding the precise mechanism that mediates this 
degradation is important for our understanding of how hyperthermia affects therapy and how 
homologous recombination and BRCA2 itself function. In addition, mechanistic insight can yield 
new therapeutic strategies to enhance the effects of local hyperthermia or to inhibit HR. In this 
chapter, we investigate the mechanisms driving hyperthermia-induced BRCA2 degradation. We 
find that BRCA2 degradation is evolutionary conserved, that BRCA2 stability is dependent on 
HSP90, that ubiquitin might not be involved in targeting BRCA2 for protein degradation via the 
proteasome and, that BRCA2 degradation might be modulated by oxidative stress and radical 
scavengers.
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among other proteins. Strand invasion - a 
central step in the HR pathway - is catalysed 
by the nucleoprotein filaments formed by 
RAD51 on the resected single stranded 
DNA. The assembly of RAD51 onto the 
DNA is aided by many proteins, including 
BRCA2 and RAD5413–15. The invaded strand 
is now used as a template for repair of the 
resected strands. Resolution of the Holiday 
junctions is the last step of HR and can have 
several outcomes, but, in effect, all result in 
faithful repair of the broken DNA12. 
As a consequence of the complexity of 
HR, the pathway can be interfered with 
at multiple levels to create a window of 
therapeutic opportunities16–18. However, 
when thinking about such approaches, one 
should consider that HR is essential and 
interfering with it could have disastrous 
consequences in normal cells19. Ideally, 
inhibition of HR in cancer treatment should 
occur in a local fashion. Hyperthermia is a 
method which has the potential to achieve 
exactly this result: by locally applying heat to 
a tumour, it triggers a pathway which induces 
degradation of BRCA2 , resulting in a failure 
to localize RAD51 to double-strand breaks 
and effectively attenuating HR20. BRCA2 
degradation is rapidly (within ~15 minutes) 
induced by hyperthermia in a temperature 
range between 41-43 °C21,22. However, the 
molecular mechanisms of heat-mediated 
degradation of BRCA2 are largely unknown, 
with exception of the last step which involves 
the proteasome21.
In this chapter, we investigate the mechanisms 
that mediate BRCA2-degradation upon 
heating, because this could yield (1) better 
understanding of the effects of hyperthermia, 
(2) an increased understanding of the 
modulation of the HR-pathway and of the 
BRCA2 protein itself, (3) new therapeutic 
targets to inhibit HR, and (4) therapeutic 
targets that may enhance the local effects of 
hyperthermia.
Results
Heat-mediated degradation of BRCA2 and 
modulation of HR
Hyperthermia induces BRCA2-degradation 
in established human cell lines of different 
origins, and in human tumours heated 
ex vivo21 (Chapters 3, 5, 6, this thesis). 
The reduction in BRCA2 levels has been 
detected using the OP95 BRCA2-antibody. 
To confirm that the observed decline in 
BRCA2-protein levels is not due to changes 
in availability of the epitope detected by the 
antibody, we exposed HeLa cells expressing 
FLAG-BRCA2 to 42 °C for one hour, and were 
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Figure 1. Heat-mediated degradation of BRCA2 and modulation of HR.
A) Immunoblot of HeLa cells stably expressing FLAG-BRCA2, treated with or without hyperthermia. B) 
Immunoblot of wild-type IB10 and Brca2GFP/GFP mES cells. The upper and lower arrow next to the upper Brca2-
panel indicate the positions of Brca2-GFP and untagged Brca2 respectively. C) Analysis of BRCA1 protein levels 
after hyperthermia in HeLa cells using 3 different BRCA1 antibodies. D) Analysis of RAD54 and RAD51 protein 
levels upon hyperthermia in BRO cells.
100
Chapter 7
7
able to detect a heat-induced reduction in 
the BRCA2 level with the FLAG-specific M2-
antibody (Figure 1A). 
The 3328-aa mouse BRCA2 shares 
59% amino acid identity with its human 
orthologue23. To determine whether murine 
BRCA2 is also susceptible to degradation 
upon hyperthermia treatment, we exposed 
wild-type (IB10) and Brca2GFP/GFP,24 mouse 
embryonic stem cells (mES) to hyperthermia. 
Because the OP95-antibody has been raised 
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Figure 2. Various inhibitors alter the heat-mediated BRCA2 degradation.
A)-E) Immunoblots of cells treated with or without hyperthermia in the presence of indicated doses of different 
inhibitors. All inhibitors were added 30-60 minutes prior to hyperthermia treatment. A) U2OS cells treated with 
the proteasome inhibitor MG132. B) HeLa cells treated with the autophagy inhibitor bafilomycin A1. C) U2OS 
cells treated with an inhibitor of the VCP-segregase. D) U2OS cells treated with the HSP90-inhibitor Ganetespib. 
E) BRO cells treated with the translation inhibitor cycloheximide. F) BRO cells treated with cycloheximide 
(50 µg/ml) and hyperthermia for the indicated periods of time. G) U2OS cells were treated with or without 
hyperthermia in the presence of DMSO and cycloheximide and irradiated with 5 Gy and fixed 90 minutes after 
irradiation. Cells were stained for EdU and RAD51. The panel shows the RAD51-staining for representative cells 
for each condition. The dotted line indicated the perimeter of an EdU-positive nucleus. Numbers in the panel 
indicate the mean number of foci ± standard error of the mean and the number of cells analysed. 
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against amino acids 1651-1821 of human 
BRCA2, a region poorly conserved in 
murine BRCA223, we immunoblotted with 
a polyclonal antibody (ab27976) recognizing 
the conserved N-terminus and with an anti-
GFP antibody. We found that both murine 
BRCA2 and murine BRCA2-GFP were 
degraded upon hyperthermia, indicating 
the heat-mediated response is evolutionary 
conserved (Figure 1B).
Another protein in the HR pathway, BRCA1, 
has also been reported to be degraded upon 
mild hyperthermia, albeit with different 
timing: degradation is only detected one 
hour after the onset of heating25. In HeLa 
cells, we found that the antibody signal 
intensity and/or position in gel from three 
different antibodies detecting BRCA1 also 
changed after one hour at 42 °C (Figure 
1C). Interestingly, we found that yet another 
protein in the HR pathway also changed 
abundance upon heat-treatment: RAD54 
(Figure 1D). As reported before, we found 
no such changes in RAD51 protein levels21 
(Figure 1D). 
Various inhibitors affect heat-mediated BRCA2 
degradation 
Although an interference of heat with 
multiple components of the HR pathway is 
interesting in the context of hyperthermia 
biology, in this study we continued by 
focussing on the mechanism of BRCA2-
degradation. Thermal stress generally causes 
protein unfolding, and it is likely that the 
BRCA2 protein shares this fate. Cells can deal 
with unfolded proteins by either refolding 
them with the aid of molecular chaperones, 
or, if a protein cannot be rescued, breaking 
it down. Two separate systems for protein 
degradation are currently recognized: 
the ubiquitine-proteasome pathway and 
lysosomal degradation (autophagy), the 
latter being primarily associated with 
processing large and aggregated proteins26. 
Heat-induced degradation of BRCA2 seems 
to proceed via the proteasome21, and we 
could indeed confirm that proteasome 
inhibitor MG132 stops this process (Figure 
2A). In contrast, we found that bafilomycin 
A1, an inhibitor of a late step in autophagy27, 
did not protect BRCA2 from degradation 
(Figure 2B), indicating that BRCA2 is 
exclusively degraded via the proteasome. 
NMS-873, which inhibits VCP (also known as 
p97 or CDC48), a “segragase” acting in many 
cellular processes, including extraction of 
ubiquitinated proteins from chromatin and 
membranes28, also protected BRCA2 from 
degradation (Figure 2C). BRCA2 is thought 
to be a client protein of the molecular 
chaperone HSP90, and a prolonged inhibition 
of HSP90 causes reduction in BRCA2 
levels29. Inhibition of HSP90 indeed enhanced 
BRCA2-degradation upon hyperthermia 
(Figure 2D, Chapter 8)21, illustrating the 
importance of HSP90 in BRCA2 homeostasis. 
To test the importance of renewed synthesis 
of BRCA2 during hyperthermia treatment, 
we treated cells with the translation 
inhibitor cycloheximide. Surprisingly, we 
found that inhibition of translation protected 
BRCA2 from degradation (Figure 2E). 
This protection expired after two hours of 
treatment, which indicates that translation is 
important to maintain BRCA2 protein levels 
(Figure 2F). 
To determine whether or not the fraction of 
BRCA2 protected by the different inhibitors 
was still functional, we performed the 
RAD51 focus formation assay (Figure 2G). 
Formation of RAD51 foci upon irradiation 
is strictly dependent on BRCA213,30 and 
has been demonstrated to be abrogated by 
heat21,22. Both MG132 and VCP inhibition 
impair RAD51 focus formation31,32, so we 
were only able to perform this assay for 
cycloheximide. Cycloheximide decreased 
the number of RAD51 foci in irradiated 
cells incubated at 37 °C, but treatment with 
heat failed to enhance this effect, indicating 
that the abundance of BRCA2 as well as its 
functionality might be protected by inhibition 
of translation. 
BRCA2 stability is dependent on HSP90
Targeting HSP90 by inhibitors like 17-DMAG 
increase the extent of BRCA2 degradation 
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upon hyperthermia21. We have now shown 
that a short exposure to the second 
generation HSP90-inhibitor Ganetespib 
achieves the same result, and makes cells 
more sensitive to hyperthermia (Figure 
2D, Chapter 8). To further explore the 
extent by which BRCA2 protein stability 
is dependent on HSP90 upon challenge by 
hyperthermia, we combined cycloheximide, 
Ganetespib and hyperthermia in a single 
experiment. We found that the protective 
effects of cycloheximide on BRCA2 were at 
least partly dependent on HSP90 (Figure 
3A). Moreover, we found that the autophagy 
inhibitor bafilomycin did not rescue BRCA2 
from the combination of hyperthermia 
and Ganetespib, while MG132 did (Figure 
3B). This indicates that BRCA2 is cleared 
by the proteasome in presence of HSP90 
inhibitor and hyperthermia, as is the case 
for hyperthermia alone (Figure 2A)21. 
All these results combined reinforce the 
hypothesis that HSP90 protects BRCA2 
under hyperthermic conditions.
Searching for the proteins that mediate
degradation of BRCA2 upon hyperthermia
The cascade of events that leads to 
proteasomal degradation of BRCA2 
upon heat treatment might yield BRCA2 
interaction partners which could be 
interesting from both a biological and 
clinical perspective. Usually, a protein is 
post-translationally marked with ubiquitin 
before being degraded by the proteasome. 
Ubiquitination is mediated by a number of 
enzymes33. First, an E1-activating enzyme 
activates and transfers a ubiquitin molecule 
to the E2-conjugating enzyme. The E2-
enzyme is recruited to an E3-ubiquitin ligase, 
which catalyses the transfer of ubiquitin to a 
target lysine of the protein. Being the last in 
B
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Figure 4. Efforts to find E2-conjugating enzyme that mediates degradation of BRCA2 upon 
hyperthermia.
A) Results of individual knock-down of all known ubiquitin E2-conjugating enzymes in U2OS cells. Effectivity 
of all siRNA’s employed was previously assessed by quantitative PCR35. B) Results of simultaneous knock-down 
of E2-conjugating enzymes within specific families in U2OS cells. C) Results of knock-down of the SUMO-E2 
enzyme UBC9 in U2OS cells. 
Figure 3. BRCA2 is a client protein of 
HSP90.
A) Immunoblot of BRO cells treated with 
or without hyperthermia in the presence 
of cycloheximide (50 µg/ml), Ganetespib 
(50 nM) or both. B) Immunoblots of HeLa 
cells treated with or without hyperthermia 
in the presence of various combinations of 
proteasomal inhibitor MG132 (50 µM), 
autophagy inhibitor bafilomycin (10 nM) and 
HSP90-inhibitor Ganetespib (50 nM).
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the ubiquitin-cascade, the E3-ligases provide 
the specificity to the target protein and are 
therefore potentially the most interesting 
interaction partners. However, over 600 
different E3-ligases have been identified 
thus far34 and pinpointing the E3-ligases 
potentially responsible for heat-mediated 
BRCA2 degradation is challenging. We 
therefore set out by individually knocking 
down all E2-conjugating enzymes by siRNA 
in U2OS-cells (Figure 4A)35. However, 
downregulation of no single E2-conjugating 
enzyme protected BRCA2 from heat-
induced degradation (Figure 4A). To test 
for redundancy between E2-enzyme families, 
we combined siRNAs to simultaneously 
downregulate multiple E2-enzymes but found 
no effect on BRCA2 levels (Figure 4B). 
The small ubiquitin-like modifier (SUMO) is 
also able to target proteins to proteasome, 
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Figure 5. Searching for the E3-ligase that mediates degradation of BRCA2 upon hyperthermia.
A) Effect of hyperthermia on BRCA2 levels upon knock-down of the HSP-associated E3-ligase CHIP in U2OS 
cells using 2 different siRNAs. Arrow on the right next to the CHIP-panel indicates the predicted height of 
the CHIP-protein. B) Effect of hyperthermia on BRCA2 levels upon knock-down of the SUMO-E3 ligases 
PIAS1-4 in U2OS cells using siRNA. C) Effect of hyperthermia on BRCA2 levels upon siRNA knock-down of 
DNA-repair-related SUMO-targeted ubiquitin ligases RNF4 and RNF111. D) Detection of BRCA2 and BRCA1 
in UWB1.289 (BRCA1-null) cells with or without complementation of wtBRCA1. E) Detection of BRCA2 in 
U2OS cells treated with increased doses of the neddylation-inhibitor MLN4924, added 30 minutes prior to 
hyperthermia. F) Detection of BRCA2 in U2OS cells treated with or without hyperthermia in the presence of 
proteasome inhibitor MG132 (10 µM) or the E1-activating enzyme inhibitor PYR-41 (10 µM). 
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and SUMOylation is increased upon heat-
shock36. We therefore downregulated the 
E2-conjugating enzyme for SUMO, UBC9 
(also known as UBE2I)37, but found that this 
also had no effect on BRCA2-protein levels 
after hyperthermia (Figure 4C).
Because no candidate E2-conjugating 
enzymes emerged from the systematic screen, 
we decided to try a candidate approach for 
several E3-ligases. The first E3-ligase we 
included, CHIP (also known as STUB1), is 
closely related to the heat-shock response38, 
cooperating with multiple E2-conjugating 
enzymes39, and has been implicated in the 
degradation of the base excision repair 
protein OGG1 upon hyperthermia40. 
However, knockdown of CHIP did not affect 
BRCA2 degradation upon heat treatment 
(Figure 5A). Knockdown of the four 
SUMO E3-ligases PIAS1-441 did not affect 
BRCA2 protein levels (Figure 5B), nor did 
knockdown of two SUMO-targeted ubiquitin 
ligases (STUbLs), RNF4 and RNF111 (also 
known as Arkadia), both implicated in DSB 
signalling37,42 (Figure 5C). We found that 
absence of BRCA1, which is closely related 
to the BRCA2 complex and has E3-ligase 
activity43–45, did not change degradation of 
BRCA2 upon hyperthermia (Figure 5D). 
Inhibition of the NEDD8-Activating Enzyme, 
which prevents neddylation and thereby 
activation of all Cullin-type E3 ligases46,47, 
also did not affect BRCA2 degradation 
(Figure 5E). Finally, we tested abolishing all 
ubiquitination by inhibiting the E1-activating 
enzyme using PYR-4148 and, surprisingly, 
found that addition of this inhibitor failed to 
protect BRCA2 upon applying hyperthermia, 
in contrast to the addition of a proteasome 
inhibitor (Figure 5F). 
Heat-mediated BRCA2 degradation from the 
protein’s perspective
Since neither the E2-wide screen nor the 
E3-candidate approach yielded proteins 
involved in mediating hyperthermia-induced 
BRCA2 degradation, we decided to approach 
the problem from the perspective of BRCA2 
itself (Figure 6A). This protein has a number 
of properties which complicate various 
proteomic approaches in the presence of 
hyperthermia; BRCA2 is 1) large (384 kDa), 
2) expressed at a relatively low level and only 
during S- and G2-phase of the cell cycle49,50, 
3) predicted to have many intrinsically 
disordered domains51, and 4) degraded upon 
treatment with hyperthermia. 
In order to side-step some of the properties 
listed above, we started by engineering three 
fragments of BRCA2: the N-terminus (amino 
acids 1-939), a middle part (amino acids 940-
2198) and the C-terminus (amino acids 2199-
3418) (Figure 6B). We tagged them with 
either GFP (Figure 6C) or FLAG (Figure 
6D) and introduced them to HeLa cells using 
a PiggyBac transposon system52. We found 
that all GFP-tagged versions of the BRCA2-
fragments displayed some degradation upon 
hyperthermia, although at much reduced 
levels compared to endogenous BRCA2 
(Figure 6C). The degradation was most 
pronounced for BRCA2-Middle (Figure 6C), 
which we also found when using a FLAG-tag 
(Figure 6D). We engineered a fourth FLAG-
construct, encoding for the N-terminus 
and C-terminus of BRCA2 (ΔMiddle), and 
found that this fragment also degraded upon 
heat, in contrast to either the FLAG-tagged 
N-terminus or C-terminus alone (Figure 
6D). This observation, together with the 
difference in the extent of degradation of 
BRCA2-fragments tagged with either GFP 
or FLAG, suggest that expression levels of 
the constructs could potentially influence 
the results in this assay; overexpression of 
the fragments may saturate the molecular 
components which mediate degradation. 
To obtain more conclusive evidence for 
which part of BRCA2 is degraded upon 
hyperthermia, we took advantage of the 
behaviour of endogenous. Since the protected 
BRCA2 is shifted to the insoluble fraction of 
cell lysates22, we subjected cells expressing 
BRCA2 fragments to hyperthermia in 
the presence of MG132 and performed a 
simple fractionation using a mild detergent 
(Figure 6E). The FLAG-tagged full-length 
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protein behaved identically to the untagged 
wild-type BRCA2: hyperthermia caused 
the BRCA2-protein to shift from soluble 
fraction and addition of MG132 dramatically 
increased its presence in the insoluble 
fraction (Figure 6E)22. The same localisation 
of BRCA2 protein fragments in supernatant 
and pellet was found in cells expressing 
BRCA2-Middle, BRCA2-C-terminus and 
BRCA2ΔMiddle (Figure 6E). Interestingly, 
the N-terminal version of BRCA2 did 
not disappear from the supernatant upon 
treatment with hyperthermia alone, but 
did so when MG132 was added (Figure 
6E). Together, these results suggest that the 
Middle and C-terminal fragments contain 
the major determinants for heat-mediated 
BRCA2 degradation, and might therefore 
be of interest to identify heat-dependent 
interaction partners. 
Semi-quantitative mass spectrometry analysis 
identifies putative BRCA2-interactors upon 
hyperthermia
In parallel to the previous approach, and as 
another way to investigate hyperthermia-
mediated degradation of BRCA2 from 
the protein’s perspective, we performed a 
proteomic analysis in Brca2GFP/GFP mES cells24, 
where BRCA2 was immunoprecipitated 
using GFP nanobody beads. A three-state 
reciprocal SILAC (Stable Isotope Labelling 
with Amino acids in Cell culture) approach 
was used to quantitatively compare three 
different treatments: 0, 20 and 60 minutes 
hyperthermia at 42 °C. Log2 SILAC ratios 
were calculated for each protein and revealed 
that 20-minute exposure to hyperthermia 
enriched the immunoprecipitate of BRCA2-
GFP for Ubiquitin, USP28 and HSPB1 (also 
known as HSP25 and HSP27) (Figure 7A). 
HSPB1 and USP28 remain enriched in the 
immunoprecipitate after 60 minutes of 
hyperthermia (Figure 7B). Hyperthermia 
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in immunoprecipitation buffer immediately after the exposure to 42 °C for 0, 20 or 60 minutes. Precipitated 
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induces BRCA2 degradation, and therefore 
the decreased abundance of BRCA2 and 
known interactors such as RAD51 and 
PALB2 after 60 min at 42 °C can be regarded 
as a quality control within this experiment 
(Figure 7B).
Oxidative stress induces BRCA2 degradation
The proteomic experiment identified HSPB1 
as a prominent addition to the BRCA2-
interactome shortly after hyperthermia 
(Figure 7A) and also confirmed the 
previously published observation that KEAP1 
is part of the BRCA2 complex45. Interestingly, 
both proteins participate in the oxidative 
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Figure 8. Oxidative stress as an inducer of BRCA2 degradation.
A) BRCA2 levels in BRO cells subjected to hyperthermia in the presence of indicated doses of antioxidant 
compounds N-acetylcysteine (NAC), ascorbic Acid (Asc) or dithiothreitol (DTT). B) BRCA2 levels in BRO cells 
subjected to the indicated dose ultraviolet-B and lysed three hours afterwards. C) BRCA2 levels in BRO cells 
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Rotenone. D) BRCA2 levels in BRO cells exposed to hyperthermia or H2O2 (0.1mM) in the presence or absence 
of proteasome inhibitor MG132 (50 µM). 
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stress response53,54. This is of interest because 
hyperthermia is thought to alter redox state 
of cells by inducing imbalance between the 
production of reactive oxygen species (ROS) 
and the presence of radical scavengers55. 
For instance, hyperthermia increases ROS 
by upregulating NADPH oxidase56 and has 
been implicated in downregulation of the 
antioxidant glutathione57. This prompted us 
to investigate whether there is a connection 
between oxidative stress and BRCA2 
protein stability. 
To test the possible relation heat-induced 
oxidative stress and BRCA2 degradation, 
we first analysed whether introduction 
of exogenous antioxidants could 
protect BRCA2 from being degraded by 
hyperthermia. We found that the anti-oxidants 
N-acetylcysteine (NAC)58 and ascorbic acid 
at low concentrations protected BRCA2 
in hyperthermic circumstances (Figure 
8A). Dithiothreitol (DTT), which reduces 
disulphide bonds of proteins, did not prevent 
BRCA2 degradation upon hyperthermia, 
but lowered protein levels upon increased 
concentration under non-hyperthermic 
conditions (Figure 8A).
Previously, it was found that ultraviolet B 
irradiation (UV-B) causes downregulation 
of BRCA2, which was not dependent on 
cell cycle differences and could be blocked 
by cycloheximide59. In the context of the 
relation between oxidative stress and 
BRCA2, this is of special interest because 
it has been reported that UV-B induces 
ROS60,61 and potentiates a disturbance in 
oxidative homeostasis. We found that UV-B 
indeed downregulated BRCA2 (Figure 
8B). Next, we added several compounds 
that increase the amount of ROS in the cell, 
further disturbing the oxidative balance. 
While the mitochondrial complex I inhibitor 
rotenone62 and the organic peroxide tert-
Butyl hydroperoxide (t-BHP) did not clearly 
decrease BRCA2 protein levels, addition of 
H2O2 did (Figure 8C). Like hyperthermia-
induced degradation of BRCA2, inhibition 
of the proteasome protected BRCA2 
from H2O2 mediated degradation (Figure 
8D). Failure of rotenone to induce 
BRCA2 degradation can be explained by 
mitochondrial localization of the ROS it 
produces. Organic (t-BHP) and inorganic 
(H2O2) peroxides are metabolised differently 
and can have profoundly different effects on 
DNA integrity, PARP activation and apoptosis 
induction63,64. Which of these differences 
is responsible for the distinct effects on 
BRCA2 requires further investigation. 
Discussion
Hyperthermia attenuates HR by 
downregulating HR-proteins, including 
BRCA2, thereby rendering innately HR-
proficient cells sensitive to PARP inhibitors. 
Understanding the mechanism by which 
hyperthermia targets BRCA2 for degradation 
is interesting from both a biological and 
clinical perspective, because it could yield 
a general understanding of hyperthermia 
biology, regulation of BRCA2 and HR, and 
eventually unravel other therapeutic targets 
that may inhibit HR or increase hyperthermia 
efficacy. In this chapter, we explore this 
mechanism and present some interesting 
molecular details of hyperthermia-mediated 
degradation of BRCA2.
Heat-mediated inhibition of HR from an 
evolutionary perspective
In the context of cancer treatment, 
hyperthermia is an effective method to 
increase anti-cancer efficacy of DNA-
damaging treatments such as radiotherapy 
and some forms of chemotherapy. However, 
in the 19th century, hyperthermia was applied 
as an anti-cancer treatment in a substantially 
different way: patients were treated with 
bacterial toxins that induced fever65,66. This 
treatment can be regarded as hyperthermia 
treatment as well as immunotherapy 
and underlines that fever, an increase in 
the core temperature of an organism, 
is a physiological situation during which 
hyperthermia occurs. Interestingly, fever 
is conserved in both warm-blooded and 
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cold-blooded vertebrates, and has several 
very important effects on the immune 
system67. Considering fever and the fever-
regulated response from this evolutionary 
and physiological perspective sheds a 
different light on the relevance of BRCA2 
degradation upon hyperthermia. It could be 
speculated that it is not the downregulation 
of BRCA2 in the fever temperature range 
that is important per se, but the functional 
effect of it: attenuation of HR. This notion is 
supported by the observation that it is not 
just BRCA2 levels that are affected by heat 
but also the levels of other HR proteins that 
act at different steps in the pathway, such as 
BRCA1 and RAD54 (Figure 1)25. 
From the evolutionary point of view, 
downregulating HR during fever could have 
an advantage for the organism. Fever is part 
of the immune response that usually occurs 
when a foreign particle has infiltrated the 
body, and we could therefore hypothesize 
that a concurrent downregulation of HR 
might protect the organism against these 
foreign particles. Indeed, it is known that 
some viruses hijack DNA damage repair 
pathways to replicate their own genomes, 
and there are examples of viruses, such as 
Epstein-Barr and human papillomaviruses, 
which employ HR proteins to do so68–70. 
However, for now this hypothesis remains 
a mere speculation. It would be interesting 
to examine whether BRCA2 orthologues 
other than human and mouse, for example 
primate71 or chicken72, are also degraded 
upon heat treatment. The latter species 
could yield valuable information about this 
possibly conserved response, because birds 
have a higher basal body temperature than 
mammals, but can still get fever58.
BRCA2 protein stability, HSP90 and 
cycloheximide
BRCA2 is expressed in the S and G2-phases 
of the cell cycle and BRCA2-transcription 
peaks at the start of S-phase49,50. Although 
the half-life of BRCA2 is not precisely 
known, it is clear that it is severely 
shortened by heat. The exact difference in 
this half-life cannot be determined by the 
straightforward application of cycloheximide 
as, this translation inhibitor protects BRCA2 
from degradation. There are at least two 
explanations this effect: 1) cycloheximide 
prevents translation of a certain factor which 
is rapidly synthesized upon hyperthermia and 
could be necessary for mediating BRCA2 
degradation, or 2) cycloheximide prevents 
synthesis of many nascent polypeptides that 
rely on HSPs to be properly folded, thereby 
allocating more HSPs to chaperone unstable 
proteins, including BRCA274. Given that the 
protection provided by cycloheximide is 
partly dependent on HSP90 (Figure 3A), 
the latter hypothesis seems more likely. 
HSP90 is an attractive target to modulate heat-
induced BRCA2 degradation
Hyperthermia-mediated degradation of 
BRCA2, localisation defects of RAD51 
and sensitivity toward irradiation are all 
enhanced by addition of 17-DMAG or 
Ganetespib (Chapter 8 of this thesis, 21). 
There is evidence that HSP90 influences 
the steady state level of BRCA2 by 
affecting both BRCA2 synthesis as well as 
degradation in hyperthermic conditions. 
The previous demonstration that BRCA2 
signals decline when cells are treated with 
an HSP90-inhibitor for a prolonged period 
of time, indicate that HSP90 is important 
for BRCA2 synthesis29. By combining 
cycloheximide with Ganetespib, we provide 
evidence for the importance of HSP90 in 
preventing BRCA2 degradation; the BRCA2 
protein signal observed after treatment 
with cycloheximide represent molecules 
which existed prior to treatment with 
hyperthermia and Ganetespib dramatically 
reduces these protected BRCA2 molecules 
in hyperthermic conditions (Figure 3A). 
Thus, HSP90 is not only important for 
proper folding of newly synthesized BRCA2, 
but also protects unfolding molecules 
from being degraded. Therefore, HSP90 
is currently among the most attractive 
targets to modulate heat-induced BRCA2 
degradation and to increase hyperthermia 
treatment efficacy.
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Ubiquitination may not be required for 
heat-mediated BRCA2-degradation by the 
proteasome
BRCA2 degradation upon heat is mediated 
by the proteasome, and the most common 
pathway of targeting proteins to the 
proteasome involves the ubiquitin system75. 
Indeed, we demonstrated that inhibition 
of the ubiquitin-selective VCP segregase 
prevents degradation and we find ubiquitin 
enrichment in immunoprecipitates of the 
Brca2-complex shortly after hyperthermia 
induction (Figure 7A), both indications 
that BRCA2 degradation might be regulated 
via ubiquitination. However, our efforts 
to determine which ubiquitin-enzymes 
might be involved in this process were 
not successful (Figure 4 and 5). One E3-
ligase we have not specifically tested as a 
candidate, but which might be important in 
BRCA2 regulation, is KEAP1. This protein 
is detected in the proteomic screen as an 
interactor of BRCA2, and has previously 
been associated with the complex 45. 
However, we did not observe any difference 
in efficiency of BRCA2-degradation when 
we added neddylation inhibitor MLN4924, 
which inhibits all cullin-based E3-ligases, 
including KEAP144,76 (Figure 5E).
The negative results of the E2- and E3-
screens can be interpreted in many ways. 
Our screens are predominantly based on 
short interfering RNA, and insufficient 
knock-down could therefore be a problem, 
considering that low levels of E2 or E3-
proteins might be enough to target the lowly 
expressed BRCA2 to degradation. Moreover, 
E2 and E3 enzymes may be redundant. This 
is supported by our finding that the middle 
and C-terminal parts of the BRCA2 protein 
are heat-labile (Figure 6). However, the key 
experiment that may explain the inability to 
find a responsible E2 or E3 ubiquitin enzyme 
is that inhibition of the E1-enzyme48, which 
effectively inhibits the entire ubiquitin-
system, still results in degradation of BRCA2 
(Figure 5F). Although the proper controls 
for this experiment need to be performed, 
this hints that ubiquitination may actually 
not be involved in hyperthermia-mediated 
BRCA2 degradation. 
Although most proteins are ubiquitinated 
before being targeted to the common 26S 
proteasome form, there is an exception to 
this rule: proteins may interact with the 26S 
proteasome via a ubiquitin-like domain, as 
is the case for RAD23B77. Similarly, it might 
be that conformational changes of BRCA2 
induced by hyperthermia result in exposure 
of such a ubiquitin-like domain. There are 
other examples of ubiquitin-independent 
degradation of proteins, but they require 
a different proteasome composition. The 
classical 26S proteasome consists of two 
19S regulatory particles which provide 
ubiquitin-specificity, while final degradation 
takes place in the 20S core78. The assembly 
of the proteolytic core itself may change 
to form the immunoproteasome which 
has different proteolytic activity than the 
classical 20S core, enabling production 
of peptides for antigen presentation79. 
Formation of the immunoproteasome is 
stimulated by γ-interferon as part of the 
adaptive immune response. The proteolytic 
20S core can act on its own or be regulated 
by particles other than the 19S subunit: the 
PA200 and the 11S/PA28αβ subunits79,80. 
The PA200 regulatory subunit is specialized 
in degrading acetylated histones and 
is therefore an example of a ubiquitin-
independent form of the proteasome81. 
The PA28αβ regulators are involved in 
degradation of oxidatively damaged proteins, 
as is the immunoproteasome82. Examples of 
proteins that may be degraded by the 20S 
proteasome on its own are proteins with 
intrinsically disordered domains which are 
degraded ‘by default’83, or proteins which are 
oxidized84.
Several properties of BRCA2 make it 
a likely candidate for degradation by a 
ubiquitin-independent proteasome. For 
instance, degradation ‘by default’ pathway, 
mediated by the 20S proteasome, is 
hypothesized to act on proteins that expose 
intrinsically disordered domains after losing 
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interactions with other components of the 
protein complex in which they normally 
reside83. BRCA2 is indeed predicted to 
have intrinsically disordered domains and 
may drastically change conformation upon 
temperature changes51. Furthermore, well-
known interactors of BRCA2, PALB285,86 
and RAD5124,87 are not degraded upon 
heat (Figure 1D)21, suggesting that BRCA2 
is released from complexes with these 
proteins before being degraded. Oxidative 
stress may be also be important for heat-
mediated BRCA2 degradation via the 
20S proteasome, immunoproteasome or 
PA28αβ-proteasomes, as is illustrated by 
the effects of oxidative stress on BRCA2 
stability (Figure 7).
Experimental possibilities of distinguishing 
between the 20S proteasome and the 
ubiquitin-dependent 26S proteasome are 
limited. Proteasome inhibitors, including 
MG132, inhibit both the 20S and 26S 
proteasome pathways. However, one way to 
distinguish between 20S and 26S proteasome 
activity is by depleting ATP, because the 26S is 
dependent on ATP, while the 20S is not88. This 
may, however, have severe consequences for 
cell viability in general and may therefore not 
be an optimal approach. Other experiments 
that could elucidate the type of proteasome 
required for heat-mediated BRCA2-
degradation involve selectively knocking 
down or inhibiting the immunoproteasome, 
the 19S regulatory particle or the PA28αβ-
subunit, which can be achieved by siRNA82,88.
BRCA2 and the oxidative stress response
In the proteomic screen aimed at 
identification of BRCA2-interactors upon 
hyperthermia, we identified HSPB1 as an 
interactor which dramatically increases 
in abundance shortly after hyperthermia 
induction. We also identify KEAP1 as a 
constitutive part of the complex (Figure 
7). Interestingly, these proteins are currently 
considered to function in the oxidative 
stress response. Since cellular response to 
hyperthermia and oxidative stress have many 
similarities55,89,90 and since important players 
of the HR machinery have been associated 
with the oxidative stress response45,91, 
we performed a screen with a limited 
number of ROS-inducing agents as well as 
antioxidants and analysed their effects on 
BRCA2. Our data indicate that the level of 
BRCA2 is in fact decreased in response to 
oxidative stress, while radical scavengers can 
protect this protein (to a certain extent) 
from hyperthermia-mediated degradation 
(Figure 8). 
Although the results are preliminary, and a 
more complete set of experiments could 
be performed to determine which type of 
ROS is particularly harmful to BRCA2 or 
which type of antioxidant is most effective in 
protecting it, it is tempting to speculate that 
hyperthermia-induced BRCA2 degradation 
is at least partly dependent on oxidative 
stress. Notably, BRCA1 and PALB2, both 
well-established BRCA2-interactors, are 
involved in the oxidative stress response45,91. 
Oxidative stress may cause dissociation of 
these proteins from the complex, resulting 
in destabilisation of BRCA2. 
Summary
In this chapter, we investigated the 
mechanisms driving BRCA2-degradation 
upon hyperthermia. We found that BRCA2-
degradation seems evolutionary conserved; 
BRCA2 stability is dependent on HSP90; 
ubiquitin may not be involved in targeting 
BRCA2 for protein degradation via the 
proteasome; BRCA2 degradation might be 
modulated by oxidative stress and radical 
scavengers. Although our results do not 
reveal clear mechanisms driving BRCA2 
degradation, they form a foundation for 
future investigations of biological and clinical 
consequences. 
Materials and methods
Cell culture
HeLa, BRO and U2OS cells were maintained 
as previously described21, as were Brca2GFP/GFP 
and the parental wild-type (IB10) mouse 
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embryonic stem cells (mES)24. The UWB-
1.289 cells with and without wtBRCA1 were 
kindly provided by Dr. Helleman of the 
Department of Medical Oncology of the 
Erasmus MC, and cultured as described92.
Generation of constructs and cell lines
A full list of constructs and oligonucleotides 
used in this study can be found in Tables 1 
and 2.  A step-wise description of engineering 
the GFP-BRCA2 encoding plasmid has been 
provided before24. The BRCA2 fragments 
used in this study were engineered in a 
similar fashion: stepwise Gibson assembly93 
was used to engineer the pGb-LPL vector 
by replacing the gene trap cassette of a 5’-
PTK-3’ PiggyBac vector52 with a puromycin 
acetyltransferase expression cassette with 
a PGK promotor, and a bovine growth 
hormone polyadenylation signal from 
pCAGGS-Dre-IRES-puro94. GFP-tagged 
constructs were engineered by inserting the 
following elements in the pGb-LPL vector: 
a BRCA2-expression cassette consisting of 
a CAG promotor from pCAGGS-Dre-IRES-
puro94, an EGFP-coding sequence (Takara 
Bio) and the indicated BRCA2 fragment 
(using primer set 1, 2 and 3), amplified from 
a human BRCA2-coding sequence, phCMV1-
MBPx2-hBRCA295. FLAG-BRCA2 sequences 
were engineered by inserting the SV40-
polyadenylation signal and CMV-sequence 
from phCMV1-MBPx2-hBRCA2, as well 
as a 3xFLAG sequence from pR6K-2T1-
2PreS-mVenus-Biotin-T2A-gb3-neo and the 
indicated BRCA2 fragment (using primer set 
4, 5 and 6) in the pGb-LPL vector. The FLAG-
BRCA2 construct was generated by excising 
the eGFP-fragment from the GFP-BRCA2-
plasmid using uniquely cutting restriction 
enzymes and restoring the excised part 
with a PCR-generated patch (using primer 
set 7) containing the 3xFLAG-sequence and 
part of the N-terminus of BRCA2 from 
FLAG-BRCA2-Nterm. FLAG-BRCA2ΔM was 
generated by excising the sequence coding 
for the middle part using uniquely cutting 
restriction enzymes. The sequence adjacent 
to the middle part that were included in 
excision, were restored by a PCR-generated 
patch (using primer set 8) from the original 
construct. All PCR-fragments amplified 
during plasmid engineering, as well as cloning 
junctions were verified by sequencing. As 
described previously for the GFP-BRCA2 
construct24, stable cell lines were created 
by co-transfecting 1 μg construct with 1 μg 
PiggyBac transposase expression construct 
Name BRCA2-region(amino acid)
Molecular 
Weight 
(kDa)
Vector Promotor Code/Reference
FLAG-BRCA2 Met 1 - Ile 3418 382 pGb-LPL CAG pAZ148
GFP-BRCA2 Met 1 - Ile 3418 406 pGb-LPL CAG pAZ11424
BRCA2-N-GFP Met 1 - Thr 939 131 pGb-LPL CAG pAZ108
BRCA2-M-GFP Gln 940 - Glu 2198 167 pGb-LPL CAG pAZ109
BRCA2-C-GFP Thr 2199 - Ile 3418 162 pGb-LPL CAG pAZ110
FLAG-BRCA2-N Met 1 - Thr 939 107 pGb-LPL CMV pAZ97
FLAG-BRCA2-M Gln 940 - Glu 2198 123 pGb-LPL CMV pAZ98
FLAG-BRCA2-C Thr 2199 - Ile 3418 118 pGb-LPL CMV pAZ104
FLAG-BRCA2-ΔM Met 1 - Thr 939Thr 2199 - Ile 3418 250 pGb-LPL CAG pAZ253
Clover-HSP90 n.a. 109 pGb-LPL CAG n.a.
FLAG-HSP90 n.a. 82 pGb-LPL CMV 99
Table 1. List of constructs.
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(mPB) per 6-well plate using X-tremeGENE 
HP DNA transfection reagent (Roche). 
One day after transfection, selection was 
started by exposure to 1.5 μg/ml puromycin 
(Invivogen) for 10 days. The resulting 
puromycin-resistant cells were assayed as a 
mixed population. 
Hyperthermia treatment
The time designated for effective 
hyperthermia treatment started 15 minutes 
(referred to as pre-heating time) after 
moving the cells to an incubator set at 42 °C. 
Unless stated otherwise, cells were treated 
with 60 minutes hyperthermia.
Chemical agents and UV-irradiation
Cells were UV-irradiated with UV-B (2 TL-12 
(40W) tubes, Philips) at the indicated doses. A 
full list of used chemical agents and suppliers can 
be found in Table 3. Unless stated otherwise, 
inhibitors were added to the medium 30-60 
minutes prior to hyperthermia and left on the 
cells for the duration of the treatment. Cells 
were treated with antioxidants and oxidative-
stress inducing agents in Hank’s Balanced Salt 
Set Name Sequence
1F GA15N-F 5’-GCTCCTGGGCAACGTGCCTCGAGATGCCTATTGGATCCAAA-GAGAGGCCAAC-3’
1R GA15N-R 5’-TTGCTCACCATGGTGGCCTCGAGGGTTGCTTGTTTATCACCT-GTGT-3’
2F GA15M-F 5’-GCTCCTGGGCAACGTGCCTCGAGATGCAAGTGTCAATTA-AAAAAGATTTGGTTTATGTTCTTGC-3’
2R GA15M-R 5’-TTGCTCACCATGGTGGCCTCGAAAGTTTCAGTTTTAC-CAATTTCCATTTTTACGTT-3’
3F GA15C-F 5’-GCTCCTGGGCAACGTGCCTCGAGATGACTTTTTCTGAT-GTTCCTGTGAAAACAAATATAGAAG-3’
3R GA15C-R 5’-TTGCTCACCATGGTGGCCTCGAGGATATATTTTTTAGTTGTA-ATTGTGTCCTGCTTATTTTTCTCACA-3’
4F BRCA2-Nterm-F 5’-CAAGGATGACGACGACAAGAGCCCTATTGGATCCAAAGAGAG-GC-3’
4R BRCA2-Nterm-R
5’-GCTGATTATGATCTAGAGTCAGGTTGCTTGTTTATCACCTGT-
GTCT-3’
5F GA04M-F 5’-CAAGGATGACGACGACAAGAGATCTACCCAAGTGTCAATTA-AAAAAGATTTGGTTTATGT-3’
5R GA04M-R 5’-GCTGATTATGATCTAGAGTCAGATCTTTTCAGTTTTAC-CAATTTCCATTTTTACGTTTTTAGGT-3’
6F GA04C-F 5’-CAAGGATGACGACGACAAGAGATCTACTTTTTCTGATGTTCCT-GTGAAAACAAATATAGAAG-3’
6R GA04C-R 5’-GCTGATTATGATCTAGAGTCAGATCTTTAGATATATTTTTTAGTTG-TAATTGTGTCCTGCTTATTTTTCTCACAT-3’
7F B2flFLAG-F1 5’-CCTGGGCAACGTGCCGATTATAAAGACCACGATGGAGACTATA-AAGATCATGACATTGACT-3’
7R B2flFLAG-R2 5’-CACTGTCCTTCCTGCAGGCATGACAGAGAA-3’
8F B2intdel-GA-F1 5’-TTCTCTGTCATGCCTGCAGGAAGGAC-3’
8R B2intdel-GA-R1 5’-CAACATTTAAGTTATTTGATAATTTGGTTGCTTGTTTATCACCT-GTGTCT-3’
Table 2. List of oligonucleotides used in this study.
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Solution (Gibco® HBSS, Thermo Fisher). 
Antioxidants were added directly prior to 
hyperthermia, while treatment with the 
oxidative stress-inducing agents lasted 75 
minutes. 
siRNA transfection
A full list of used siRNAs with suppliers and 
references can be found in Table 4. Cells were 
transfected with a final concentration of 60 
nM siRNA’s using Lipofectamine RNAiMAX 
(life Technologies). The systematic E2 screen 
was performed as previously described35. 
Experiments were performed 48-72h after 
transfection.
Immunoprecipitation
For each immunoprecipitation, cells were 
prepared in a 15-cm dish at 70-80% 
confluency. After treatment, cells were 
washed twice in ice-cold PBS and lysed for 
30 minutes on ice in NETT-buffer (100 mM 
NaCl, 50 mM Tris pH 7.5, 5 mM EDTA pH 
8.0, 0.5% Triton-X100, 1x protease inhibitors 
(Complete, Roche®) and 1 mM pefabloc). 
Anti-GFP beads (Chromotek) was prepared 
according to the manufacturer’s protocol. 
After scraping the cells, the suspensions 
were centrifuged (12000 rcf, 15 min), and the 
resulting supernatant (input) was added to the 
beads and incubated for 4 hours, rotating at 4 
°C. The immunoprecipitation was completed 
according to the manufacturer’s protocol.
Cell fractionation, lysis and immunoblotting
The cell fractionation was performed as 
described for immunoprecipitations. The 
pellet and supernatant resulting from the 
centrifugation step were analysed. Cell lysis 
and immunoblotting were performed as 
described previously22, with exception of 
gel type, which included acrylamide, 3-8% 
Tris-Acetate gels (Novex, Thermofisher 
Scientific) or 4-20% TGXTM-gels (Biorad) 
and blotting membrane, which included both 
PVDF and nitrocellulose. 
Immunofluorescent staining and analysis of 
RAD51-foci
Cells were treated with hyperthermia and 
subsequently irradiated with a caesium-137 
source with a dose rate of 0.64 Gy/min. 
EdU (Invitrogen) was added to the cells 45 
minutes prior to fixation to identify S-phase 
cells. Cells were fixed 1.5 hours after 
irradiation. Cell fixation, immunofluorescent 
staining, image acquisition and analysis were 
performed as described in 22. 
Antibodies 
A full list of antibodies and used dilutions can 
be found in Table 5.
SILAC-based mass spectrometry
Cells were cultured in DMEM medium 
without lysine or arginine, supplemented with 
dialysed serum for two weeks prior to the 
experiment. Isotopes of L-lysine and L-Arginine 
(Cambridge Isotope Laboratories) were added 
to the medium to label the following three 
SILAC-states: Light (K0R0), Medium (K4R6) 
and Heavy (K8R10). Immunoprecipitations 
were performed for each state separately as 
described above. As published before96, bound 
proteins of all three states were mixed after 
immunoprecipitation and digested ‘on bead’. 
Data was analysed using the Andromeda Search 
Engine within the MaxQuant software package 
version 1.5.3.897,98.
Name Reference / Suppliers
Bafilomycin Sigma-Aldrich
NMS-873 Selleckchem
Ganetespib Syntha Pharmaceuticals
MG132 Merck Millipore
Cycloheximide Sigma-Aldrich
MLN4924 MedChem Express
PYR-41 Calbiochem
NAC Sigma-Aldrich
Ascorbic Acid Sigma-Aldrich
DTT Sigma-Aldrich
H2O2 Sigma-Aldrich
t-BHP Sigma-Aldrich
Rotenone MP Biomedicals
Table 3. List of used chemicals.
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siRNA SenseSequence Reference/Supplier
siLuc CGUACGCGGAAUACUUCGA Thermo Scientific
siAKTIP#1 GAAUUUACCUUGGUUGUGA 35
siAKTIP#2 AGAAAACAGUGGCGACUUA 35
siBIRC6#1 UCAUUGCCUUACUCACAUA 35
siBIRC6#2 GGUCAAAGAUCACUUAGUA 35
siTSG101#1 AGUAGCCGAGGUUGAUAAA 35
siTSG101#2 AAACUGAGAUGGCGGAUGA 35
siUBE2A#1 UGAUGUGUCUUCCAUUCUA 35
siUBE2A#2 GAUGAACCCAAUCCCAAUA 35
siUBE2B#1 AUAGACAACUGGUCUGUUA 35
siUBE2B#2 UUGGACCAGAAGGGACACC 35
siUBE2C#1 GCAAGAAACCUACUCAAAG 35
siUBE2C#2 UAAAUUAAGCCUCGGUUGA 35
siUBE2D1#1 UACUGUAUGUGUUGUCUAA 35
siUBE2D1#2 CAACAGACAUGCAAGAGAA 35
siUBE2D2#1 CAGUAAUGGCAGCAUUUGU 35
siUBE2D2#2 CCAACCAGAUUAAACUCUA 35
siUBE2D3#1 UGAUGUAAAGUUCGAAAGA 35
siUBE2D3#2 CCACAAUUAUGGGACCUAA 35
siUBE2D4#1 CAGCGUUGACUGUGUCAAA 35
siUBE2D4#2 GGAAUUAACCGACUUGCAG 35
siUBE2E1#1 GCGAUAACAUCUAUGAAUG 35
siUBE2E1#2 GGUGUAUUCUUUCUCGAUA 35
siUBE2E2#1 ACUUGAAAGAUUUGGGAUU 35
siUBE2E2#2 UCACCAGACUAUCCGUUUA 35
siUBE2E3#1 GCAUAGCCACUCAGUAUUU 35
siUBE2E3#2 GCUAAGUUAUCCACUAGUG 35
siUBE2F#1 GGAAUAAAGUGGAUGACUA 35
siUBE2F#2 CAACAUAAAUACAGCAAGA 35
siUBE2G1#1 UGUUGAUGCUGCGAAAGAA 35
siUBE2G1#2 GGGAAGAUAAGUAUGGUUA 35
siUBE2G2#1 AUGAUGACUUAAUGUCGAA 35
siUBE2G2#2 UGACGAAAGUGGAGCUAAC 35
siUBE2H#1 CGAGAGUAAACAUGAGGUU 35
siUBE2H#2 CUACUGAACUGUCGAAGGA 35
siUBE2J1#1 GAACUGGCUAGGCAAAUAA 35
siUBE2J1#2 GAAAGAAGCGGCAGAAUUG 35
siUBE2J2#1 GAAGGUGGCUAUUAUCAUG 35
siUBE2J2#2 GCACAAGACGAACUCAGUA 35
siUBE2K#1 CUCUCCGCACGGUAUUAUU 35
siUBE2K#2 GAAUCAAGCGGGAGUUCAA 35
siUBE2L3#1 UGAAGAGUUUACAAAGAAA 35
siUBE2L3#2 GGGCUGACCUAGCUGAAGA 35
siUBE2L6#1 UGAUCAAAUUCACAACCAA 35
siUBE2L6#2 UCAAUGUGCUGGUGAAUAG 35
Table 4. List of siRNAs.
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Table 4. List of siRNAs, continued.
siRNA SenseSequence Reference/Supplier
siUBE2M#1 AGCCAGUCCUUACGAUAAA 35
siUBE2M#2 GAUGAGGGCUUCUACAAGA 35
siUBE2N#1 GCGGAGCAGUGGAAGACCA 35
siUBE2N#2 CUAUCUAGCUUGUGUGUCA 35
siUBE2NL#1 AAACGUGAACUAUUACUUG 35
siUBE2NL#2 GACAAGUUGGAAAGAAUAA 35
siUBE2O#1 ACAUCGACUGUGCCGUCAA 35
siUBE2O#2 GGGACUACAUUGCCUAUGA 35
siUBE2Q1#1 UCAUCUCCGACCUGUGUAA 35
siUBE2Q1#2 GAAAGGGAAUACUCUGCUA 35
siUBE2Q2#1 UACAGAUCACAGAGUUAUA 35
siUBE2Q2#2 GUAUGGAACUUCUCACAAA 35
siUBE2R1#1 CGCAGAACGUCAGGACCAU 35
siUBE2R1#2 GGAAGUGGAAAGAGAGCAA 35
siUBE2R2#1 UGUGAGGACUAUCCUAUUA 35
siUBE2R2#2 CCACAACCCUGGCGGAAUA 35
siUBE2S#1 AUGGCGAGAUCUGCGUCAA 35
siUBE2S#2 ACAAGGAGGUGACGACACU 35
siUBE2T#1 AGAGAGAGCUGCACAUGUU 35
siUBE2T#2 CCUGCGAGCUCAAAUAUUA 35
siUBE2U#1 ACAGGCCAUUACAAAUGAA 35
siUBE2U#2 GAAGUGGAAUACAAACUAU 35
siUBE2V1#1 GGACAGUGUUACAGCAAUU 35
siUBE2V1#2 GUGGAUGCAUACCGAAAUA 35
siUBE2V2#1 AGUUGUACUUCAAGAGCUA 35
siUBE2V2#2 GUUAAAGUUCCUCGUAAUU 35
siUBE2W#1 CGACCACCGGAUAAUUCUU 35
siUBE2W#2 GCGAACAUGUAACAAGAAU 35
siUBE2Z#1 AUGUUCGUUGUACCUGAUA 35
siUBE2Z#2 GGGAAAGUCUGCUUGAGUA 35
siUEV3#1 CGAUGGACCUUGAAAUCUU 35
siUEV3#2 AGAAAGACCUGCUGAAUUU 35
UBC9 GGGAUUGGUUUGGCAAGAA 37
CHIP#1 GCGCUCUUCGAAUCGCGAAGA Invitrogen
CHIP#2 UGCCGCCACUAUCUGUGUAAU Invitrogen
PIAS1 GGAUCAUUCUAGAGCUUUA 41
PIAS2 CUUGAAUAUUACAUCUUUA 41
PIAS3 CCCUGAUGUCACCAUGAAA 41
PIAS4 GGAGUAAGAGUGGACUGAA 41
RNF4#1 GAAUGGACGUCUCAUCGUU 37
RNF111 GGAUAUUAAUGCAGAGGAA 37
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Host Epitope Dilutions used Reference / Suppliers
Mouse BRCA2 (OP95) WB 1:1000 EMD Millipore
Mouse FLAG (M2) WB 1:1000-1:5000 Sigma-Aldrich
Mouse ORC2 (68348) WB 1:1000 Abcam
Rabbit Brca2 (27976) WB 1:500 Abcam
Mouse GFP (clones 7.1 and 13.1) WB 1:1000-1:5000 Sigma-Aldrich
Mouse PARP-1 (C2-10) WB 1:5000 Enzo Lifesciences
Mouse BRCA1 (OP92) WB 1:250 EMD Millipore
Mouse BRCA1 (D9) WB 1:500 Santa Cruz
Mouse BRCA1-17F8 (3A2) WB 1:500 Genetex
Rabbit Cyclin A (C-19) WB 1:5000 Santa Cruz
Goat RAD54 (D-18) WB 1:1000 Santa Cruz
Rabbit RAD51 (2307) WB 1:10000 Home-made100 
Rabbit RAD51 (2308) IF 1:10000 Home-made100
Mouse GRB2 WB 1:1000 BD Pharmingen
Mouse HSP90 (AC88, 13492) WB 1:5000 Abcam
Rabbit CDC37 (3618S) WB 1:1000 Cell Signaling
Goat UBC9 (N-15) WB 1:1000 Santa Cruz
Rabbit CHIP (PA1-015) WB 1:1000 Thermo Scientific
Sheep Peroxidase anti-Mouse IgG (H+L) WB 1:2000 Jackson Immunoresearch
Donkey Peroxidase anti-Rabbit IgG (H+L) WB 1:2000 Jackson Immunoresearch
Donkey Peroxidase anti-Goat IgG (H+L) WB 1:2000 Jackson Immunoresearch
Goat Alexa-Fluor-594 (red) IF 1:1000 Thermo Scientific
Table 5. List of antibodies.
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Introduction
DNA-damaging agents, such as ionizing 
radiation, topoisomerase inhibitors, DNA 
intercalators or cross-linkers, are among 
the most effective anticancer modalities 
exploited in diverse clinically relevant 
therapies. However, the intricate DNA repair 
mechanisms that evolved to maintain the 
integrity of genetic information of healthy 
cells, protect DNA of cancer cells, effectively 
increasing their resistance to therapy1. 
DNA double-strand breaks (DSBs) are 
arguably the most dangerous DNA lesions 
induced by anticancer treatments. In 
mammalian cells, DSB repair is executed by 
two major pathways, called non-homologous 
end joining (NHEJ) and homologous 
recombination (HR). NHEJ is a robust and 
conceptually simple mechanism, active 
throughout the cell cycle. The pathway 
involves a direct rejoining of the broken 
DNA ends, often at the cost of inducing 
nucleotide deletions or insertions2. In 
contrast to NHEJ, HR is a more complex 
and precise mechanism – relying on BRCA1, 
BRCA2 and RAD51, among other proteins 
– that can utilize an intact DNA fragment 
as a repair template3. The activity of HR is 
tightly coupled to cell cycle progression 
and is limited to the S and G2 phases of the 
cell cycle. Given the involvement of DSB 
repair in the resistance to DNA-damaging 
agents, its inactivation in cancer cells could 
increase their sensitivity to therapy. Despite 
considerable efforts, however, safe, potent, 
selective and bioavailable inhibitors of DSB 
repair have yet to emerge4.
Hyperthermia – elevation of the tumor 
temperature above physiological levels, 
usually to 41-42.5 °C – is a clinically applied 
anticancer therapy that affects multiple 
aspects of cellular metabolism, including 
DNA repair5. Hyperthermia is an excellent 
radiosensitizer and chemosensitizer, as 
demonstrated by in vitro and in vivo studies, 
as well as by randomized clinical trials5–7. 
One important feature of hyperthermia is 
that its application can generally be limited 
to the tumor volume, sparing the non-
transformed surrounding tissues. Notably, 
hyperthermia efficiently inhibits HR, likely by 
inducing degradation of its essential protein 
BRCA28,9, as well as NHEJ, possibly in part 
by affecting DNA-PKcs or LIG410,11. This may 
explain how hyperthermia sensitizes cells to 
agents such as ionizing radiation or cisplatin, 
because DNA lesions induced by these 
agents require HR and NHEJ for repair. 
Abstract
Hyperthermia – application of supra-physiological temperatures to cells, tissues or organs – is a 
pleiotropic treatment that affects most aspects of cellular metabolism, but its effects on DNA are 
of special interest in the context of cancer research and treatment. Hyperthermia inhibits repair 
of various DNA lesions, including double-strand breaks (DSBs), making it a powerful radio- and 
chemosensitizer, with proven clinical efficacy in therapy of various types of cancer, including 
tumors of head and neck, bladder, breast and cervix. Among the challenges for hyperthermia-
based therapies are the transient character of its effects, the technical difficulties in maintaining 
uniformly elevated tumor temperature and the acquisition of thermotolerance. Approaches to 
reduce or eliminate these challenges could simplify the application of hyperthermia, boost its 
efficacy and improve treatment outcomes. Here we show that a single, short treatment with a 
relatively low dose of HSP90 inhibitor Ganetespib potentiates cytotoxic as well as radio- and 
chemosensitizing effects of hyperthermia and reduces thermotolerance in cervix cancer cell 
lines. Ganetespib alone, applied at this low dose, has virtually no effect on survival of non-heated 
cells. Our results thus suggest that HSP90 inhibition can be a safe, simple and efficient approach 
to improving hyperthermia treatment efficacy and reducing thermotolerance, paving the way for 
in vivo studies.
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The radiosensitizing and chemosensitizing 
effects of hyperthermia are desirable 
in anticancer therapies, but they are 
counteracted by chaperone proteins that 
protect cells from the effects of various 
forms of stress, including heat. Heat-
shock proteins (HSPs) are a subgroup of 
chaperone proteins that strongly respond to 
increased temperatures to regulate various 
genes and metabolic pathways as well as to 
physically protect their client proteins from 
heat-induced unfolding, inactivation and 
degradation12. One member of this group, 
HSP90, is of special interest in the context of 
cancer treatment and hyperthermia. HSP90 
is an evolutionarily conserved chaperone, 
crucial in mammalian proteostasis, with 
affinity for a vast number of client proteins13. 
In addition to its important functions in 
normal cells, the chaperone can promote 
stability of misfolded oncogenic proteins in 
cancer cells, allowing the development of 
oncogene addiction and therapy resistance14. 
Inhibition of this chaperone affects the 
stability of some essential DNA repair 
factors, including BRCA1, BRCA2, RAD51, 
CHK1 and DNA-PKcs15. 
Recently, we reported that inhibition of 
HSP90 by 17-DMAG, the derivative of the 
antibiotic geldanamycin, can enhance the 
effects of hyperthermia on DSB repair, likely, 
at least in part, by stimulating hyperthermia-
induced degradation of BRCA28. 17-DMAG 
also potentiates hyperthermic sensitization 
of cancer cells to PARP1 inhibition in vitro 
and in vivo. Importantly, the drug showed 
only limited cytotoxicity as a single agent, 
suggesting that HSP90 inhibition could be 
a safe and effective approach to potentiate 
effects of hyperthermia. In the current study, 
we focus on Ganetespib, a new-generation, 
more specific and well-tolerated HSP90 
inhibitor that has been extensively studied in 
vitro, in animal models and in multiple clinical 
trials16,17. Since hyperthermia is routinely 
applied to a subset of cervical cancer 
patients18, we use two cervical cancer cell 
lines, SiHa and HeLa to show that Ganetespib 
enhances the induction of DNA damage and 
cell killing by hyperthermia. Moreover, we 
demonstrate that Ganetespib potentiates 
hyperthermia-induced sensitization of 
cervix cancer cells to a number of DSB-
inducing agents and reduces hyperthermia-
induced thermotolerance, suggesting that 
HSP90 inhibition could be a safe, simple and 
effective strategy to improve the outcomes 
of clinical treatments involving hyperthermia.
Results
HSP90 inhibitor Ganetespib potentiates the 
inhibitory effects of hyperthermia on HR
To investigate whether Ganetespib promotes 
the inhibitory effects of hyperthermia on 
DSB repair, we first analyzed hyperthermia-
induced changes in the levels of BRCA2 
protein. As expected, we found that treatment 
for 60 min at 42 °C reduced the levels of 
BRCA2 (Figure 1A). Importantly, addition 
of Ganetespib further enhanced BRCA2 
degradation in a dose-dependent manner. 
We found that a 1.5 hour treatment with 
Ganetespib alone (up to 100 nM) had only 
modest effects on clonogenic cell survival, 
but this was enhanced after hyperthermia, 
at least at Ganetespib concentrations 
exceeding 3 nM (Supplemental Figure 
1). We therefore decided to use the 30 
nM concentration of Ganetespib in the 
subsequent experiments. One of the 
hallmarks of hyperthermia-induced HR 
deficiency is a disturbed accumulation of 
RAD51 at sites of DSBs8,9. Indeed, we found 
that hyperthermia temporarily abolished 
recruitment of RAD51 to α-particle-
induced DSBs. This effect was enhanced by 
Ganetespib, as RAD51 accumulation was 
impaired for considerably longer periods of 
time, in both SiHa and HeLa cells (Figure 
1B). Treatment with Ganetespib alone did 
not affect RAD51 accumulation. 
One of the most challenging aspects in 
successful clinical application of hyperthermia 
is the maintenance of the elevated tumor 
temperature for a sufficiently long period 
of time. Therefore, any approach to reduce 
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the time required for efficient radio- or 
chemosensitization could greatly facilitate 
and boost hyperthermia treatments. To 
examine whether Ganetespib can shorten 
hyperthermia time required for efficient 
degradation of BRCA2, we heated HeLa and 
SiHa cells for 30 or 60 minutes, in the presence 
or absence of Ganetespib, and analyzed 
BRCA2 levels. Results show that a 30 minute 
hyperthermia + Ganetespib combination 
treatment is at least as effective in reducing 
BRCA2 levels as a 60 minute hyperthermia 
treatment without the inhibitor (Figure 
1C). In summary, these results confirm that 
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Figure 1. HSP90 inhibitor Ganetespib potentiates the effects of hyperthermia (HT) on HR. 
A) SiHa cells were incubated with the indicated concentrations of Ganetespib (HSP90-i) for 30 minutes at 37 
°C, then for an additional hour at 37 or 42 °C. Next, cells were lysed and lysates were analyzed by western 
blotting, using antibodies against BRCA2 and Cyclin A (loading control). B) Cells were treated as in (A), except 
Ganetespib was used at a concentration of 30 nM. At the indicated time after treatment, cells were irradiated 
with α-particles, fixed 30 minutes later and stained using antibodies against ɣH2AX (red) and RAD51 (green). 
The pictures are representative for cells irradiated 6 hours after the treatment. The graphs show average 
percentage of cells containing tracks of ɣH2AX foci that were also positive for RAD51. C) Cells were treated 
and analyzed as in (A), except the duration of incubation at elevated temperature was 0, 30 or 60 minutes. 
Equal sample loading was confirmed by probing for ORC2.
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Ganetespib can potentiate the inhibitory 
effects of hyperthermia on HR in cervical 
cancer cells in vitro. 
Inhibition of HSP90 enhances induction of 
DNA damage by hyperthermia
Hyperthermia has been suggested to 
induce DSBs in at least two ways19. First, 
it has been speculated that the elevated 
temperature induces damage directly, as 
heating leads to the focal accumulation of 
some repair factors, which are considered 
to mark sites of ongoing DSB repair20,21. 
Second, hyperthermia has been suggested 
to stabilize the topoisomerase 1 (TOP1)-
DNA cleavage complexes, which may lead 
to DSB formation in the next S-phase, 
when replication forks collide with single-
stranded breaks (SSBs) induced by removal 
of the TOP122. To examine whether HSP90 
inhibition can potentiate these effects as 
well, we first analyzed the induction of 
ɣH2AX foci at various time points (up to 
48 hours after hyperthermia treatment). 
We observed, in both cell lines, that 
hyperthermia led to increased frequencies 
of foci-containing cells immediately after 
treatment, and that these frequencies 
diminished at later time points (Figure 2A). 
After treatment with Ganetespib alone, the 
frequencies of ɣH2AX foci-positive cells 
were not affected immediately, but they did 
moderately increase at later time points (2-
24 hours), only to return to the baseline 
at 48 h after treatment. Combination 
of hyperthermia with Ganetespib led to 
a further increase of foci-positive cell 
frequencies, especially at later time points (at 
16 and 24 hours after treatment). ɣH2AX 
is an indirect marker of DSB formation 
and, especially after hyperthermia, it may 
mark sites of other lesions23. Therefore, 
we subsequently measured the induction 
of micronuclei (MN), which are a direct 
Figure 2. Inhibition 
of HSP90 enhances 
induction of 
DNA damage by 
hyperthermia (HT). 
Cells were incubated for 
30 minutes with 30 nM 
Ganetespib (HSP90-i) 
at 37 °C, then for 60 
minutes at 37 or 42 
°C (HT). Medium was 
refreshed and cells 
were incubated at 37 
°C for the indicated 
time period, fixed and 
stained for ɣH2AX 
(A) and DNA (B). A) 
Average percentages of 
cells with more than 5 
ɣH2AX foci after the 
indicated treatments. 
B) The pictures (top 
panel) show micronuclei 
(MN)-containing HeLa 
cells at 48 hours after 
treatments. The graphs 
(bottom panel) show the 
average frequencies of 
MN-containing (MN+) 
cells.
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consequence of unrepaired DSBs24 (Figure 
2B). Our results show that hyperthermia 
alone increased MN+ cell frequency at >8 
hours after treatment, strongly suggesting 
induction of DSBs. In contrast, treatment 
with Ganetespib alone did not significantly 
affect MN+ cell numbers, whereas 
combinational treatment (hyperthermia 
+ Ganetespib) led to an increased MN 
induction at later time points (at 24 and 48 
hours), as compared to hyperthermia alone 
(Figure 2B). The frequency of MN+ cells 
after the combinational treatment at 48 
hours was 3.5-fold (HeLa cells) and 6-fold 
higher (SiHa cells) than in untreated control 
cells. Combined, these results strongly 
suggest that hyperthermia does induce 
DSBs, probably indirectly, and that this effect 
is potentiated by HSP90 inhibition.
Inhibition of HSP90 enhances radiosensitizing 
and chemosensitizing effects of hyperthermia
Since HSP90 inhibition enhances the 
inhibitory effects of hyperthermia on 
DSB repair, we investigated whether 
Ganetespib can potentiate cytotoxicity of 
treatment combining various DSB-inducing 
agents (radiation and chemotherapy) with 
hyperthermia. We focused on ionizing 
radiation (IR), cisplatin, gemcitabine and 
etoposide – chemotherapeutics that 
are known to induce DSBs and that are 
relevant in clinical cancer treatment25–27. 
We performed clonogenic survival assays 
to measure the effects of hyperthermia 
and/or Ganetespib on the cytotoxicity of 
these agents (Figure 3). IR directly induces 
DSBs that are then repaired by NHEJ or 
HR, depending on the cell cycle phase and 
hyperthermia has been shown to sensitize 
cancer cells and tumors to IR28. When 
combined with IR alone, Ganetespib did not 
induce additional cytotoxicity (Figure 3B), 
suggesting that short inhibition of HSP90 is 
insufficient for detectable downregulation 
of DSB repair. However, we detected a 
statistically significant decrease in survival 
after addition of Ganetespib to IR when it 
was combined with hyperthermia, even at 
the relatively low dose of 2 Gy, in both cell 
lines (Figure 3B). Cisplatin is an effective 
DNA cross-linking agent and repair of 
cisplatin-induced lesions in replicating 
cells requires HR and nucleotide excision 
repair29,30. Hyperthermia has been reported 
to be a strong sensitizer to cisplatin31, which 
is confirmed by our results (Figure 3C). This 
was in contrast to Ganetespib treatment 
alone, which did not enhance cytotoxicity 
of cisplatin, similar to that of IR. However, 
Ganetespib further enhanced cytotoxicity of 
the cisplatin and hyperthermia combination 
treatment, at least at cisplatin concentrations 
exceeding 0.9 μM (Figure 3C). Gemcitabine 
is a clinically-applied nucleoside analog 
that directly targets HR32,33, but its main 
mechanism of action involves inhibition of 
DNA synthesis34, which can lead to collapse 
of replication forks and induction of DSBs35. 
We found that the cytotoxicity of a 24 h 
Figure 3. Inhibition of HSP90 enhances radiosensitizing and chemosensitizing effects of 
hyperthermia (HT). 
A) Schematic overview of the treatment schedule for the clonogenic assay, results of which are presented in 
B-D and F. B) Normalized clonogenic survival after increasing doses of IR alone or combined with HT and/
or Ganetespib (HSP90-i). Bar graphs (right-hand panels outlined by red dashed line) show the enlargement 
of the data points from the 2 Gy dose. C) Normalized clonogenic survival after increasing concentration 
of cisplatin (Cispl.) alone or combined with HT and/or HSP90-i. At the highest concentration (33 µM) no 
clones were detectable (n.d.). Bar graphs (outlined by dashed lines) show the enlargement of the data points 
from the 3.3 µM concentration. D) Relative clonogenic survival after increasing concentration of gemcitabine 
(Gem.) alone or in combination with HT and/or HSP90-i. The dotted line indicates the cell survival after 
treatment with gemcitabine alone. E) Normalized clonogenic survival of cells incubated at 42 °C for the 
indicated period of time, in the presence or absence of HSP90-i and exposed to the indicated dose of IR. F) 
Normalized clonogenic survival after increasing concentration of etoposide (Etop.) alone or combined with 
HT and/or HSP90-i. Bar graphs (right-hand side panels outlined by dashed lines) show the survival at 3.3 µM 
concentration of Ganetespib.
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incubation period with gemcitabine was 
generally potentiated by hyperthermia, but 
not by Ganetespib alone (Figure 3D). A 
combination of hyperthermia, gemcitabine 
and Ganetespib, however, significantly 
decreased cell survival, as compared to the 
hyperthermia + gemcitabine combination 
treatment. This was observed at nearly all 
tested concentrations of gemcitabine, in 
both HeLa and SiHa cells (Figure 3D). 
Since our earlier results showed that 
Ganetespib can shorten the time of 
hyperthermia treatment that is required 
for efficient BRCA2 degradation (Figure 
1C), we speculated that HSP90 inhibition 
can also enhance radiosensitization by short 
hyperthermia treatments. Remarkably, we 
indeed found that a 30 minute hyperthermia 
+ Ganetespib combination sensitized HeLa 
and SiHa cells to a similar degree as a 60 
minute exposure to heat alone (Figure 3E).
Finally, we tested whether Ganetespib 
potentiates cytotoxicity of etoposide, an 
inhibitor of topoisomerase 2 (TOP2), which 
blocks the TOP2/DNA cleavage complexes, 
leading to DSB formation36. Hyperthermia 
did not sensitize SiHa cells to etoposide, and 
there was only a moderate sensitization in 
HeLa cells, at concentrations exceeding 1 
μM (Figure 3F). HeLa cells were similarly 
sensitized by addition of Ganetespib alone 
or hyperthermia alone. The combination 
of Ganetespib and hyperthermia did not 
decrease cell survival in SiHa cells and only 
slightly (and not significantly, p = 0.09) in 
HeLa cells. Combined, these results suggest 
that chemical inhibition of HSP90 can 
potentiate the cytotoxicity of combinational 
approaches including hyperthermia and 
some, but not all, chemotherapeutic agents 
that inflict DNA damage. At the same 
time, it is apparent that the treatment with 
Ganetespib alone, at concentrations that 
stimulate cytotoxic effects of hyperthermia, 
does not induce significant toxicity in vitro.
Inhibition of HSP90 combined with 
hyperthermia and IR or cisplatin affects cell 
cycle progression and cell fate
To further explore how HSP90 inhibition 
enhances the cytotoxic effects of 
hyperthermia in combination with radiation 
and chemotherapy, we recorded time-
lapse movies of HeLa and SiHa cells after 
single-agent and different combinational 
treatments. We focused on IR and cisplatin 
because these modalities are often combined 
with hyperthermia for treatment of cervical 
cancer37,38 and because our results indicated 
that HSP90 inhibition generally enhances 
the cytotoxicity of these agents when 
combined with hyperthermia (Figure 3). 
All treatment protocols mirrored those 
used for measuring the clonogenic survival 
(Figure 3A), except after refreshment of 
the medium cells were transferred to a live-
cell microscope and time-lapse images were 
recorded for up to 96 hours. Sample images 
captured after selected treatments are 
shown in Figure 4A and 4E. We measured 
various parameters related to cell cycle 
progression, cell division and cell fate. First, 
we determined the average duration of the 
cell cycle under normal conditions, in both 
cell lines (Supplemental Figure 2A). Next, 
we focused on the DNA-damaging agent IR 
and quantified the percentage of treated and 
control cells that were able to enter mitosis 
within a single or double cell cycle time (plus 
two standard deviations) after the treatment 
(Figure 4B). We observed that treatment 
without hyperthermia, including exposure 
to IR, did not significantly affect cell cycle 
progression, since nearly all cells were able 
to enter mitosis within the first 23 hours 
after treatment. In contrast, hyperthermia-
Figure 4.Treatments combining inhibition of HSP90 with hyperthermia (HT) and IR/cisplatin 
affect the cell cycle progression and cell fate. 
A-D) Cells were pre-incubated with vehicle or 30 nM Ganetespib (HSP90-i) for 30 min at 37 °C, then 
mock-treated or exposed to 2 Gy of γ-radiation and incubated at 37 (control) or 42 °C (HT) for one hour. 
Medium was then refreshed and cells were imaged for 96 hours at intervals of 15 minutes. E-H) Cells were 
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96 hours at time intervals of 15 minutes. A, E) Representative pictures of SiHa and HeLa cells at 48 h after 
the indicated treatments. B, F) Average percentage of cells that successfully divided within a single (23 hours 
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134
Chapter 8
8
C
el
ls
 w
ith
 R
AD
51
+  f
oc
i [
%
]
0
20
40
60
80
100
HSP90-i:
HT:
−
−
+
−
−
+
+
+
+HT
Day 0: −HT
SiHa
0
20
40
60
80
100
HSP90-i:
HT:
−
−
+
−
−
+
+
+
+HT
Day 0: −HT
HeLa
C
el
ls
 w
ith
 R
AD
51
+  f
oc
i [
%
]
Day 1
Day 1
**
***
***
*
**
*
***
B C
A
ctrl
HT + HSP-i
HT
HSP-i
SiHa
BRCA2
ORC2
WB: day 0 WB: day 1 WB: day 0 WB: day 1
Day 0: +HT
(thermotolerant)
Day 0: +HT
(thermotolerant)
1h, 42 °C:
HSP90-i:
Day 0: −HT
HeLa
−
−
+
−
−
−
+
−
−
+
+
+
−
−
+
−
−
+
+
+
Day 0: −HT
−
−
+
−
−
−
+
−
−
+
+
+
−
−
+
−
−
+
+
+Day 0:
−/+ HT
Day 1:
−/+ HT
−/+ HSP90-i
WB
24 h
WB
Day 0:
−/+ HT
Day 1:
−/+ HT
−/+ HSP90-i
+IR
24 h
IF
Day 1:
−/+ HT
−/+ HSP90-i
-/+ IR
Fix/stain
24 h 8-12 d
Day 0:
−/+ HT
HeLa
0 2 4 6
IR dose [Gy]
100
10-1
101
102
0 2 4 6
IR dose [Gy]
100
10-1
101
102
Day 0: −HT
Day 0: +HT
(thermotolerance)
N
or
m
al
iz
ed
 s
ur
vi
vi
ng
 fr
ac
tio
n 
[%
]
SiHa
0 2 4 6
IR dose [Gy]
100
10-1
101
102
0 2 4 6
IR dose [Gy]
100
10-1
101
102
N
or
m
al
iz
ed
 s
ur
vi
vi
ng
 fr
ac
tio
n 
[%
]
Day 0: −HT
Day 0: +HT
(thermotolerance)
ctrl
HT + HSP-i
HT
HSP-i
Figure 5. Inhibition of HSP90 reduces thermotolerance.
A) SiHa or HeLa cells were sham-treated or rendered thermotolerant by incubation for 1 hour at 37 or 42 
°C (HT), respectively. Some of the treated cell samples were immediately lysed and analyzed by Western 
blotting to confirm the effectiveness of hyperthermia (HT) treatment by analyzing BRCA2 levels (WB: day 0). 
One day later, the remaining samples were subjected to a second HT treatment, in the absence or presence 
of 30 nM Ganetespib (HSP90-i), lysed, and BRCA2 levels were determined by Western blotting (WB: day 1). 
The experimental design is schematically represented in the left-hand panel. ORC2 was used as a loading 
control. B) SiHa or HeLa cells were treated as in (A), except immediately after the second HT treatment cells 
were irradiated using α-particles, fixed 30 minutes later and immunostained against ɣH2AX and RAD51. 
Graphs represent the average percentage of cells containing α-particle induced tracks of ɣH2AX foci that 
were also positive for RAD51. The experimental design is schematically represented in the top panel. C) Cells 
were rendered thermotolerant as in (A). Twenty-four hours later the cells were trypsinized, counted and seeded 
into 6-well plates. Four hours after seeding, they were incubated for 1 hour at 37 or 42 °C, in the absence or 
presence of HSP90-i, and exposed to the indicated dose of IR. Normalized clonogenic survival was determined 
8 (HeLa) or 12 (SiHa) days later. The experimental design is schematically represented in the top panel.
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based treatments reduced the percentage 
of cells that entered mitosis during the 
first 23 or 48 hours. The largest reduction 
was observed after the hyperthermia + 
Ganetespib combination, with or without IR. 
Additionally, hyperthermia-based treatments 
increased the frequency of abnormal first 
mitoses (Supplemental Figure 2B). 
These differences were not accompanied 
by an altered duration of the cell cycle in 
cells that successfully completed the first 
mitosis (Figure 4C) but the frequencies 
of these cells were strongly reduced after 
hyperthermia-based double and triple-
combinational treatments (Supplemental 
Figure 2D). Furthermore, these treatments 
generally caused considerably increased 
frequencies of abnormal cell division, 
senescence and apoptosis (Figure 4D). One 
notable exception was the triple-modality 
treatment of SiHa cells, which did induce 
substantial cell cycle delay (Figure 4B) but 
did not cause abnormalities in those cells 
that were able to successfully divide (Figure 
4D).
Treatments with cisplatin showed even 
stronger effects of double- and triple 
modalities involving hyperthermia and, 
interestingly, of the cisplatin + Ganetespib 
double treatment. This was apparent in 
quantification of successful cell divisions 
(Figure 4F), abnormal first mitosis 
(Supplemental Figure 2C) and of cell 
fate after the second mitosis (Figure 
4H). Also here, frequencies of these cells 
were strongly reduced after hyperthermia-
based double and triple-combinational 
treatments (Supplemental Figure 2E). 
Similarly to experiments involving IR, most 
combinations, except for triple modality in 
SiHa cells, did not considerably affect the 
length of the first cell cycle after treatment 
(in those cells that were able to successfully 
divide) (Figure 4H). Importantly, the triple 
combination regimen was clearly superior 
in causing disturbance of the cell cycle and 
mitosis as well as apoptosis and senescence. 
In conclusion, these observations generally 
confirm that HSP90 inhibition potentiates 
cytotoxicity of combinational treatments 
including hyperthermia and cisplatin/IR. They 
also provide further details on how this 
toxicity is manifested in living cells.
Inhibition of HSP90 reduces thermotolerance
Thermotolerance is a hyperthermia-
induced state of resistance to subsequent 
hyperthermia treatments, driven – at least 
partially – by expression of HSPs, including 
HSP70 and HSP9039. It has been shown 
earlier that benzoquinone ansamycin 
inhibitors of Hsp90 can delay the recovery 
from heat stress and suppress some aspects 
of thermotolerance in Drosophila40. To 
establish whether Ganetespib can affect 
these processes in mammalian cells, we first 
evaluated the effects of thermotolerance 
on hyperthermia-mediated reduction of 
BRCA2 levels. To induce thermotolerance, 
we first treated SiHa and HeLa cells for 
1 hour at 37 or 42 °C. Twenty-four hours 
later, we exposed these cells to a second 
hyperthermia treatment, with or without 
Ganetespib, and analyzed levels of BRCA2 
by Western blotting (Figure 5A). As 
expected, in control (non-thermotolerant) 
cells, hyperthermia reduced BRCA2 levels 
and Ganetespib exacerbated this effect, 
while hyperthermia failed to induce BRCA2 
degradation in cells pre-treated at 42 °C, 
confirming their state of thermotolerance. 
However, addition of a HSP90 inhibitor 
partially abolished this effect, as BRCA2 
levels in thermotolerant cells heated in the 
presence of Ganetespib were reduced, albeit 
not as dramatically as in non-thermotolerant 
cells (Figure 5A). 
Thermotolerance was also manifested by a 
significantly reduced ability of hyperthermia 
to inhibit RAD51 foci formation in cells 
heated 24 hours before α-particle irradiation 
(Figure 5B, compare bars 5 and 6 in each 
panel). However, even in thermotolerant 
cells, RAD51 focus formation was inhibited 
nearly as effectively as in non-thermotolerant 
cells when they were heated in the presence 
of Ganetespib (Figure 5B, compare bars 6 
and 8). 
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Finally, we investigated whether Ganetespib 
can reduce clinically-relevant effects of 
thermotolerance. We observed that 
hyperthermia-mediated radiosensitization 
of thermotolerant cells was reduced, as 
compared to their non-thermotolerant 
counterparts, but it could be restored by 
the addition of Ganetespib (Figure 5C). 
In summary, our results demonstrate that 
HSP90 inhibition can reduce multiple 
aspects of thermotolerance in cervix cancer 
cell lines.
Discussion
Strategies for efficient and targeted inhibition 
of DNA repair can help to improve clinical 
cancer therapies that rely on induction of 
DNA damage to destroy malignant cells. 
One example of such strategy is inhibition of 
PARP-1, a protein involved in repair of SSBs, 
DSBs and in the regulation of the chromatin 
environment41. PARP-1 inhibitors are used 
to target HR-deficient tumors, while sparing 
HR-proficient healthy tissues, in a reframed 
synthetic-lethality approach42,43. Our previous 
in vitro and in vivo results suggested that 
mild hyperthermia in clinically-obtainable 
temperature range (41-42.5 °C) can be used 
for on-demand induction of HR deficiency 
in cells and tissues8 and implied that HSP90 
inhibition can potentiate this effect. In the 
current study, we further explored this 
hypothesis and show that Ganetespib – a 
new-generation HSP90 inhibitor – enhances 
hyperthermia-mediated degradation of 
BRCA2 and inhibition of HR (Figure 1). 
These data are in line with studies showing 
that BRCA2 is a client of HSP90 and that 
HSP90 inhibition affects BRCA2 stability44. In 
addition to BRCA2, HSP90 manages multiple 
other proteins associated with DNA repair, 
including important HR factors BRCA1 and 
RAD51, and the stability of these factors 
is affected by inhibition of HSP9044,45. The 
combination of a HSP90 inhibitor with 
hyperthermia thus emerges as a self-
reinforcing strategy to disable HR, creating 
on-demand conditions of stimulated synthetic 
lethality.
Except for the effects on HR, our 
results suggest induction of DSBs after 
longer periods of time (16-48 h) after 
hyperthermia and – to a larger degree – 
after hyperthermia + Ganetespib treatment 
(Figure 2). In particular, the highly increased 
MN formation is a strong indicator of cells 
entering mitosis with unrepaired DSBs24. 
Induction of MN formation by hyperthermia 
has been reported over three decades ago46 
and confirmed more recently47, albeit but its 
stimulation by HSP90 inhibition is a novel 
observation. The late appearance of MN 
and ɣH2AX foci suggests that they are not 
directly induced by treatment, but rather 
arise with the progression of the cell cycle. 
This is in line with the previously advanced 
hypothesis that the induction of DSBs after 
hyperthermia is caused by inhibition of TOP1, 
leading to formation of SSBs22. Unrepaired 
SSBs can then derail replication forks and 
result in DSB formation in the next S-phase. 
Such one-ended DSBs are likely similar to 
those hypothetically induced after PARP1 
inhibition. Since collapsed replication forks 
require HR for repair48, inhibition of HR by 
hyperthermia contributes to the resulting 
toxicity, but this contribution may be limited 
by the temporary and reversible character 
of hyperthermia-mediated HR suppression 
(Figure 1B).
The observation of enhanced and prolonged 
HR inhibition by hyperthermia + Ganetespib 
invites the combination of stimulated 
synthetic lethality with induction of DSBs 
in the temporary therapeutic window of 
HR deficiency. This is clearly supported 
by our results showing potentiation of 
hyperthermia-induced radiosensitization and 
chemosensitization by Ganetespib (Figure 
3 and 4). Similar to late DSB induction by 
hyperthermia + Ganetespib treatment, 
clonogenic cell death and late effects on 
the cell cycle and division capabilities are 
observed when treatment is combined with 
DSB-inducing agents including IR, cisplatin 
and gemcitabine. In contrast to these 
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agents, we do not detect significant thermal 
sensitization of cells to the TOP2 inhibitor 
etoposide, whether or not Ganetespib is 
present during hyperthermia treatment. This 
can be explained by the previously described 
inhibitory effects of hyperthermia on the 
formation of TOP2 cleavage complex, which 
may reduce the efficiency of DSB induction 
and treatment cytotoxicity49.
Our results show at least three different 
aspects of treatments comprising HSP90 
inhibition and hyperthermia that can be 
beneficial in cancer treatment. First, the 
treatments produce DSBs in dividing cells 
and likely also cause cytotoxicity by other 
mechanisms. In nearly all experiments, we 
observed that Ganetespib considerably 
potentiates cell killing by hyperthermia, 
in line with a recent study that reported 
enhancement of the effects of hyperthermia 
by 17-DMAG50,51. It is worth noting that 
prolonged administration of Ganetespib 
alone can also sensitize cancer cells to 
radiation and some chemotherapeutic 
drugs52–55. Second, the increased inhibition 
of HR (and, potentially, other DNA 
repair mechanisms) by hyperthermia and 
Ganetespib sensitizes cells to multiple DSB-
inducing agents, indirectly increasing their 
cytotoxicity. Third, Ganetespib could be 
potentially used to reduce thermotolerance 
and thus enable more frequent hyperthermia 
treatments. 
Importantly for clinical application, our 
results imply that a single, short pulse of 
Ganetespib, combined with hyperthermia, is 
sufficient for a temporary but considerable 
downregulation of HR (Figure 1)8. This 
approach is in conceptual opposition to 
the long-term application of Ganetespib 
that has been tested in clinical trials17, 
including the phase III trial of Ganetespib 
in combination with docetaxel which failed 
in patients with advanced non-small cell 
lung cancer (https://clinicaltrials.gov/ct2/
show/NCT01798485). Long-term exposure 
to Ganetespib has been found to be well 
tolerated17 and the single application that is 
required for boosting hyperthermia efficacy 
should be safe in clinical practice. Strategies 
allowing potentiation of the cytotoxic and 
sensitizing effects of hyperthermia can 
lead to improved therapy outcomes via 
multiple avenues, e.g. by inducing stronger 
cytotoxicity while sparing the non-heated 
healthy tissues, by allowing reduction of the 
required dose of DNA-damaging agents 
or by rendering hyperthermia treatments 
effective at decreased temperatures or 
shorter durations. Our study suggests that 
inhibition of HSP90 is one such strategy, with 
limited systemic side-effects, paving the way 
for rational design of improved hyperthermia 
treatment protocols and for in vivo studies 
involving animal models.
Material and methods
Cell lines and cell culture
SiHa and HeLa cervical cancer cell lines 
were obtained from the American Type 
Culture Collection (ATCC) and cultured in 
EMEM medium (Lonza) enriched with 10% 
fetal bovine serum (FBS) and 1% of penicillin/
streptomycin (Gibco, 10000 U/mL). Cells 
were maintained at 37 °C, in an atmosphere 
containing 5% CO2. During the experiments 
with hyperthermia, cells were incubated 
for 65 minutes at 42 °C in an atmosphere 
containing 5% CO2 (the medium in the 
wells needed approximately 5 minutes to 
reach the target temperature of 42 °C). For 
experiments involving α-particles, cells were 
cultured in custom-made dishes with 4 μm-
thick polypropylene bottom, as described 
earlier56.
Chemical agents, hyperthermia treatments and 
irradiation 
Cells were treated with the indicated 
concentrations of Ganetespib (STA-9090, 
Synta Pharmaceuticals), cisplatin (cDDP; 
Platosin®, Pharmachemie), gemcitabine 
(Actavis) and etoposide (Sigma Aldrich). 
Ganetespib and cisplatin were added 30 
minutes before and removed immediately 
after the end of hyperthermia treatments, 
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by washing cells and adding fresh medium. 
Gemcitabine was added 24 hours before 
the start of hyperthermia experiments. 
Hyperthermia was applied by partially 
submerging cell culture dishes in a 
calibrated water bath, at the appropriate 
CO2 concentration. The temperature was 
monitored by a thermocouple directly in 
cell culture dishes. To allow for temperature 
increase from 37 to 42 °C, cells were always 
incubated five minutes longer than what is 
indicated in the text/figures. In experiments 
involving irradiation, cells were exposed 
to the indicated doses from a 137Cs ɣ-ray 
source (~0.5 Gy/minute) or from a 241Am 
α-particle source. To produce linear tracks 
of DSBs, cells were irradiated through the 
polypropylene bottom of culture dishes 
for one minute, with the α-particle source 
positioned under an angle of approximately 
45° below the bottom of the dish, as 
described previously56.
Immunohistochemistry
At the indicated time points after irradiation, 
cells were fixed with 2% paraformaldehyde 
in PBS for 15 minutes at room temperature. 
Fixed samples were washed twice with PBS 
and incubated in TNBS (PBS supplemented 
with 1% FCS and 0.1% Triton-X100) for 30 
minutes. Samples were then incubated with 
the primary mouse anti-ɣH2AX (1:100, 
Millipore) and rat anti-Rad51 (1:50)57 
antibodies diluted in TNBS for 2 hours. After 
being washed twice in TNBS, samples were 
incubated with the secondary anti-mouse-
Cy3 and anti-rat-FITC (both 1:100, Jackson 
ImmunoResearch Laboratories) diluted in 
TNBS, for one hour. Finally, mounting gel 
containing DAPI (Thermo Scientific) was 
added and samples were covered with glass 
coverslips. Slides were imaged and scored 
using the wide-field fluorescence microscope 
(DM-RA and DM-RXA, Leica).
Clonogenic assays
Twenty-four hours before treatment, 2x106 
cells were seeded into a 10-cm dish. On the 
day of the experiment, cells were trypsinized, 
counted and plated in triplicates of two 
densities per condition in 6-well plates. After 
four to six hours incubation required for cell 
attachment, cells were treated with 30 nM 
Ganetespib for 90 minutes with or without 
cisplatin or etoposide. After the first 30 min 
of incubation at 37 °C, plates were either 
transferred to a 42 °C water bath or were 
incubated at 37 °C for the remaining 65 
minutes. In clonogenic survival experiments 
involving ionizing radiation (IR), cells were 
irradiated after the 30 minute treatment 
with Ganetespib, immediately prior to the 
hyperthermia treatment. Directly after 
hyperthermia, cells were washed with PBS 
and incubated in fresh medium for eight 
(HeLa) or thirteen (SiHa) days. Next, colonies 
were fixed, stained and counted according 
to the previously published protocol58. In 
experiments involving gemcitabine, cells 
were treated for 24 hours, starting directly 
after plating into 10-cm dishes and until the 
start of the experiment (0 h). A schematic 
overview of the treatment schedules is 
depicted in Figure 3A. 
Time-lapse microscopy
Twenty-four hours prior to the indicated 
treatments, cells were plated in 6- or 12-well 
plates at a density of 15,000 or 7,000 cells 
per well, respectively. After treatment, cells 
were washed with PBS and fresh medium 
was added. The medium was covered with 
a layer of mineral oil (Sigma-Aldrich) to 
prevent evaporation during imaging. Cells 
were imaged for 96 hours, at intervals of 15 
minutes, using a wide-field phase-contrast 
microscope (Leica). The cell cycle time was 
defined as the time between the first and 
second successful mitosis observed after 
treatment; senescence was absence of cell 
division for at least 48 hours and abnormal 
mitosis was division that gave rise to 
abnormal progeny.
Western blotting
Cells were harvested immediately after 
treatments and lysed in Laemmli sample 
buffer (4% SDS, 20% glycerol and 120 mM 
Tris pH 6.8). Protein levels were quantified 
with the Lowry protein assay. A total of 50 
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μg protein supplemented with bromophenol 
blue and β-mercaptoethanol was loaded and 
separated on a NuPage 3-8 % Tris-Acetate 
protein gel (Thermo Fisher Scientific). The 
protein samples were transferred to a PVDF 
membrane, incubated for 1 hour in blocking 
buffer at 4 °C (PBS with 0.05% Tween (PBS-T) 
and 3% nonfat dry milk) and then overnight 
with the primary mouse anti-BRCA2 
(OP95-Ab-1, Merck Millipore), rabbit anti-
cyclin A (C-19, Santa Cruz Biotechnology) 
or mouse anti-ORC2 (ab68348, Abcam) 
antibodies (diluted 1:1000 in blocking 
buffer). The membrane was washed five 
times for eight minutes with PBS-T and 
incubated with the relevant secondary 
antibodies (horseradish peroxidase (HRP)-
conjugated sheep anti-mouse or donkey-anti 
rabbit IgG, both 1:2000 in blocking buffer, 
Jackson ImmunoResearch Laboratories) 
for two hours at room temperature. The 
proteins on the membrane were visualized 
with enhanced chemiluminescence (ECL) 
substrate and imaged with the Alliance 
imager 4.7 (Uvitec Cambridge).
Data collection and statistics
The unpaired t-test was used for inter-group 
comparisons of the means. Graphs presented 
in Figure 4 show results of two independent 
experiments that each included both IR (B-
D) and cisplatin (G-I) arms. Therefore, the 
same results obtained from control as well as 
single and double-agent treatments involving 
HT and HSP90-i are shown in both arms. In 
the case of the cisplatin+HSP90-i treatment, 
n was 1. The numbers of cells analyzed in 
these experiments for each panel of Figure 
4 (1340 HeLa cells and 1850 SiHa cells in 
total) are presented in Supplemental 
Figure 2D and 2E. In Figure 3C, when 
33 μM cisplatin was combined with 
hyperthermia and HSP90-i, n = 1 because 
no colonies could be detected at this 
concentration in the remaining experiments. 
All other graphs summarize the results of at 
least three independent experiments, with 
error bars indicating standard deviation. 
Asterisks indicate statistical significance with 
the p-values as follows: * < 0.05, ** < 0.01, 
*** < 0.001.
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Supplementary Figure 2. Treatments combining inhibition of HSP90 with hyperthermia (HT) 
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analyzed are dramatically reduced in the double/triple treatment groups.
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AppendixA
Summary and conclusions
Local hyperthermia, a method during 
which the temperature of a tumor is 
elevated, clinically increases the efficacy of 
radiotherapy and chemotherapy, without 
increasing side-effects. One of the reasons 
that explains why hyperthermia increases 
effectivity of these therapies is that it 
induces degradation of BRCA2. BRCA2 is 
an essential protein for double strand break 
DNA repair via homologous recombination 
(HR). Double strand breaks are the types 
of damage that occur after radiotherapy 
and specific types of chemotherapy, and are 
the basis for the anti-cancer effects of these 
therapies. By inhibiting HR, hyperthermia 
prevents repair of these breaks, and 
therefore increases anti-cancer efficacy of 
radiotherapy and chemotherapy. 
This thesis describes the journey of 
hyperthermia-mediated BRCA2 degradation, 
from bedside to bench and back again. 
In the Prequel we describe bedside to 
bench research that has provided biological 
explanation for why hyperthermia sensitizes 
to radiotherapy through hyperthermia-
mediated degradation of BRCA2. By taking a 
Step Back we identify the thermal doses and 
the hyperthermia-radiotherapy sequencing 
necessary to best exploit heat-mediated 
BRCA2 degradation in the clinical setting. 
Next, with a Bench to Bedside approach, 
we explore what hyperthermia-mediated 
BRCA2 degradation and the resulting HR-
deficiency can currently contribute to clinical 
hyperthermia treatment. Lastly, we close the 
Bedside to Bench-circle by addressing 
how clinical hyperthermia can be improved 
by exploring new targets for increasing 
effectiveness of hyperthermia-mediated 
BRCA2 degradation, using laboratory 
experiments. 
Part I Prequel
Recent technological advances in methods 
and equipment designed to treat patients 
have greatly increased the enthusiasm for 
hyperthermia. Moreover, scientific research 
directed to elucidating the biological 
mechanisms that cause hyperthermia to be 
so effective on tumors, has greatly advanced 
the field and continues to do so. In Chapter 
2, we provide context for the importance 
of biological research for hyperthermia 
treatment, by illustrating how biological 
discoveries have changed the rationale for 
treatment and how they have yielded new 
treatment opportunities. We describe how 
physiological changes in perfusion and vessel 
permeability have prompted the discovery of 
thermosensitive liposomes to enhance drug 
delivery, how inhibitors of the heat-shock 
response may be used to enhance efficacy, 
how changes in the cellular membrane 
can affect drug-uptake in a cell, and how 
hyperthermia-driven immunological changes 
may provoke very specific tumor responses. 
Finally, we describe how hyperthermia-
induced attenuation of DNA repair by HR 
provides rationale for new therapeutic 
combinations, which could greatly increase 
the number of patients that benefit from 
PARP inhibitors, a precision medicine which 
is currently used to target an innate genetic 
HR defect in some tumors. 
Part II A Step Back
Hyperthermia attenuates HR by causing 
degradation of BRCA2, which in turn results 
in defective localization of RAD51 to DNA 
breaks. Besides providing a rationale for 
new strategies, hyperthermia-mediated HR 
deficiency may be valuable for reinventing 
current hyperthermia treatment schedules. 
To fulfill this clinical promise, it is important 
to find the optimal treatment schedules and 
boundaries of hyperthermia-mediated HR 
deficiency. In Chapter 3, we therefore aim 
to find the optimal thermal dose necessary 
to achieve HR deficiency by investigating 
to what extent thermal dose influences 
BRCA2 degradation and RAD51 localization 
into foci. We find that, to optimally inhibit 
HR, hyperthermia should be applied in the 
range between 41 and 43 °C for one hour. 
In Chapter 4, we continue by asking when 
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such an optimal dose should be applied 
relative to radiotherapy. We use RAD51 
localization as a marker for hyperthermia 
effectivity in inhibition of HR, and find that 
hyperthermia disturbs HR most effectively 
when it is applied in a short time-frame 
before or after radiotherapy. However, 
because hyperthermia can disturb existing 
RAD51 foci, the most versatile way of 
inhibiting HR would most likely be the 
application of hyperthermia after irradiation. 
Part III From Bench to Bedside
To exploit hyperthermia-induced BRCA2 
degradation and the resulting HR deficiency 
in a clinical setting, it is important to 
validate whether BRCA2 degrades upon 
hyperthermia in target material: human 
tumors of various origins. In Chapter 5, we 
demonstrate that BRCA2 indeed degrades 
in human tumors heated ex vivo, indicating 
that the molecular pathways that mediate 
BRCA2 degradation upon hyperthermia are 
present in tumors. Besides strengthening 
the rationale for hyperthermia/PARP 
inhibitor combinations, this data suggested 
that inhibition of HR could be a valuable 
biomarker to measure or predict effectivity 
of hyperthermia in vivo. However, we find 
that tumor heterogeneity prevented us 
from obtaining interpretable results in the 
case of BRCA2 degradation. In Chapter 
6, we therefore explore the feasibility of 
employing an ex vivo assay measuring RAD51 
focus formation defects in bladder cancer, 
and find that this can potentially be used as a 
predictive marker.  
Part IV From Bedside to Bench 
Although heat-mediated BRCA2 degradation 
and resulting HR deficiency have clear clinical 
potential in current practice, it is important 
to explore the molecular mechanisms which 
mediate BRCA2 degradation. Understanding 
these mechanisms can provide valuable 
knowledge on hyperthermia biology, HR 
regulation and BRCA2 itself, and consequently 
yield new therapeutic targets to disrupt 
HR without using hyperthermia, or to 
enhance hyperthermia efficacy. In Chapter 
7, we share our endeavors to elucidate the 
molecular mechanisms responsible for heat-
mediated BRCA2 degradation. Although we 
do not fully comprehend these mechanisms 
as of yet, we find some very important 
leads that will elucidate the mechanism in 
the future. One lead that has potential to 
increase hyperthermia efficacy is further 
explored in Chapter 8. In this chapter, we 
demonstrate that HSP90 inhibition has the 
ability to aggravate the HR defect induced 
by hyperthermia, as well as to increase 
hyperthermia-mediated sensitization to 
radiotherapy and chemotherapy. HSP90 
inhibition may therefore be used to boost 
hyperthermia efficacy, and may be used to 
reduce treatment duration and prevent 
thermotolerance.
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Nederlandse samenvatting
Lokale hyperthermie, een methode waarbij 
de temperatuur van een tumor wordt 
verhoogd, vergroot de effectiviteit van radio- 
en chemotherapie, zonder de bijwerkingen 
te verergeren. Eén van de redenen waarom 
hyperthermie de effectiviteit van radio- en 
chemotherapie verhoogt is de inductie 
van BRCA2-afbraak. BRCA2 is een 
essentieel eiwit in homologe recombinatie 
(HR), een DNA-reparatieproces dat 
DNA-dubbelstrengsbreuken repareert. 
Dubbelstrengsbreuken zijn een type DNA-
schade dat kan ontstaan na radiotherapie 
en sommige typen chemotherapie, en zijn 
de basis zijn voor de antikankereffectiviteit 
van deze therapieën. Door HR te remmen 
voorkomt hyperthermie reparatie van deze 
breuken, en zorgt dus voor een verhoging van 
de activiteit van deze antikankertherapieën. 
Deze thesis beschrijft de reis van 
hyperthermie-gemedieerde BRCA2-afbraak, 
van kliniek naar het laboratorium en weer 
terug. In de Proloog beschrijven we het 
kl iniek-naar-laboratorium-onderzoek 
dat verklaart waarom hyperthermie-
geïnduceerde BRCA2-afbraak de 
gevoeligheid voor bestraling vergroot. Door 
een Stap Terug te nemen zoeken we de 
optimale thermische dosis en de optimale 
volgorde van radiotherapie en hyperthermie 
om hitte-gemedieerde BRCA2-afbraak in de 
kliniek te gebruiken. Daarna verkennen we 
met een Laboratorium-naar-Kliniek-
aanpak wat hyperthermie-gemedieerde 
afbraak van BRCA2 op dit moment kan 
bijdragen aan de klinische toepassing van 
hyperthermie. Als laatste sluiten we de 
cirkel (Kliniek-naar-Laboratorium) 
door middels laboratoriumexperimenten 
te onderzoeken hoe de effectiviteit van 
hyperthermie-gemedieerde BRCA2-afbraak 
kan worden verbeterd en hoe klinische 
hyperthermie daarmee geholpen wordt.
Deel I Proloog
Het enthousiasme voor hyperthermie is 
recent flink toegenomen door technologische 
vooruitgang in de behandelingsmethodes 
en -machines. Het vakgebied is en wordt 
daarnaast bevorderd door wetenschappelijk 
onderzoek gericht op het onthullen van 
biologische werkingsmechanismen die 
ervoor zorgen dat hyperthermie zo effectief 
werkt op tumoren. In Hoofdstuk 2 geven 
we context aan het belang van dit laatste 
onderzoek door te illustreren hoe biologische 
ontdekkingen de gedachte achter de 
hyperthermiebehandeling hebben veranderd, 
en hoe deze ontdekkingen kunnen leiden 
tot nieuwe behandelingsmogelijkheden. We 
beschrijven hoe fysiologische veranderingen 
in bloedsomloop en bloedvatpermeabiliteit 
de ontdekking van thermisch gevoelige 
liposomen (die chemotherapieën beter bij 
de tumor kunnen krijgen) heeft gebracht, 
hoe remmers van de ‘heat-shock response’ 
gebruikt kunnen worden om effectiviteit 
van behandelingen te vergroten, hoe 
veranderingen in het membraan van een cel 
medicijnopname kunnen verbeteren, en hoe 
hyperthermie-gestuurde immunologische 
veranderingen hele specifieke tumorreacties 
kunnen opwekken. Als laatste beschrijven 
we hoe hyperthermie-geïnduceerde 
verzwakking van homologe recombinatie de 
weg vrijmaakt voor nieuwe therapeutische 
combinaties. Deze zijn specifiek gericht op 
het vergroten van het aantal patiënten dat 
voordeel kan hebben van een PARP-remmer, 
een precisiemedicijn dat op dit moment 
alleen gebruikt wordt voor inherente, 
genetische HR-defecten in tumoren.
Deel II Een Stap Terug
Hyperthermie verzwakt HR door een 
inductie van BRCA2-afbraak, wat vervolgens 
zorg voor een probleem in de lokalisatie 
van RAD51 op dubbelstrengsbreuken in 
het DNA. Behalve dat dit kansen biedt 
voor nieuwe behandelingsstrategieën kan 
hyperthermie-gemedieerde HR-deficiëntie 
ook van waarde zijn bij de aanpak van 
huidige hyperthermiebehandelingen. Om 
deze klinische belofte te vervullen is het 
belangrijk om te bepalen wat de optimale 
149
ASamenvatting en conclusies
behandelingsschema’s zijn van hyperthermie-
gemedieerde HR-deficiëntie. In Hoofdstuk 
3 zoeken we daarom de optimale thermische 
dosis om HR-deficiëntie te induceren door 
te onderzoeken hoe de thermische dosis 
BRCA2-degradatie en RAD51-lokalisatie 
beïnvloedt. We vinden dat de behandeling 
voor optimale HR-remming één uur zou 
moeten duren, met temperaturen tussen 
de 41 en 43 °C. In Hoofdstuk 4 vervolgen 
we door te vragen wanneer zo’n optimale 
dosis dan toegepast moet worden in relatie 
tot radiotherapie. We gebruiken RAD51-
lokalisatie als een marker voor hyperthermie-
effectiviteit, en vinden dat hyperthermie 
HR het meest effectief verstoort wanneer 
het in een kort tijdsinterval vóór of na 
radiotherapie wordt gegeven. We vinden 
echter ook dat hyperthermie in staat is om 
bestaande foci te verstoren wanneer het ná 
radiotherapie wordt gegeven, en daarom is 
het geven van hyperthermie na bestraling de 
meest flexibele manier om HR te remmen.
Deel III Van Laboratorium naar Kliniek
Om hyperthermie-geïnduceerde BRCA-
afbraak en de daaruit volgende HR-deficiëntie 
in de kliniek toe te passen is het belangrijk 
om te valideren dat BRCA2 afbreekt 
na hyperthermie in het doelmateriaal: 
menselijke tumoren van gevarieerde afkomst. 
In Hoofdstuk 5 demonstreren we dat 
verwarming van menselijke tumoren buiten 
het lichaam inderdaad zorgt dat BRCA2 
afbreekt, wat aantoont dat de moleculaire 
mechanismen die ervoor zorgen dat BRCA2 
degradeert na hyperthermie in deze tumoren 
werkzaam zijn. Deze data pleit niet alleen 
voor de combinatie hyperthermie/PARP-
inhibitie, maar suggereert ook dat remming 
van HR een goede biologische paramater 
kan zijn om de effectiviteit van hyperthermie 
in de kliniek te meten of te voorspellen. We 
ontdekken echter dat tumorheterogeniteit 
de interpretatie van BRCA2-degradatie 
verstoort. Daarom onderzoeken we in 
Hoofdstuk 6 of het haalbaar is om een ex 
vivo-assay te gebruiken waarbij de RAD51-
focusformatie wordt gemeten in blaaskanker, 
en we vinden dat dit inderdaad gebruikt 
zou kunnen woorden als een voorspellende 
marker. 
Deel IV  Van Kliniek naar Laboratorium 
Hoewel hitte-gemedieerde BRCA2 
degradatie en de resulterende homologe-
recombinatiedeficiëntie duidelijk een 
toegevoegde waarde kunnen hebben 
in de kliniek is het ook belangrijk om 
te onderzoeken wat de moleculaire 
mechanismen zijn die ervoor zorgen dat 
BRCA2 degradeert. Het begrijpen van deze 
mechanismen zou ons veel kunnen leren over 
de biologie van hyperthermie en de regulatie 
van HR en BRCA2, en zou dus nieuwe 
therapeutische opties kunnen opleveren om 
HR te verstoren zonder hyperthermie te 
gebruiken, of om hyperthermie zelf effectiever 
te maken. In Hoofdstuk 7 beschrijven 
we onze pogingen om de moleculaire 
mechanismen die verantwoordelijk zijn voor 
BRCA2-afbraak na hitte uit te zoeken. We 
kunnen deze mechanismen nog niet volledig 
doorgronden, maar we presenteren wel 
belangrijke informatie die zou kunnen helpen 
om ze in de toekomst te verduidelijken. Eén 
van de gevonden aanknopingspunten heeft 
de potentie om hyperthermie-effectiviteit 
te verhogen en wordt verder uitgediept in 
Hoofdstuk 8. In dit hoofdstuk laten we 
zien dat HSP90-remmers de mogelijkheid 
hebben om het HR-defect geïnduceerd 
door hyperthermie te verergeren, en 
om de gevoeligheid voor bestraling en 
chemotherapie verder te verhogen. HSP90-
remming zou daarom gebruikt kunnen 
worden om de hyperthermie-efficiëntie te 
vergroten, thermotolerantie te voorkomen 
en de behandelingsduur te verkorten.
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en 9 maanden aan het maken ben geweest. 
Ik ben de laatste twee maanden een heuse 
treinforens en realiseerde me na een week 
of twee dat het cliché ook echt waar is: de 
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155
ADankwoord
de eindsprint nog zo goed hebt kunnen 
helpen. Hanny, dankjewel voor al je blots en 
je gedrevenheid om elk experiment tot een 
goed einde te brengen. Berina zei het geloof 
ik al eerder, iets met die gouden handjes? 
Beste ‘Amsterdammers’: Przemek, Lianne, 
Arlene en Klaas, bedankt voor de mooie 
samenwerking op het HSP90-project, het 
is voor mij een kroon op het werk van de 
afgelopen vier jaar en ik ben blij dat we het 
zo snel tot een goed einde hebben kunnen 
brengen. 
Alex, Peter, Przemek, Jeroen, Jurgen and 
Pier, thank you for all the help with the 
endeavours to elucidate the mechanism of 
heat-mediated BRCA2 degradation. Yaron, 
Christine and Steve, the two weeks I have 
spent in Cambridge were probably one of 
the most effective weeks of my scientific life. 
Thank you for the time you invested in my 
project. And Tony and Dilly: thank you for 
your hospitality during this period. Michael, 
it was an honour to write the hyperthermia 
review together and it was a pleasure to 
meet you. 
A marathon cannot be run without training. 
Anton, Manfred, Mannis, Arwin, Willy, 
Godfried, Berina, thanks for providing 
me with the basis to do science. Jan, Wim, 
Dik, Koos and Jeroen, dank jullie voor 
het voortzetten van die opleiding: goed 
voorbeeld doet volgen. Claire and Joyce, 
your scientific capabilities and knowledge 
are admirable. 
Zoals altijd zijn collega’s ontzettend 
belangrijk in het leven van de onderzoeker 
en ik zou jullie graag allemaal willen bedanken 
voor de leuke tijd die ik heb gehad op het 
laboratorium, de Sinterklaas-feestjes en de 
rest. Yanto, ik weet zeker dat we de Pandalist 
ooit zullen ontmaskeren! Stefan, dank 
voor het delen van sportfanatisme en alle 
gezellige volleygesprekken. Nicole, Bibi, Titia, 
Julie en Joyce: dank jullie voor het aanhoren 
van mijn frustratie-rants en het delen van 
die van jullie. Én natuurlijk voor alle leuke 
gesprekken over legpuzzels, panda’s, koffie, 
kipjes etc). Kishan, ik weet niet hoe ik al die 
avonden op het lab zonder jou had moeten 
volhouden. Nicole en Anja (moet in een 
adem), bedankt voor jullie levenswijsheden 
en jullie gezelligheid. Inger, bedankt voor 
alle gezelligheid in en buiten het lab. Jouw 
behulpzaamheid kent geen grenzen. Ik 
heb genoten van onze schildercursus en 
hardloopsessies in Schiedam en Londen. 
Alex, thanks for all your lessons about life, 
science and especially about vocabulary. 
You are truly an inspiring scientist, and I 
hope our paths may cross again. Charlie, 
dankjewel voor het delen van de liefde voor 
webcomics en andere flauwe nonsens. Het 
was leuk! Cecile en Paula, zonder jullie zou 
het lab niet kunnen werken en ik ben jullie 
daar heel dankbaar voor. Cecile, met al die 
kaart- en bootinfo kunnen we zeker uit de 
voeten en als onze sloep ooit zeewaardig 
is, kom ik je opzoeken! João, thanks for the 
good times we enjoyed in our office and in 
the canoes! Wenhao, Marcel, Gosia, Klaas, 
Sari, Petra, Levi, Winnie, Natasha, Luuk, 
Arshdeep, Maarten, Dejan, Giorgia, Natasa, 
Nathalie, Yannika, Guus and Ingrid: thank you 
for sharing the good and the bad times with 
me.
Also thanks for all the floor-buddies on both 
the sixth and the seventh floor: Michael, 
Lennart, Ayestha, Fabrizia (thanks alot ;)!), 
Arjan, Imke, Barbara, Marjolein, Serena 
and Hester and all the others I have not 
mentioned.  
Ik heb geleerd dat je naast je promotie best 
een bijbaan kan hebben, mits je daar ook op 
begrip voor je drukke schema kan rekenen 
én je fijne collega’s hebt. Wouter, Robert, 
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te houden en het is altijd heel leuk om je te 
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ik dichter in de buurt woon nu! Pap, mam, 
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nou allemaal doe in heb lab, hebben jullie dat 
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Bastiaan, mijn trein is bijna aangekomen in 
het noorden, dus de laatste woorden zijn 
voor jou. Dankjewel voor alles wat je voor 
mij betekend hebt de afgelopen jaren. Je bent 
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